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Blood-brain barrier (BBB) is a unique membranous barrier, which segregates 
brain from the circulating blood. It works as a physical and metabolic barrier 
between the central nervous system (CNS) and periphery. In mammals, 
endothelial cells were shown to be of BBB and are characterized by the tight 
junctions along with efflux system which are responsible for the restriction of 
movement of molecules within the cells. Efflux system consists of multidrug 
resistance proteins such as P-glycoprotein (P-gp). P-gp removes substances 
out back from the brain to the blood before they reach to the brain. So the barrier 
is impermeable to many compounds such as amino acids, ions, small peptides 
and proteins, making it the most challenging factor for the development of new 
drugs for targeting CNS. 
Curcumin is a bioactive compound that has a number of health promoting 
benefits such as anti-inflammatory, anticancer, anti-oxidant agent; as well as a 
role in neurodegenerative diseases, but low oral bioavailability is the major 
limiting factor. Low water solubility and rapid metabolism are the two important 
factors responsible for poor bioavailability of curcumin. Galaxolide is a musk 
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compound and previously known for the bioaccumulation of toxic components 
in the aquatic animals by interference with the activity of 
multidrug/multixenobiotic resistance efflux transporters (MDR/MXR). The 
bioavailability of curcumin can be enhanced when administered with galaxolide. 
This study was carried out to investigate the effect of galaxolide on the 
permeation of curcumin through the epithelial cell monolayers. MDCKII-MDR1 
cell monolayer is used an in vitro blood-brain barrier model while Caco-2 
monolayer is used as an in vitro intestinal model, which also expresses the P-
glycoprotein. The curcumin and galaxolide were separately solubilised in the 
DMSO and used in combination to perform permeation study, to determine the 
effect of galaxolide on curcumin permeation through epithelial cell monolayers.  
The galaxolide shows an efflux protein inhibition activity and this activity was 
used to enhance permeation of curcumin through the Caco-2 monolayer. In 
summary, galaxolide is a novel permeation enhancer molecule, which can be 
used for the improvement of drug delivery of other bioactive compounds in 
future.   
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1 : Introduction 
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A number of mechanisms are available in a biological system to protect it from 
exposure to almost any foreign substance with exception to nutrient uptake. 
The physiological arrangement and the chemical and biochemical barriers 
associated with the physiological structures form the first line of defence. Any 
drug, delivered by any route, will almost certainly face some of these barriers 
before reaching their target site. The physicochemical and biochemical 
properties of the drug molecule determine its interaction with these barriers.  
The body is protected against external invaders and toxins through number of 
biological barriers which are present in body. The blood-brain barrier (BBB) is 
one of such barrier that forms the tightest membrane and limits the entry of 
molecules from the bloodstream to the brain. Similarly, for the drug molecules 
to be orally bioavailable, another barrier is there called epithelial layers of 
gastrointestinal tract. It is necessary to breach these barriers for the successful 
delivery of drugs through the intestinal mucosa or the BBB. The hurdles to drug 
delivery can be categorized as physiological, biochemical, and chemical 
barriers. The physiological barrier in the intestinal mucosa or the blood-brain 
barrier protects the body from various molecules such as toxins, by inhibiting 
their passage through the barriers. Next obstacle is biochemical barrier that 
must be overcome by drug, which consists metabolizing enzymes that can 
degrade the drug molecules before reaching to its target site. Finally, the drug 
should have optimal physiochemical properties for its permeation across the 
biological barriers. Thus, these various factors have to be taken into account 
when designing drugs with improved absorption characteristics. 
In order to achieve efficient treatments of central nervous system (CNS) 
cancers, it is necessary to transport therapeutic agents across the specialized 
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vascular system of the brain, the BBB. Transport across BBB presents 
challenges especially in case of brain tumours due to undefined nature of 
cerebrovascular system associated with cancer progression and development 
of biomarkers which can be coupled to therapeutic agents for targeted delivery 
but bypassing the resistance mechanism. A great deal of effort, therefore, is 
presently focused on improving CNS bioavailability, and tumours thereof, of 
therapeutic drugs that can be specifically targeted to diseased tissue, improving 
therapeutic opportunities, efficiency, and patient survival, while decreasing 
side-effects to normal cells. Various pharmacological agents have been used 
to open the BBB and direct invasive methods can introduce therapeutic agents 
into the brain substance. It is important to consider not only the net delivery of 
the agent to the CNS, but also the ability of the agent to access the relevant 
target site within the CNS. Major challenge in drug delivery is strong efflux 
mechanisms present at BBB as well as in cancer tissue. Drug permeation can 
be improved across BBB and in cancer tissues by suppression of these efflux 
transport systems. 
Sufficient concentrations of therapeutic agents or xenobiotic compounds are 
needed at the site of action to show their pharmacological and toxicological 
actions. These compounds when in desired concentration can bind to the 
targeted receptor or enzymes and show their response. To achieve the desired 
response against the site of action, drug molecule need to cross the biological 
membranes which is an important determinant for absorption, distribution, 
elimination and therapeutic or toxic effects of drug molecules. Biological 
membranes are not just a lipid bilayer, but lipid bilayers with number of 
embedded proteins including various transporters. These transporters play an 
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important role to pass drug molecules through biological membranes along with 
physicochemical characteristics of drug. Numerous transporters are present in 
the biological membranes; amongst them a group is present called an efflux 
transporter. The group of efflux transporters includes mainly P-glycoprotein 
(Pgp, MDR1), multidrug resistance-associated proteins (MRPs) and breast 
cancer resistance proteins (BCRP). These proteins mainly involved in removal 
of wide range of molecules, which are structurally and functionally different, 
from the cells against a concentration gradient. These efflux proteins show their 
transport activity against number of anticancer agents which are clinically 
important, and prevent their intracellular accumulation which can lead to 
inappropriate cell killing and poor treatment, and this phenomenon known as 
“multidrug resistance” (MDR) and MDR is one of the major hurdle to achieve 
successful cancer chemotherapy (David R. Hipfner1, 1999; Ira and Pastan, 
1988; Pastan, 1993; T. Litmana et al., 2001).  In reverse of this, these 
transporters could be beneficial and can improve the therapeutic efficacy of a 
particular drug molecule by improving poor bioavailability of some anticancer 
agents with inhibition of P-glycoprotein and other efflux proteins (Johan W. 
Jonker and Beijnen, 2000; Kimura et al., 2002; Kruijtzer et al., 2002). So if P-
glycoprotein is inhibited by using various inhibitors, reversers or modulators; 
then it may increase the absorption of drug into the intestine and result into the 
high oral availability of particular drug molecule, which then lead to the 
successful chemotherapy (Robert and Jarry, 2003). 
Cell based assays are necessary in pharmaceutical research to study the tissue 
permeability ability of lead drug molecules. These assays are widely used after 
primary screening of drug molecules with desired pharmacological properties 
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to identify drug properties with regards to the tissue permeability. These 
approaches with cell based assays are not only cost effective but it also 
minimizes use of animal sources. Various different cell lines and cell based 
assays are used in this study in order to achieve the desired outcome of study.  
1.1 Galaxolide 
Galaxolide or HHCB (1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-
hexamethylcyclopenta[g]-2-benzopyran) is an artificial polycyclic musk 
compound with a clean sweet musky floral woody odour used as fragrancing 
agent in huge extent for the preparation of number of personal care products 
such as cosmetics, perfumes, detergents, air freshener, cleaning agents, body 
lotions etc (Kannan et al., 2005) . Amongst all polycyclic musk compounds, 
galaxolide is one of the most widely used musk compound (Rimkus, 1999).  
According to some reports, it is cleared that the musk compounds accumulates 
in the aquatic animals including fish, mussels etc (Kannan et al., 2005), while 
some reports shown that the musk compounds were found in the human milk, 
human adipose tissues and blood plasma (Rimkus and Wolf, 1996).  Excess 
use and bioaccumulation of these compounds raised the issues of toxicity on 
human and wild life.  
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Figure 1.1:Chemical Structure of HHCB (Galaxolide) 
 
The musk compounds are also responsible for the interference with activity of 
multidrug/multixenobiotic resistance efflux transporters (MDR/MXR) and it 
shows dominant activity against P-glycoprotein like transporters. The study on 
marine mussel Mytilus californianus shows that these musk compounds are 
responsible for inhibition of activity of efflux transporters and inhibitory effects 
of them lasts for about 24-48 hrs even after termination of exposure to these 
musks (Luckenbach and Epel, 2005). The MDR efflux transporters are referred 
as the first line of defense mechanism as they prevent bioaccumulation of toxic 
compounds inside the cells. So if these efflux transporters are inhibited, the 
sensitivity to toxic compounds which are normally excluded by cells increases 
and allow them to enter cells and accumulate (Epel, 1998). This property of the 
galaxolide can be useful in the drug therapy against the cells which show MDR; 
especially cancer cells which shows poor response to drugs.  
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1.2 Curcumin 
Curcumin is the phenolic compound andprimarycurcuminoid of the Indian spice 
turmeric (Curcuma longa), found along with other two curcumionoids named 
demethoxycurcumin (D-Cur) and bisdemethoxycurcumin (BD-Cur) in the 
rhizome of plant.It is used as food additive in many Indian recipes. In addition 
to this, Curcumin has number of therapeutic effects as it acts as anti-
inflammatory, anticancer, antioxidation, antimicrobial agent;along with these 
properties, curcumin also acts against neurodegenerative, cardiovascular, 
pulmonary, metabolic, autoimmune and neoplastic diseases (Aggarwal and 
Harikumar, 2009).  
 
Figure 1.2: Chemical structures of the three major curcuminoids 
 Curcumin, demethoxycurcumin (D-Cur) and bisdemethoxycurcumin (BD-
Cur) 
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The clinical trials on human have proved that it is safe to consume up to 8000mg 
curcumin per day, as it is well tolerated and have less adverse effect. Also in 
vitro studies shown that the curcumin has beneficial effects for humans in 
chemoprevention against colon cancer (Johnson and Mukhtar, 2007). Cancer 
is not a single disease as it is a combination of number of neoplastic disease; 
that is why it is hard to apply targeted drug therapies against it, so it needs 
combination of different targeted therapies. Curcumin is a compound which can 
act as anti-carcinogenic, antiangiogenic, immunomodulatory, proapoptotic and 
antioxidant agent which is effective against cancer as a potential drug (Hasima 
and Aggarwal, 2012). In addition with all these therapeutic effects curcumin has 
beneficial activity in Alzheimer’s disease as it is the compound which has anti-
amyloidogenic property (Ono et al., 2004). Alzheimer’s disease is one of the 
growing disease worldwide in recent days and patients with it are increasing at 
high rate i.e. more than 35 million peoples are affected worldwide with 
Alzheimer’s. The beta-amyloid (Aβ) peptide is one of the major marker of 
Alzheimer's disease which aggregates in the brain to form amyloid plaques 
(Selkoe, 2001). The Aβ peptide is responsible for the neurotoxicity by affecting 
membrane receptors and intracellular signalling (Behl and Moosmann, 2002). 
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Figure 1.3: Cancer targets with FDA approved drugs 
 Curcumin has therapeutic action against all those cancer targets, against 
which FDA has approved drugs (Hasima and Aggarwal, 2012) 
 
1.3 Outline of thesis 
This thesis investigates the characteristics of galaxolide as a novel efflux 
inhibitor molecule. Galaxolide is a musk compound, widely used in the personal 
care products to add musk smell. Galaxolide is used as novel P-glycoprotein 
(P-gp) inhibitor throughout the study and administered in combination with drug 
molecules. The approach is to enhance the drug therapy to the cells which 
shows multidrug resistance, for example cancer cells and to pass the drug 
through biological membranes which expresses efflux proteins like P-gp and 
other proteins from efflux transporter protein family. The chapter-1 of thesis 
introduces the drug delivery approaches through intestinal barrier and blood-
brain barrier (BBB) and then followed by the chapter-2 which describes 
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background, and focuses on brief introduction to the cancer physiology, 
Alzheimer’s disease, structure of blood-brain barrier and in vitro models of 
blood-brain barrier. Chapter-3 describes aims and objectives of the study. 
Chapter-4 describes materials and methods used for this study. Chapter-5 
focuses on the galaxolide toxicity on cells, P-gp expression and inhibition 
studies, while chapter-6 explains the results for development of HPLC methods 
and the permeability study of curcumin and effect of galaxolide on curcumin 
permeation. Chapter-7 explains the results and discussions for the histology 
studies and trans-epithelial electrical resistance (TEER). Also the chapter 
explains the effect of matrigel on histology of membranes. Finally, chapter-8 
focusses on conclusions and future works and chapter-9 bibliography. 
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2 : Background 
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This chapter briefly introduces cancer disease, along with its hallmarks and also 
focuses on the Alzheimer’s disease. The BBB and efflux system present within 
is the major obstacle during the treatment of brain cancer and Alzheimer’s. This 
chapter later describes the structure of BBB and P-glycoprotein (P-gp). The P-
gp is one of the key proteins present in BBB and responsible for the drug efflux 
from the brain to blood stream. 
2.1 Cancer 
Cancer is a condition where cells in a specific part of the body grow and 
reproduce uncontrollably. Unlike other diseases, cancer is not a result of single 
gene defect, so it is not a single disease; it is a group of number of neoplastic 
diseases, which is result of the misbehaviour of multiple cell signalling pathways 
(Vogelstein and Kinzler, 2004). Cancer is most harmful disease and is one of 
the most leading cause of mortality in all over the world (Kong et al., 2000). 
Now a days there are many advances in oncology; however, as per the World 
Health Organization within next two decades the chances of cancer incidence 
will be double than today. 
Cancer is a disease of cell growth and division, where cells continue to grow 
and divide in an uncontrolled and indefinite manner. Normal cells have a wide 
number of internal defence mechanisms against becoming a cancerous cell, 
and so many changes need to occur before cell start to grow uncontrollably to 
form cancer. Douglas Hanahan and Robert Weinberg have been mentioned the 
six hallmarks of cancer which include sustaining proliferative signalling, evading 
growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis and activating invasion and metastasis (Hanahan and 
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Weinberg, 2000) later two more hallmarks mentioned by them as the result of 
conceptual progress in last few years, which are reprogramming of energy 
metabolism and evading immune destruction. The following Figure 2.1 shows 
the total 10 established hallmarks of cancer including six previous and two new 
emerging hallmarks with two enabling factors: inflammation and genomic 
instability (Hanahan and Weinberg, 2011).These hallmarks can provide useful 
framework of concept to understand the complex cancer biology. 
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2.1.1 Hallmarks of cancer 
The earlier six hallmarks of cancer proposed by Hanahan and Weinberg are 
sustaining proliferative signaling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis and activating 
invasion and metastasis.  
 
Figure 2.1: Hallmarks of Cancer 
 The figure describes the total 10 hallmarks of cancer. Out of which 
six hallmarks are originally proposed in 2000 which includes 
sustaining proliferative signalling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing 
angiogenesis and activating invasion and metastasis; and recently 
two additional hallmarks are proposed; known as emerging 
hallmarks; which are reprogramming of energy metabolism and 
evading immune destruction; along with two enabling factors: 
inflammation and genetic instability (Hanahan and Weinberg, 2011) 
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2.1.1.1 Sustaining Proliferative Signalling 
Growth signalling in normal cells is a highly regulated process wherein 
proliferative signals are activated whenever necessary and deactivated when 
no longer necessary; this tight regulation ensures cell homeostasis. However, 
in cancer cells this regulation is compromised. As a disease of uncontrolled cell 
division, cells must acquire the ability to continually grow in order to become 
cancerous. Cancer cells constitutively activate signalling pathways to become 
self-sufficient in providing their own growth signals, so that they are no longer 
dependent on external signals to prompt them to progress through the cell 
cycle. Cancers also become resistant to anti-growth signals, meaning they can 
ignore normal signalling that limits the growth of cells to prevent abnormal 
division. This ability to sustain chronic proliferation is one of the fundamental 
trait of cancer cells (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 
2011).There are several alternative ways through which cancer cells can 
sustain proliferative signalling which includes production of growth factor 
ligands by themselves so they can respond with expression of cognate 
receptors which then leads to autocrine proliferative stimulation. On the other 
hand cancer cells have ability to pass signals to stimulate normal cells which 
are present within the tumour associated stroma to reciprocate various growth 
factors to cancer cells (Bhowmick et al., 2004; Cheng et al., 2008). Along with 
these ways cancer cell can use other phenomenon as well to maintain its 
proliferative signalling like increasing the number of receptors on the cell 
surface, structurally altering receptors to facilitate cancer cell signalling, and 
activating proteins in the downstream signalling pathway (Hanahan and 
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Weinberg, 2011).Recent studies also highlight the ability of cancer cells to 
disrupt negative feedback loops that constitute a safety mechanism to dampen 
a signalling pathway whenever a mitogenic signal is hyper-activated. One key 
example of this is the RAS oncoprotein. Oncogenic activity of RAS is not the 
result of overactive RAS signalling but rather the disruption of normal negative 
feedback mechanisms operated by the oncogenic GTPase (Bardeesy and 
Sharpless, 2006). Other examples of this process include loss-of-function 
mutations in phosphatase and tensin homolog (PTEN), which amplify 
phosphatidylinositol 3-kinase (PI3K) signalling(Jiang and Liu, 2009; Yuan and 
Cantley, 2008).These are several ways through which cancer cells can sustain 
its proliferative signalling property. 
 
 
Figure 2.2: RAS Signalling Pathway 
Tumour cells disrupt negative feedback loops in the oncogenic RAS 
signaling pathway, leading to sustained proliferative signaling in 
tumour cells (Bardeesy and Sharpless, 2006) 
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2.1.1.2 Evading Growth Suppressors 
Cell proliferation in normal cells is a tightly controlled process wherein the pro- 
and anti-proliferation signals coordinate their activities at the cell cycle level. 
Particularly, the G1phase of the cell cycle is a vital checkpoint wherein the 
antigrowth signals exert their influence to block cell proliferation (Ringshausen 
et al., 2006) 
 
Figure 2.3:RB and p53 Regulate Cell Cycle Checkpoint Controls 
Rb and p53 are 2 common tumor suppressors that are inactivated in tumor 
cells, leading to uncontrolled growth and proliferation (Sherr, 2004) 
 
The two tumour suppressors most commonly dysregulated in cancer cells are 
retinoblastoma protein (Rb) and p53 and as a result of which cancer cell keeps 
proliferating without limits. In normal tissue, these proteins are part of a large 
network that controls the cell cycle. Rb actively inhibits cell passage through 
the restriction point in the G1 cell cycle phase, while cancer cells with mutated 
Rb remove this gatekeeper and allow for ongoing cell proliferation. The p53 
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functions as a central regulator of apoptosis because it arrests the cell cycle in 
cells with DNA damage. Dysregulation of p53 allows for cell cycle progression 
despite DNA damage and cellular stresses.(Hanahan and Weinberg, 2011; 
Ringshausen et al., 2006).  
2.1.1.3 Resisting Cell Death  
In case of aberrant and potentially cancerous growth signalling, normal cells 
activate programmed cell death called apoptosis. Apoptosis also activated in 
the situations like DNA damage and other cellular stresses, which can also be 
features of cancerous cells, and so apoptosis represents a crucial mechanism 
to avoid accumulation of damage and mutations that can culminate in cancer 
formation. Cancer cells acquire the ability to evade this induction of cell death, 
which is crucial for both maintaining tumour growth and allowing cancerous 
cells to form in the first stage of disease development. Cancer cells circumvent 
normal growth suppressors in order to continue proliferating. Apoptosis or 
programmed cell death is considered as the natural barrier for the cancer 
development (Adams and Cory, 2007). Apoptosis occurs through two pathways 
named the intrinsic and the extrinsic pathways. Intrinsic pathway or 
mitochondrial pathway is initiated by intracellular stresses, while the extrinsic or 
death-receptor pathway is initiated by engagement of cell surface receptors 
with specific ligands. Both pathways lead to the activation of proteases, 
caspases 8 and 9 respectively. These proteases then start proteolysis with the 
initiation of cascade and finally lead to the apoptosis. A cell then disassembles 
and engulfed by the neighbour cells and phagocytic cells. The intrinsic pathway 
may be important in cancer, as many of the cellular stresses encountered by 
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cancer cells are activators of the intrinsic pathway (Hanahan and Weinberg, 
2011).The intrinsic pathway is tightly regulated by a group of related proteins 
called the BCL-2 family which consists. The BCL-2 family of proteins are known 
as important gatekeepers to the apoptotic response. This group of structurally 
related proteins consists pro-apoptotic (Bax and Bak) and anti-apoptotic (Bcl-
xL, Bcl-w, Mcl-1, A1) members that interact with one another (Adams and Cory, 
2007; Hanahan and Weinberg, 2011). Many cancers resist the apoptotic 
pathway with dysregulation of BCL-2 family members. Cancer cells are thought 
to achieve this through two main mechanisms: by a down-regulation of pro-
apoptotic proteins, or by an increase in BCL-2 expression (Letai, 2008). 
2.1.1.4 Enabling Replicative Immortality 
The cells growing in a culture generally have a finite potential of replication. 
Such cells after particular number of doublings, stop their growth and this stage 
is termed as senescence. This senescence can be reversed by disabling the 
tumour suppressor proteins like p53 and pRb, and cells are allowed to grow 
further for multiple generations until they reach to second phase called crisis. 
This stage is characterised by large number of cell deaths, karyotypic disarray 
which is associated with end-to-end fusion of chromosomes and occasionally 
emergence of variant cells, which has ability to multiply limitlessly, and the trait 
is termed as immortalization (Wright et al., 1989).Recently molecular cancer 
research has uncovered some additional functions of telomerase which are 
independent of telomere normal functions and may responsible for the 
tumour growth. These additional functions are Enhancement of cell proliferation 
and/or resistance to apoptosis (Kang et al., 2004), DNA damage repair 
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(Masutomi et al., 2005), RNA-dependent RNA polymerase function (Maida et 
al., 2009) and Association with chromatin (Masutomi et al., 2005; Park et al., 
2009). 
 
Figure 2.4: Enabling replicative immortality 
A shortening of telomere length activates replicative 
senescence in normal cells; however, tumour cells overcome 
the finite replicative ability by overexpressing telomerase, an 
enzyme that maintains telomere length (Artandi and DePinho, 
2010) 
 
2.1.1.5 Inducing Angiogenesis 
Like normal tissue, a tumour mass requires a blood supply. For a tumour to be 
able to grow it must induce the creation of its own blood supply. This process 
by which the host’s normal blood supply is extended and grows into the tumour 
is called angiogenesis. In tumour cells, the process of angiogenesis, or the 
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formation of new blood vessels, is important for sustained tumour growth and 
metastasis. Tumour angiogenesis is a multistep process and involves signalling 
input from several pro-angiogenic growth factors (Bergers and Benjamin, 2003; 
Hicklin and Ellis, 2005).The tumour vasculature induction; the moment at which 
a tumour begins to overexpress pro-angiogenic factors like vascular endothelial 
growth factor-A (VEGF-A), is known as the “angiogenic switch (Bergers and 
Benjamin, 2003; Hanahan and Weinberg, 2011). Angiogenesis results in the 
delivery of oxygen and nutrients, and production of growth factors that benefit 
tumour cells which finally leads to the tumour expansion and local invasion. 
Recent studies also revealed that the two additional components have 
important roles in tumour neovasculature. First is pericytes, which are 
supporting cells associated in normal tissue vasculature. These pericytes, in 
recent studies have found that they are important for the tumour angiogenesis 
(Raza et al., 2010). Second component is bone marrow; the research also 
indicates that bone marrow derived cells may help to initiate the angiogenic 
switch (Hanahan and Weinberg, 2011). 
2.1.1.6 Activating Invasion and Metastasis 
The mechanism of invasion and metastasis is not fully understood and it 
remained an unsolved mystery till date. Tissue invasion and metastasis are 
integral components in how tumour cells escape from the primary site and 
spreads into distant organs. In general, process of invasion and metastasis 
involves changes in the cell-cell/matrix attachment by alteration in gene 
expressions encoded for corresponding proteins like E-cadherin. The 
progression of invasion and metastasis is inversely proportional to E-cadherin 
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expression (Hanahan and Weinberg, 2011).Invasion and metastasis is 
basically a complex process. This process of invasion and metastasis has 
several steps like Local tissue invasion, Intravasation, Transition through the 
blood and lymphatic system and Colonization of foreign tissue. This multistep 
process of invasion and metastasis is often termed as invasion-metastasis 
cascade (Fidler, 2003; Talmadge and Fidler, 2010). This cascade begins with 
the changes in the biology of cells occurred due to the ‘invasion’ which then 
followed with the ‘intravasation’ by cancer cell into the blood and lymph vessels 
located in the vicinity of cancer cells. These cells then transported through 
lymphatic and hematogenous systems to the various parts located apart and 
finally these cells were escaped from these vessels and the process is reverse 
to the intravasation and named as ‘extravasation’. After escape from the lumina 
of the vessels, these cells forms small cancerous nodules termed as ‘micro-
metastasis’, and finally these micrometastatic lesions grown into the 
macroscopic tumours and this step is known as the ‘colonization’ (Hanahan and 
Weinberg, 2011). 
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2.1.2 Emerging hallmarks and enabling characteristics 
Apart from these earlier six hallmarks, the recent research studies reveals two 
new emerging hallmarks; reprogramming of energy metabolism and evading 
immune destruction; which are responsible for the progression of cancer 
pathogenesis in almost all types of cancer. Along with new emerging hallmarks, 
two enabling characteristics of cancer are also revealed; inflammation and 
genomic instability; which were described below. 
 
 
Figure 2.5: Emerging hallmarks and enabling characters 
 Image present two new hallmarks of cancer – reprogramming of energy 
metabolism and evasion of immune destruction – that have emerged as 
critical capabilities of cancer cells and two “enabling characteristics” - 
properties of neoplastic cells that facilitate acquisition of hallmark 
capabilities - that include genome instability/mutation and tumour-
promoting inflammation (Hanahan and Weinberg, 2011) 
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2.1.2.1 Emerging Hallmark-1: Reprogramming of energy metabolism 
Reprogramming energy metabolism has been identified as an emerging 
hallmark of cancer. To maintain uncontrolled cell division and proliferation, 
cancer cells needs more energy and to get that required energy cancer cells 
make alterations in energy production programme as per their need. These 
alterations were done in various means like, reprogramming their glucose 
metabolism, upregulating glucose transporters such as glucose transporter 1 
(GLUT1) and Depending on alternate metabolic pathways. Normal cells, in 
aerobic conditions metabolise glucose first to the pyruvate and this process 
takes place in cytosol, and then formed pyruvate transported to the 
mitochondria to follow TCA cycle to generate energy, while in anaerobic 
conditions cells prefer glycolysis for energy production. But cancer cells behave 
in strange way to produce their energy, as they re-programme their glucose 
metabolism for energy production and remains depend on glycolysis even in 
presence of oxygen. This kind of glycolysis is termed as ‘aerobic glycolysis. 
This reprogramming of energy metabolism by cancer cells is low efficient 
process as compared to the mitochondrial phosphorylation, and is supported 
by the glycolysis. Cancer cells does this by increasing the glucose intake to the 
cancer cells and the glucose intake is increased by upregulation of glucose 
transporter 1 (GLUT 1). Cancer cells splits available glucose to lactate 
irrespective of the availability of oxygen (the Warburg effect), and diverts 
glucose metabolites to useful anabolic processes that accelerate cell 
proliferation (DeBerardinis et al., 2008; Hanahan and Weinberg, 2011; Hsu and 
Sabatini, 2008; Jones and Thompson, 2009; Marie and Shinjo, 2011). 
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Figure 2.6: The Warburg effect 
Cancer cells convert available glucose to lactate irrespective of the 
availability of oxygen (the Warburg effect), thereby diverting glucose 
metabolites to useful anabolic processes that accelerate cell proliferation 
(Marie and Shinjo, 2011) 
 
2.1.2.2 Emerging Hallmark-2: Evading Immune Destruction 
Cells have immune system to protect themselves from almost all types of 
external harms. Immune surveillance is an essential cellular process that 
actively prevents tumour formation in the human body. Preclinical studies have 
suggested that an active immune system continuously recognizes and 
eliminates the vast majority of cancer cells before they establish themselves 
and form a tumour mass. The process is known as immunoediting. However, 
cancer immunoediting includes 3 key phases: elimination, equilibrium, 
and escape. 
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The immune system successfully recognizes and eliminates cancer cells, a 
process often described as the elimination phase. During the elimination phase, 
some weakly immunogenic cells remain un-eliminated and eventually turns into 
solid tumours and such tumour cells, remained un-eliminated by the immune 
system proceed to the equilibrium phase, in which the immune system controls 
cancer cell growth but does not completely eliminate the transformed cells. 
Tumour cells not susceptible to immune destruction enters into the escape 
 
Figure 2.7: Cancer Immunoediting: Elimination, Equilibrium and 
Escape 
Cancer immunoediting, an emerging hallmark, comprises 3 key phases 
elimination, equilibrium, and escape. Cancer cells that successfully 
navigate these phases acquire the ability to evade immune destruction 
(Prendergast, 2008) 
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phase. In this phase, the “escaped” tumour clones; cells which are not 
effectively detected and destroyed by the immune system; continue to divide 
and grow (Hanahan and Weinberg, 2011; Prendergast, 2008; Teng et al., 
2008). 
2.1.2.3 Enabling characteristics-1: Genome Instability and Mutation 
All above mentioned hallmarks are acquired by the tumour cells and are 
somewhere interlinked and depended on the genome alterations. Multiple 
alterations in the genomes of cancer cells serve as the platform for many 
oncogenic processes. Cancer cells take advantage of increased rates of 
mutations in order to accumulate several mutations needed to boost 
tumorigenesis. Cancer cells does this with several ways including; increased 
sensitivity to mutagenic agents, breakdown in one or more of the cell’s DNA 
repair mechanisms mediated by genes such as p53 or breast cancer type 1 
susceptibility protein (BRCA1) and/or a combination of these factors. 
Accumulation of these mutations is accelerated by altering DNA-maintenance 
machinery-termed as “caretaker” of genomes (Kinzler and Vogelstein, 1997). 
These caretakers were involved in the processes like detecting DNA damage 
and activating repair machinery, directly repairing damaged DNA, inactivating 
or intercepting mutagenic molecules. Tumour cells can inactivate or suppress 
these caretaker genes and increase the rate of mutations and tumorigenesis. 
Studies on cancer cell genome also explores that that the genetic instability 
increases tumour progression (Hanahan and Weinberg, 2011). 
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2.1.2.4 Enabling characteristics-2: Tumour promoting inflammation 
The tumour microenvironment is densely infiltrated by innate and adaptive 
immune system cells that enable tumours to mimic inflammatory conditions 
seen in normal tissues (Dvorak, 1986). Current studies in molecular cancer 
research reveals that this tumour-associated inflammation might have role in 
tumour growth. Studies also indicates that tumour-associated inflammation 
may play role in tumour growth by supplying the tumour microenvironment with 
various components like growth factors, survival factors, pro-angiogenic 
factors, extracellular matrix (ECM)–modifying enzymes that promote 
angiogenesis, invasion, and metastasis and inductive signals that activate 
epithelial-mesenchymal transition (EMT) and other hallmark-facilitating 
mechanisms (DeNardo et al., 2010; Grivennikov et al., 2010; Qian and Pollard, 
2010). Above all, inflammation is seen in early stages of neoplastic disease. 
Early inflammation can release chemicals into the tumour microenvironment 
and may lead to genetic mutations that enable and accelerate the formation of 
a tumour (Hanahan and Weinberg, 2011). 
Cancer is caused by many more dysregulated genes which occur over a long 
period before emerging its symptoms. So targeting any single gene is not of 
any use while developing drug against cancer. However some targeted drugs 
and chemotherapies are developed which are effective against these gene 
products or pathways. But there are also some limitations like drug resistance 
and ineffective targeting which effects on efficacy of these therapies (Vogelstein 
and Kinzler, 2004). So an approach of combination chemotherapy should be 
the next paradigm against cancer. It includes targeting multiple gene targets by 
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the combination of several drugs or the single drug which can modulate multiple 
targets (Aschele et al., 2002). For the treatment of various types of cancer U.S. 
Food and Drug Administration (FDA) have been approved many different drugs 
which can able to modulate multiple targets. However these drugs have higher 
costs and number of undesirable side effects and even though they are not 
effective enough (Hasima and Aggarwal, 2012). The major problem associated 
with failure of chemotherapy in cancer is MDR caused by the membrane 
transporter P-gp molecules. In humans P-gp is encoded by the MDR1 genes 
and is expressed at high level in cancer cells. So MDR is the most accepted 
reason responsible for the chemo resistance in cancer treatment (El-Readi et 
al., 2010; Huang et al., 2012; Sui et al., 2012; Thomas and Coley, 2003). 
 Before the modern era of chemotherapy the natural sources of drugs were 
used for the treatment and prevention of cancer for the centuries. The drugs 
derived from natural sources are not fully understood for their mechanism of 
action against particular target, however according to some estimates about 
80% of today’s anticancer drugs have roots from natural products (Hasima and 
Aggarwal, 2012). 
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2.2 Alzheimer’s disease 
Alzheimer’s disease (AD) is a chronic neurodegenerative disease which leads 
to progressive loss of memory and other cognitive functions. Alzheimer’s 
accounts for 60-70% of cases of dementia. Alzheimer’s is a progressive 
condition that means the symptoms develop gradually and becomes more 
severe over the time. Alzheimer’s disease is one of the growing diseases 
worldwide and in recent days number of patients diagnosed is increasing due 
to increased aging population. Alzheimer’s has a higher risk in older age, as 
severity of symptoms doubles every 5 years after age of 65 (Hirtz et al., 2007).  
The most common symptoms of Alzheimer’s are difficulty in remembering 
recent events i.e short term memory loss, problems with language, 
disorientation, mood swing loss of motivation etc. The symptoms lead to death 
after 3 to 9 years of diagnosis of Alzheimer’s.  
The beta-amyloid (Aβ) peptide is one of the major marker of Alzheimer's 
disease which aggregates in the brain to form amyloid plaques (Figure 2.8). 
The Aβ peptide is responsible for the neurotoxicity by affecting membrane 
receptors and intracellular signalling (Behl and Moosmann, 2002; Selkoe, 
2001). Aβ peptides are the natural metabolites consists 36-43 amino acids in 
their structure. These peptides spontaneously aggregate and form a deposits 
of amyloid plaques in brain parenchyma and cerebral blood vessels. These 
plaques are termed as congophilic angiopathy or cerebral amyloid angiopathy 
(CAA). The Aβ peptide self-aggregates in various physiological structures; 
some aggregates as small oligomers which consists 2 to 6 peptides, while some 
forms fibril structure and arrange themselves in β-pleated sheets. The β-pleated 
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sheets are advance form of amyloid plaques and are insoluble fibres. Besides 
this, other symptoms are also occurred in Alzheimer’s like loss of neurons and 
white matter, inflammation and oxidative damage (Anand et al., 2014; Querfurth 
and LaFerla, 2010). 
 
Figure 2.8: Plaques and Tangles in Alzheimer's 
Image showing the pathological characteristics of Alzheimer's disease: 
beta-amyloid (Aβ) peptide; which aggregates in the brain to form amyloid 
plaques and Neurofibrillary tangles  (Image courtesy : 
http://www.brightfocus.org/alzheimers) 
 
Neurofibrillary tangles (Figure 2.8) are another major marker of Alzheimer’s. 
These tangles are occurred in Alzheimer’s disease and other 
neurodegenerative diseases. These are filamentous inclusions present in the 
pyramidal neurons and termed as the tauopathies (Lee et al., 2001).  The 
tangles serve as the pathologic markers of the severity of disease, as the high 
number of tangles represents the more severe the disease. These tangles are 
formed by the hyper-phosphorylated ‘Tau’ proteins aggregates (Figure 2.9). 
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‘Tau’ proteins are present in high numbers in the neurons and are less common 
in other parts of the body. These proteins have a role to stabilize microtubules. 
The ‘Tau’ protein, due to several mutations in genes goes under hyper-
phosphorylation. These hyper-phosphorylated proteins lack the affinity towards 
the microtubules and self-associate to form double helix structures (Iqbal et al., 
2005). Like Aβ peptide, aggregated tangles of ‘Tau’ proteins are also cytotoxic 
and can impair cognition (Khlistunova et al., 2006; Querfurth and LaFerla, 2010; 
Santacruz et al., 2005). 
 
Figure 2.9: Tau Protein Tangles 
 In Alzheimer’s disease, changes in tau protein lead to the disintegration of 
microtubules in brain cells (Rodgers, Anne B. 2002).  
 
FDA currently approved the drugs for the treatment of the Alzheimer’s diseases 
which includes acetylcholine esterase inhibitors. The drug inhibits the enzyme 
acetylcholine esterase and increases the level of neurotransmitter 
acetylcholine, which seems to have depleted in the Alzheimer’s brain. Besides 
these, there are several other targeting sites for the treatment of Alzheimer’s 
disease which includes the targeting of Aβ peptide targeting of ‘tau’ proteins, 
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as these are the major biomarkers of Alzheimer’s and causes the cellular 
deaths in brain which results in the neurotoxicity. Along with these clinical 
targets, several other targets are also taken into consideration to treat 
Alzheimer’s like targeting ApoE4, other approaches like application of 
antioxidants, anti-inflammatory drugs or mitochondrial protectors, because 
there are several evidences available in Alzheimer’s like oxidative damage, 
inflammation and mitochondrial impairment (Cummings, 2004; Huang and 
Mucke, 2012). 
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2.3 Blood-Brain Barrier (BBB) 
The Brain is separated from the blood circulation by the membranous barrier; 
this physiological barrier is known as the Blood-brain barrier (BBB). The BBB 
plays the dual function as barrier and carrier. The barrier can protect brain from 
the harmful toxic substances which can be present in blood circulation by 
preventing their entry to the brain and the carrier function allows the useful 
substances like nutrients to enter inside the brain and removal of metabolites 
(Sloan et al., 2012; Wilhelm et al., 2011). The BBB is the major obstacle in drug 
development as it provides poor permeability for drug candidates by preventing 
them to penetrate into the brain and it is the main problem faced by 
pharmaceutical industries (Terasaki et al., 2003).  
 
Figure 2.10:The three cell model of blood-brain barrier 
The cells; endothelial cell, pericyte and astrocyte end foot; that are involved in 
structure of blood-brain barrier (Sloan et al., 2012) 
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2.3.1 Structure of Blood Brain Barrier 
The BBB is mainly composed of endothelial cells, astrocytes and pericytes. 
Other cell components like neurons and microglia are also important elements 
in the function of BBB (Hawkins and Davis, 2005). The Figure 2.10 shows the 
three cell model of the brain vasculature. The endothelial cell located at the 
centre and regulates the BBB permeability. It shares close relationship with 
other two cells; pericyte and astrocyte end foot. Pericyte shares the common 
basement membrane with the endothelial cell. The pericyte is phagocytic cell 
and there is approximately one pericyte for every three endothelial cells. About 
99% of the brain surface of the capillary basement membrane is covered by the 
astrocyte end foots (Pardridge, 1999). 
Brain microvessel endothelial cells (BMVEC) are the major components of the 
BBB. These endothelial cells are tightly connected to each other, and this 
junction is known as Tight junction (TJ) (Liu et al., 2012a).  The tight junctions 
are made up of with combination of transmembrane proteins and cytoplasmic 
accessory proteins. Specialized transmembrane proteins like claudin, 
occluding, cadherins and junctional adhesion molecules (JAM) which hold 
endothelial cells together. Cytoplasmic accessory proteins like ZO-1, ZO-2, ZO-
3, cingulin and others form a bonding with actin-membrane protein, which 
provides the primary cytoskeleton to endothelial cells for their structural and 
functional integrity (Ballabh et al., 2004; Liu et al., 2012a).  Measurement of trans 
endothelial electrical resistance (TEER) can be used for the evaluation of the 
tightness of these junctions (Sloan et al., 2012). 
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Figure 2.11: Schematic representation of proteins involved in tight 
junction (TJ) formation in blood-brain barrier 
Interaction of proteins associated with the tight junction in blood-brain 
barrier. Occludin, claudin, junctional adhesion molecules and cadherins are 
transmembrane proteins while others; ZOs, 7H6; are cytoplasmic proteins. 
Actin is membrane protein which forms a primary cytoskeleton of cells 
(Huber et al., 2001) 
 
The Figure 2.11 shows an interaction of proteins associated with the tight 
junction in BBB. Occludin, claudin, junctional adhesion molecules and 
cadherins are transmembrane proteins while others are cytoplasmic proteins. 
Actin is membrane protein which forms a primary cytoskeleton of cells. 
2.3.2 Tight Junction (TJ) Proteins 
Tight junctions are complex combination of the transmembrane proteins and 
cytoplasmic accessory proteins. These proteins links to actin-based 
cytoskeleton to form seal between two cells. These tight junctions are mainly 
formed with three integral proteins; claudin, occludin and junctional adhesion 
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molecules (JAM) (Gonzalez-Mariscal et al., 2003; Huber et al., 2001; Liu et al., 
2012b) 
2.3.2.1 Occludin 
Amongst all these transmembrane proteins, Occludin is the first identified 
protein in the TJ having molecular weight about 60-65kDa. Occludin has both 
the terminus; N-terminus and C-terminus located intracellular and it consists of 
four transmembrane domains, two extracellular domains and three cytoplasmic 
domains (Feldman et al., 2005). Two occluding molecules from adjacent cells 
form a dimer by binding with each other. Occludin shows a unique characteristic 
compared to other transmembrane proteins that it binds 150 amino acid 
sequence in the C-terminus to F-actin. The C-terminus of occludin is also binds 
to the cytoskeleton localized in cell membrane through the cytoplasmic proteins 
like zona occludens (ZOs). The GK domain of ZOs involved in this binding with 
C-terminus of occludin (Gonzalez-Mariscal et al., 2003).  
2.3.2.2 Claudins 
Claudins are a protein family having 24 different proteins with molecular weight 
ranging from about 20 to 24 kDa. Like occludins claudins also has four 
transmembrane domain, two extracellular domains and a short intracellular 
carboxyl chain (Gonzalez-Mariscal et al., 2003). Similar to occludins; claudins 
extracellular domains form homotypical dimmer with adjacent endothelial cells 
and forms backbone of TJ (Huber et al., 2001). Claudins binds to the PDZ 
domain of ZOs with the help of C-terminus of their intracellular domains. 
However claudins and occludin has many similar characters, claudins are not 
homologous to occludin in sequence (Liu et al., 2012a). There are various 
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claudins found in brain endothelial cells like Claudin-1, claudin-2, claudin-3, 
claudin-5, claudin-11 and claudin-12 (Huber et al., 2001; Romanitan et al., 
2010; Sandoval and Witt, 2008). Claudin-5 is considered as hallmark of BBB, 
and in CNS angiogenesis it plays an important role in earlier stages (Tam and 
Watts, 2010). Claudin-5 is expressed in almost all segments of brain endothelial 
cells, also in the blood vessels of kidney and lungs (Liu et al., 2012a). 
2.3.2.3 Junctional Adhesion Molecules (JAM) 
The junctional adhesion molecules (JAM) are the recently identified protein 
amongst transmembrane proteins involved in the tight junctions. JAM is 
glycosylated protein with molecular weight 45kDa, which found in epithelial cells 
and endothelial cells. JAM has three different structural domains which consists 
extracellular region having 215 amino acid sequence with two variable type Ig 
domains, one transmembrane domain and a single intracellular tail having 45 
amino acids in it; the tail links with the type-II PDZ binding motif (Gonzalez-
Mariscal et al., 2003; Martin-Padura et al., 1998). JAM belongs to the 
immunoglobulin superfamily which has the single transmembrane domain with 
two immunoglobulin like loops and these loops are formed by disulfide bonds 
(Ballabh et al., 2004). Besides tight junctions, JAM shows several other cellular 
functions like leukocyte transmigration, platelet activation, angiogenesis and 
virus binding (Bradfield et al., 2007; Mandell and Parkos, 2005). 
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Figure 2.12:Schematic representation of Structural arrangement of 
transmembrane proteins present in TJ 
a) Occludin b) Claudin-1 and c) JAM   
a )Occludin has four transmembrane domains with two extracellular 
loops. b) Claudin-1 also has four transmembrane domains, but shows no 
sequence similarity to occludin. Note that the cytoplasmic tail of claudin-1 
is shorter than that of occludin. c) Junctional adhesion molecule (JAM) has 
a single transmembrane domain, and its extracellular portion bears two 
immunoglobulin-like loops that are formed by disulphide bonds (Tsukita et 
al., 2001). 
 
2.3.2.4 Cytoplasmic Accessory Proteins 
Cytoplasmic accessory proteins including Zonula Occludins proteins (ZO-1, 
ZO-2 and ZO-3), Cingulin, 7H6 and several others are involved in the formation 
of TJ. The ZOs are belongs to the membrane-associated guanylate kinase-like 
proteins (MAGUKs) family having sequence similarity with each other. The 
molecular weights of ZOs are like ZO-1 220kDa, ZO-2 160kDa and ZO-3 
130kDa. The ZOs contains three PDZ domains includes PDZ1, PDZ2 and 
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PDZ3, one SH3 domain and one guanyl kinase-like (GUK) domain. The 
domains are act as protein binding molecules and help to organize proteins at 
the plasma membrane (Ballabh et al., 2004). PDZ-1 domain of ZOs directly 
binds to claudins through COOH-terminal (Itoh et al., 1999) and occludins are 
linked through GUK domain of ZO-1 (Mitic et al., 2000) while JAM binds directly 
to ZO-1 and other PDZ containing proteins (Ebnet et al., 2000). Actin, the 
primary skeleton protein is also binds to the ZO-1 and ZO-2 through their 
COOH-terminal forming a complex cross-links transmembrane elements which 
gives structural support to the endothelial cells (Haskins et al., 1998). 
2.3.3 Blood Brain Barrier Transport Mechanism  
The endothelial cells present in BBB are very different from the one which are 
present in peripheral blood vessels. As described earlier the endothelial cells 
present in BBB contains TJ which allow the entry to very few small hydrophilic 
molecules such as ethanol or mannitol and restrict large number of compounds 
to enter inside the brain. The membrane has highly negative charge, so 
generally anionic compounds are removed from the site (Abbott et al., 2008a; 
Sloan et al., 2012). 
However there are number of restrictions to enter the BBB, most molecules 
could transported through the BBB by using one of the mechanisms described 
below (Abbott et al., 2008b). 
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Figure 2.13:Blood brain barrier transport mechanism  
Schematic representation of blood-brain transport mechanisms available for 
the molecules to cross the barrier. Small, lipid-soluble substrates are able to 
diffuse across the membrane passively (transcellular passive diffusion) but 
active efflux system may remove back some of them into the circulation 
(carrier mediated efflux). Small hydrophilic substances may pass through the 
tight junctions either by experimental manipulation or by opening paracellular 
pathways (tight junction modulation). Small endogenous molecules, including 
amino acids, nucleosides, and glucose, are transported across the blood-
brain barrier by transport proteins (carrier-mediated transport). Endogenous 
large plasma proteins, including albumin, are transported across the blood-
brain barrier by adsorptive-mediated endocytosis. Larger molecules, 
including insulin and transferrin, are recognized by receptors on the luminal 
side of the endothelium and are transported across the cell for release into 
the brain parenchyma (receptor-mediated endocytosis) (Abbott et al., 2008a; 
Sloan et al., 2012). 
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2.3.3.1 Transcellular Passive Diffusion 
This transport mechanism can include the passive diffusion of small sized 
lipophilic compounds across the endothelial membrane. More the compound is 
lipophilic, greater the ability for permeation and vice versa. Acetaminophen and 
fluoxetine are the examples of the compounds which are transported by this 
mechanism (Abbott et al., 2008a; Sloan et al., 2012). 
2.3.3.2 Carrier-Mediated Transport 
Numbers of carrier transporters are used to transport the molecules across the 
BBB. Generally essential polar molecules such as amino acids, nucleoside, 
peptide, vitamin and glucose transporters are transported into the brain by this 
mechanism. Some neurotransmitters like dopamine and serotonin are unable 
to cross the barrier, so in such case precursors of them levodopa and 
tryptophan can be transported into the brain by this mechanism (Abbott et al., 
2008a; Sloan et al., 2012). 
2.3.3.3 Receptor-Mediated Endocytosis 
This is the most common method and generally used for transport of large 
molecules like peptides and proteins. The molecules are bind to the receptors 
present on membrane and then entered into the membrane by the process of 
endocytosis. Insulin, transferring, cytokines and other large peptides are the 
examples of the molecules transported by this approach (Abbott et al., 2008a; 
Sloan et al., 2012). 
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2.3.3.4 Adsorptive-Mediated Endocytosis 
The BBB is highly anionic in character so the cationic molecules are adsorbed 
to it non-specifically. Once the molecules adsorbed to the membrane they 
undergo endocytosis. This type of transport mechanism has higher capacity as 
compared to the receptor-mediated endocytosis. The example of the molecules 
transported by this type of transport mechanism includes the highly positively 
charged molecules like histones, cationized albumin, and arginine-containing 
peptides (Abbott et al., 2008a; Sloan et al., 2012). 
2.3.3.5 Transport by TJ Modulation 
Generally, TJs present in the endothelial cells at the BBB are very protective 
against transport of molecules. They restrict the entry of even highly hydrophilic 
compounds through BBB via paracellular diffusion. However, if the TJs are 
disrupted, the molecules which would be excluded normally can make the entry 
across the BBB. Such changes in the resistance of the TJs are usually occurred 
by the disease or the drug administration, which can disrupt the protein which 
are involved in the TJ formation. Experimentally, the administration of 
hyperosmolar solutions like 25% mannitol can disrupt the TJs. The cells 
undergo shrinking which may open the TJs due to the high ionic strength when 
such solution is applied. For brain tumour treatment, this method is employed 
clinically. TJs can also modified by the leukocytes and immune cells to cross 
the BBB via transcellular mechanism. In case of ischemia or brain trauma the 
TJs can also change their properties. 
Along with all these transport mechanisms present at the BBB which transports 
the substances from blood to brain, there is efflux mechanism located which 
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removes the substances back in to the blood from the endothelial cells before 
they reach to the brain. In case of attempting drug delivery to the brain, these 
carrier-mediated efflux mechanisms provide a great challenge to the scientists 
working in pharmaceutical area. The carrier-mediated efflux system at the BBB 
includes the multidrug resistance proteins such as P-glycoprotein (P-gp) 
(Abbott et al., 2008a; Sloan et al., 2012). 
 When it comes to drug permeability, efflux transporter proteins play an 
important role in permeation of drugs through the blood-brain barrier. This is 
because large number of drug molecules are substrates of the ABC 
transporters (efflux transporters) and because of that drug molecules get 
interacted with these efflux transporters and cannot reach to their targets in 
required concentrations (Wilhelm et al., 2011).    
2.4 In vitro Blood-Brain Barrier Models 
As seen in section (2.3.1), blood-brain barrier is a very tight membrane which 
allows only specific components to pass through it depending on their different 
biochemical characteristics. This property of blood-brain barrier is very 
important and can be taken into consideration during the drug delivery to the 
CNS through blood-brain barrier. Besides the drug delivery, some scientific and 
industrial interests towards the blood-brain barrier with regards to its physiology 
and pathology results in the development of number of in vitro blood-brain 
barrier. Some widely used in vitro BBB models are described below. Cell culture 
models are widely used as primary screening tools for the BBB drug 
permeability (Sloan et al., 2012). 
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To mimic in vitro blood-brain barrier, there are few basic characteristics and 
requirements and any in vitro model need to achieve maximum of these 
characteristics and requirements to get acceptable in vitro blood-brain barrier 
model. These characteristics and requirements are described in following Table 
2.1 (Reichel et al., 2003) 
Table 2.1: Basic Characteristics and Requirements in vitro BBB model 
 (Reichel et al., 2003) 
 
Characteristics 
 
Specific requirement for in vitro blood-
brain barrier 
 
Restricted paracellular 
Pathway 
 
 
 
 
 
Brain capillary endothelial cell 
characteristics 
 
Functional expression of BBB-
specific transport mechanisms 
 
 
In vivo like modulation 
 
 
Practicality 
 
TEER ≥ 2KΩ cm2(despite this ideal TEER 
value, TEER value minimum of more than 
150-200 Ω cm2 accepted for permeability 
studies through in vitro BBB) 
Low paracellular permeability 
 
Morphology, endothelial cell and BBB 
markers, enzyme expression 
 
Nutrient transfer (glucose and L-amino acid 
), efflux pumps (P-gp, BCRP), receptors 
(insulin), low leukocyte adherence 
 
Permeability altered by bradykinin, 
interleukins, glial factors, dexamethasone 
 
Availability, convenience, predictability and 
reproducibility 
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2.4.1 In vitro Blood-brain barrier models from cells of non-cerebral origin 
Number of publications are available which shows that the cells from non-
cerebral origin have been used as an in vitro blood-brain barrier. Cells like 
MDCK (Madin-Darby Canine Kidney) are one of the most widely used cell line 
as an in vitro model to carry out permeability studies across blood-brain barrier. 
This cell line have relatively faster growth and may form cell monolayer in 
shorter time to mimic blood-brain barrier. These cells shows similarities with TJ 
present in the brain endothelial cells and forms the intact cell membrane. 
Despite this, there are some differences in TJ proteins of MDCK cells and brain 
endothelial cells. Claudine-1 is prominent protein in MDCK cells while Claudine-
5 is major in brain endothelial cells, also brain endothelial cells lack the ZO-3 
proteins, as it does not express it (Wilhelm et al., 2011). Blood-brain barrier 
shows the presence of efflux transporter proteins in its structure. The 
transfected MDCK cells with MDR1 genes; the genes encoding for the efflux 
protein, P-glycoprotein (P-gp overexpressing MDCK cells) are widely used as 
in vitro blood-brain barrier for permeability screening (Wang et al., 2005a). The 
disadvantage over this cells is, these are from canine origin and not from the 
human. Even though the cell lines is not from human origin, the P-gp 
overexpressing MDCK cells (MDCK-MDR1) are considered as one of the best 
in vitro blood-brain barrier for the permeability studies from non-cerebral origin 
(Nicolazzo et al., 2006; Wang et al., 2005a). 
Human umbilical vein endothelial cells (HUVECs) is another cell line from non-
cerebral origin, which is used as in vitro blood-brain barrier. This cell line is 
derived from the human origin (Langford et al., 2005). In some studies. Caco-2 
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cells are also used as an in vitro blood-brain barrier for the estimation of 
permeability studies. But recent studies shown that the Caco-2 forms a poor 
blood-brain barrier model (Lundquist et al., 2002; Nicolazzo et al., 2006) 
2.4.2 In vitro Blood-brain barrier models from origin of cerebral 
endothelial cells 
Primary brain capillary endothelial cells are used as in vitro blood-brain barrier 
models. These cells provides the close resemblance with the in vivo blood-brain 
barrier phenotype (Lundquist et al., 2002). To obtain these brain capillary 
endothelial cells, sources like bovine, porcine, rat or humans are generally 
used. Bovine brain microvessel endothelial cells (BBMECs) and porcine brain 
microvessel endothelial cells (PBMECs) are most commonly used models for 
the blood-brain barrier transport studies by the researchers as a primary cell 
models (Gumbleton and Audus, 2001). These endothelial cell culture models 
have characteristics of blood-brain barrier to express efflux transporter proteins 
such as P-glycoprotein, which is one of the common hurdle during the treatment 
of anticancer drugs in brain cancers (Sloan et al., 2012).  
Other endothelial cell lines used as an in vitro blood-brain barrier is RBE4 cell 
line, which is obtained from the rat brain endothelial cells and transfected with 
the plasmid having E1A genes (Roux et al., 1994). RBE4 cell lines shows 
characteristics of blood-brain barrier like expression of P-glycoproteins, 
gamma-glutamyl transpeptidase activity and high alkaline phosphatase activity. 
The cell line is used to study signalling characteristics of brain endothelial cell 
and also used to study P-glycoprotein regulation (Wilhelm et al., 2011). 
hCMEC/D3 is another cell line and is one of the best characterised human cell 
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line used as an in vitro blood-brain barrier. The cell line shows the expression 
of junctional proteins as well as expression of efflux transporter proteins 
(Weksler et al., 2005). 
Brain endothelial cells play the central role in the formation of blood-brain 
barrier and is a major component of the barrier as well. Along with endothelial 
cells, other cells such as pericytes, glial cells and neurons have regulatory roles 
to maintain blood-brain barrier (Deli et al., 2005). Co-culture of these cells with 
endothelial cells are used to form in vitro blood-brain barrier. The co-culture of 
glial cells and endothelial cells are used to obtain in vitro blood-brain barrier. 
The endothelial cells used to co-culture are the primary cultures of rat, bovine 
or mouse origin, or sometimes cell lines are also used. Similarly, the glial cells 
obtained from the primary cells or in some cases C6 cell lines are also used. 
The blood-brain barrier obtained from co-culture of endothelial cells and glial 
cells is one of the widely accepted in vitro blood-brain barrier (Wilhelm et al., 
2011). 
Co-culture of endothelial cells with pericytes are also used to obtain in vitro 
blood-brain barrier. Pericytes remain in close contact with the endothelial cells, 
because of that they are used to get co-culture models for the in vitro blood-
brain barrier. These co-culture models shows the high trans epithelial electric 
resistance (TEER) and also they shows the expression efflux transporters. 
Other cells like neurons are also used to co-culture with endothelial cells to get 
blood-brain barrier models. To achieve blood-brain barrier properties in 
endothelial cells, either differentiating embryonic neural progenitor cells or 
mature neurons are used (Weidenfeller et al., 2007; Wilhelm et al., 2011).  
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2.5 P-Glycoprotein (P-gp) 
P-glycoprotein is a transporter protein and belongs to the ATP-binding cassette 
(ABC) superfamily which has been described as a as sensitive tissues 
protected by it from toxic substances and at same time, on the other hand in 
cancer cells it shows MDR which prevent effective chemotherapy (Sharom, 
2008). P-glycoprotein (Pgp, ABCB1) is a membrane protein plays an important 
role in the removal of toxic compounds from the cells by its efflux mechanism, 
which confers the multidrug resistance (MDR) to the cells (Loo et al., 2012). 
The ATP-binding cassette (ABC) family of transport proteins is one of the 
biggest protein families found in the living organisms (Dean and Annilo, 2005; 
Dean et al., 2001). The ABC protein family consists large number of membrane 
proteins which transports wide variety of substrates like sugars, amino acids, 
drugs, antibiotic, toxins, peptides, nucleotides, ions across the plasma 
membrane and this transport is energy driven as ABC protein binds to ATP 
molecule to carry out transport (Dean et al., 2001; Sharom, 2008). 
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2.5.1 Structure of P-Glycoprotein (Pgp) 
 
Figure 2.14: Stereo structure of P-Glycoprotein 
 (A) Front View(B) Back View 
The N- and C-terminal half of the molecule is coloured yellow and blue 
respectively. TMs 4 and 5 and TMs 10 and 11 crossover to form 
intertwined interfaces that stabilize the inward-facing conformation. 
Horizontal bars represents the approximate positioning of the lipid bilayer. 
The N- and C- termini are labelled in (A). Transmembrane (TM) domains 
and nucleotide binding domain (NBDs) are also labelled (Aller et al., 
2009a).  
 
The Figure 2.14 shows the stereo structures of Pgp from both front and back 
view. The Pgp consists of two membrane bound domains, each made up of six 
transmembrane (TM) helices and two cytoplasmic nucleotide binding (NB) 
domains. The Pgp structure has inward facing conformation and is achieved by 
the two bundles of transmembrane (TM) helices, forming the large cavity open 
to the cytoplasm. The cytoplasmic nucleotide binding domains are separated 
by ~30A0 and are involved in the binding and hydrolysis of ATP (Aller et al., 
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2009b). There are three highly conserved sequence motifs; Walker A, Walker B 
and signature C motifs; present in nucleotide binding domains (NBDs) of all 
ABC proteins which play an important role in the process of ATP binding and 
hydrolysis. Signature C motif is unique to the ABC superfamily while Walker A 
and Walker B motifs are present in most of the protein molecules. The Walker 
A and Walker B motifs of one NBD and the LSGGQ Signature C motif from the 
partner NBD subunit together form the ATP binding site. So at the dimer 
interface of NBD, two molecules of ATP are bound and the structure is known 
to be a “sandwich dimer” (Sharom, 2008). This “sandwich dimer” is able to form 
a stable structure when inactivation of ATPase activity of the protein conferred 
by mutation (Hanekop et al., 2006; Smith et al., 2002). So it seems that in the 
catalytic cycle of ABC proteins these NBD dimerization process has important 
role (Sharom, 2008). 
2.5.2 Cellular localization of P-glycoprotein (Pgp) 
Studies on human and rodents have been shown that the P-glycoprotein is 
expressed in most of the cells at the very low level but the epithelial cells of 
colon, small intestine, bile and kidney tubules, adrenal glands shows the higher 
expression of Pgp at their apical region, it means the epithelial cells which play 
role in the excretory function generally express the Pgp (Croop et al., 1989; 
Thiebaut et al., 1987). The Pgp transporter is also expressed at the endothelial 
cells of blood-brain barrier (Beaulieu et al., 1997), blood-testes barrier (Melaine 
et al., 2002), blood-mammary tissue barrier (Edwards et al., 2005) and in the 
endothelial cells of the cochlea and vestibule in the blood-inner ear barrier 
(Saito et al., 1997). So the Pgp plays an important role of protection in human 
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physiology as it protects susceptible organs like brain, testes, inner ear from 
the toxic compounds. Pgp has a broad range of substrates and is recognizes 
the compounds having smallest size 330Da up to the larger molecules with 
4000Da (Lam et al., 2001; Ramachandra et al., 1998). Most of the Pgp 
substrate molecules are hydrophobic in nature, and that is why Pgp is 
considered as “molecular hydrophobic vacuum cleaner” which removes 
substrates from the membrane and expels them out to confer MDR (Aller et al., 
2009b; Raviv et al., 1990). The Pgp has been considered as “double-edged 
sword” as it protects sensitive tissues from the toxic substances and on the 
other hand at the same time it causes MDR to prevent chemotherapy treatment 
in tumours (Sharom, 2008). 
2.5.3 Mechanism of action of P-glycoprotein (Pgp) 
The mechanism of action of P-gp in not revealed fully yet. Many important 
aspects like stoichiometric coupling between movement of drug molecule and 
the hydrolysis of ATP are still remains as a mystery. However some studies on 
the transport mechanism of P-gp shows that the drug transport is carried out by 
the two cycles, which are interconnected to each other (Callaghan et al., 2006). 
The first is catalytic cycle, which involves the hydrolysis of ATP which is useful 
for driving the transport. And the second cycle is substrate transport cycle, 
which carries the translocation of the drug molecule to the extracellular side of 
the membrane from the cytoplasmic side (Sharom, 2008). 
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2.5.3.1 The transport cycle of P-glycoprotein 
Transport cycle of P-gp consists the hydrolysis of ATP molecule by catalytic 
cycle and the movement of drug-substrate molecule to the extracellular side. 
Assumption by Higgins and Linton says that the affinity for the ATP molecule 
has been increased by the drug-substrate binding, as drug binding lowers the 
activation energy required for the formation of closed NBD dimer (Ambudkar et 
al., 2006). In the catalytic cycle ATP molecules are bound with low affinity to 
the both NBDs (Sharom, 2008). Each NBD contains Walker A, Walker B and 
Signature C motif. Binding of ATP leads to the formation of ‘sandwich dimer’ 
between two NBDs (Janas et al., 2003), in which walker A and Walker B motif 
of one NBD binds with the signature C motif of partner NBD and vice versa. 
Due to the close association of NBDs and the formation of dimer, the two 
catalytic sites are formed within the dimer, to which two ATP molecules were 
bound. There are two mechanisms were proposed for the study of catalytic 
cycle of ATP as ‘processive clamp’ mechanism and ‘alternating catalytic’ site 
mechanism.  
2.5.3.1.1 Processive Clamp Mechanism 
The ‘processive clamp mechanism’ model is shown in Figure 2.15, which 
proposes that the hydrolysis of both the ATP molecules were takes place in a 
succession which leads to formation and release of ADP and Pi. As shown in 
given diagrammatic model, in step-1 two ATP molecules are bound to both 
NBDs which lead to the formation of the dimer complex as shown step-2. After 
the formation of dimer, ATP hydrolysis starts by the first NBD shown in step-3, 
which either release the first Pi followed by the hydrolysis of second ATP on the 
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other NBD to release second Pi shown in step-4,5 and 8; or as shown in step-
6,7,and 8, the second ATP is hydrolysed before release of Pi and then both 
phosphates are released. Once the both ATP molecules were hydrolysed to 
ADP and Pi, both phosphates are released from the dimer, which leads to the 
dissociation of dimer complex and as a result of which, ADP molecules are 
released as shown in step-9 and 10. The both NBDs are now free again to start 
new catalytic cycle on binding with ATPs  (Janas et al., 2003). 
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Figure 2.15:Processive clamp model for the ATPase cycle of the NBD 
of ABC transporter 
Step-1 two ATP molecules are bound to both NBDs which lead to the 
formation of the dimer complex as shown step-2. After the formation of 
dimer, ATP hydrolysis starts by the first NBD shown in step-3, which either 
release the first Pi followed by the hydrolysis of second ATP on the other 
NBD to release second Pi shown in step-4,5 and 8; or as shown in step-
6,7,and 8, the second ATP is hydrolysed before release of Pi and then both 
phosphates are released. Once the both ATP molecules were hydrolyzed to 
ADP and Pi, both phosphates are released from the dimer, which leads to 
the dissociation of dimer complex and as a result of which, ADP molecules 
are released as shown in step-9 and 10. The both NBDs are now free again 
to start new catalytic cycle on binding with ATPs  (Janas et al., 2003) 
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2.5.3.1.2 Alternating catalytic site mechanism 
The diagrammatic model (Figure 2.16) shows the alternating catalytic site cycle 
of ATP hydrolysis. Two P-gp transmembrane domains (TMDs) represented by 
the rectangles, while circle, square and the hexagon represents the different 
conformational structures of N- and C-catalytic sites. 
 
 
Figure 2.16:Alternating site mechanism for the ATPase cycle of the 
NBD of ABC transporter 
Two P-gp transmembrane domains (TMDs) represented by the rectangles, 
while circle, square and the hexagon represents the different conformational 
structures of N- and C-catalytic sites (Senior et al., 1995) 
 
The structure at top left side shows that the ATP molecule is bound to the C-
catalytic site, while N-catalytic site is empty. And the drug molecule is also 
bound at the inside-facing transport site. As shown in the structure at the top 
right, the ATP hydrolysis takes place at the C-catalytic site, which is induced by 
the ATP binding at the N-catalytic site. The hydrolysis of ATP at C-catalytic site 
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leads to the conformational change within the C-catalytic site, which then 
prohibits the hydrolysis of ATP at the N-catalytic site. The conformation of C-
catalytic site immediately after bond cleavage is shown by hexagon in the 
structure, and this conformation with bound ADP.Pi is a high chemical potential 
state. The bottom right structure shows the release of the Pi and the relaxed 
conformation of C-catalytic site. This relaxed conformation of C-catalytic site 
allows the movement of drug molecule from the higher affinity inside-facing to 
the lower affinity outside-facing. And the last structure at the bottom left shows 
the complete dissociation of the drug molecule and the ADP. The next cycle 
now starts at the N-catalytic site, in the same way on binding of the new drug 
molecule at the inside-facing transport site as shown in top left structure (Senior 
et al., 1995). 
2.5.4 P-Glycoprotein Modulation 
P-gp is responsible for the MDR and is the major reason to cause failure of 
chemotherapy treatment to cure cancers. Still it is controversial that the extent 
of P-gp involved in the MDR in cancers and the survival rate of patients on 
modulation of P-gp (Sharom, 2008). P-gp inhibition can show dramatic effect 
on drug accumulation within the cells, as blockage of P-gp couldn’t able to 
eliminate the drug molecules from the intestine. Initially P-gp inhibition was 
focused to improve the efficacy of cancer chemotherapy by using the P-gp 
modulators with the anti-cancer drugs, but afterwards it’s been realized that the 
modulators could be useful to improve the delivery of anticancer drugs by 
altering their pharmacological behaviour (Sikic et al., 1997). An addition of 
effective P-gp modulators may increase the absorption of drugs into the 
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intestine and also the penetration through the protective barriers like blood-
brain barrier which is useful to treat brain diseases. This study has been carried 
in a mouse model using PSC833 modulator (Mayer et al., 1997). So 
development of effective P-gp modulator may improve the drug delivery to the 
brain. 
The first generation P-gp modulators including verapamil, cyclosporine A, 
tamoxifen and calmodulin antagonists were identified in 1980s (Krishna and 
Mayer, 2000). The first generation modulators were generally used clinically for 
the treatment of medical conditions. But the problem associated with these 
modulators is high toxicity and low efficacy. Because of the low binding affinity, 
they need to be administered in higher dose and as a result of which these 
modulators have been shown adverse pharmacological results like 
unacceptable toxicity (Krishna and Mayer, 2000; Sharom, 2008). 
Second generation modulators are more potent and less toxic than the first 
generation P-gp modulators, these includes dexverapamil, dexniguledipine, 
valspodar (PSC833) and biricodar (VX-710) (Krishna and Mayer, 2000). When 
the both modulators and the treatment drugs were the substrate for the 
cytochrome P450 3A, serious pharmacological effects were observed (Sharom, 
2008). The second generation modulators have some limitations as these 
compounds do not able to metabolize and excrete the cytotoxic compounds 
results into the unuseful toxic effect which may impact on the chemotherapy 
dose (Krishna and Mayer, 2000).  
To overcome the limitations of the second generation modulators, the new 
modulators were developed using the structure-activity relationships and 
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combinational chemistry known as third generation P-gp modulators. The third 
generation P-gp modulators show the low toxicity and increased selectivity with 
high potency, which includes LY335979 (zosuquidar), XR9576 (anthranilamide 
derivative tariquidar)   and OC144-09 (ontogen). As these third generation 
modulators have different origin and chemical structures, they have common 
characteristics like high potency and specificity for the P-gp transporter (Krishna 
and Mayer, 2000; Sharom, 2008). 
The best and most promising example for the third generation P-gp modulator 
is tariquidar as it binds with high affinity and noncompetitively to the P-gp and 
inhibits its activity. On the other hand second generation modulators compete 
with cytotoxic agent as a substrate to bind with the P-gp transporter (Krishna 
and Mayer, 2000; Roe et al., 1999). 
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3 : Aims and Objectives 
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3.1 Aim 
The aim of this study is to evaluate galaxolide as novel efflux transporter 
inhibitor to improve the drug delivery through epithelial cell layers such as 
intestinal barrier and blood-brain barrier.  
3.2 Objectives 
 To determine cytotoxicity of galaxolide on various cell lines (Caco-2, SH-
SY5Y, LN229, U87MG, MDCK, MDCKII, MDCKII-MDR1, MDCKII-BCRP 
and MDCKII-MRP1). To study effect of galaxolide on drug toxicity. To 
study P-glycoprotein expression and inhibition. 
 To develop HPLC method for curcumin quantification. To study curcumin 
permeability through cell membranes. To study effect of galaxolide on 
curcumin permeation through in vitro intestinal and blood-brain barrier 
models. 
 To perform histological study to assess the integrity of membrane and 
ability of various cells to form membrane. To study effect of matrigel on 
membrane formation by various cells.  
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4 : Materials and Methods 
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This chapter will provide details about materials used for this study and the 
methods followed to complete objectives 
4.1 Materials 
All materials used including media, cell lines, chemicals, lab consumables and 
instruments were listed in following tables with their product/catalogue numbers 
and source/manufactures. 
Table 4.1: Media and Chemicals 
Sr. 
No. 
Media and Chemicals Catalog 
no. 
Source 
1. EMEM Media 30-2003 ATCC 
2. McCoy’s 5A Media 30-2007 ATCC 
3. DMEM Media 61965-026 Gibco/Life Technologies 
4. RPMI 1640 R5886 Sigma 
5. Hank’s Balanced Salt 
Solution 
H9269 Sigma 
6. Trypsin-EDTA T4049 Sigma 
7. L-Glutamine 25030 Gibco/Life Technologies 
8. Sodium Pyruvate 11360 Gibco/Life Technologies 
9. Penicillin/Streptomycin P4333 Sigma 
10. Fetal Bovine Serum 10500-064 Gibco/Life Technologies 
11. Doxorubicin Hydrochloride D1515 Sigma 
12. MatrigelTM 734-1100 VWR/BD 
13. Bouin’s Solution HT10132 Sigma 
14. Trifluoroacetic acid T6508 Sigma 
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15. Emodin E7881 Sigma 
16. Bovine Serum Albumin A7030 Sigma 
17. HEPES H0891 Sigma 
18. Phosphate Buffer Saline 
(PBS) 
20-741-05 Severn Biotech Ltd. 
19. Thiazolyl Blue Tetrazolium 
Bromide (MTT dye) 
M5655 Sigma 
20. Curcumin 00003927 ChromaDexTM 
21. Galaxolide® 00070290 International Flavours and 
Fragrances 
22. Verapamil V4629 Sigma 
23. Cyclosporine A C3662 Sigma 
24. Rhodamine 123 R8004 Sigma 
25. Temozolomide T2577 Sigma 
26. Vinblastine sulfate salt V1377 Sigma 
27. Anti-ABCB1/MDR1 
Antibody 
LS-
C178472 
Source BioScience 
28. Anti P-glycoprotein Mouse 
Antibody (C219) 
517310 Merck 
29. Mouse IgG1 Negative 
control Antibody 
CBL610 Merck 
30. Anti-Actin Antibody MAB1501 Merck 
31. Protease Inhibitor Cocktail P8340 Sigma 
32. Phosphatase Inhibitor 
Cocktail 
P5726 Sigma 
33. Page ruler plus pre-stained 
protein (Protein Marker) 
26619 Fermentas/Thermo 
Scientific 
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34. RIPA Buffer R0278 Sigma 
35. Tween 20 P1379 Sigma 
36. Histoclear II 12954900 Fischer Scientific/National 
Diagnostics 
37. DPX Mounting Medium - Raymond A Lamb 
38. Harris Hematoxilin HHS32 Sigma 
39. Paper Developer (Ilford 
Multigrade) 
1155073 Harman Technologies 
40.  Fixer Solution (Ilford Rapid 
Fixer) 
1984262 Harman Technologies 
41. Acetonitrile (HPLC Grade) - Fischer Scientific 
42. Ethanol - Fischer Scientific 
43. Xylene - Fischer Scientific 
44. DMSO - Fischer Scientific 
 
Table 4.2: Consumables 
Sr. No. Consumable Catalog no. Source 
1. Hybond ECL Membrane RPN2020D GE Healthcare 
2. Symmetry C18 Column WAT054275 Waters Ltd. 
3. HPLC Vials 186000847C Waters Ltd. 
4. Collagen coated Transwells 3496 Corning 
5. Black bottom sterile 96 well  
plates 
732-2699 VWR 
6. 96 well MTT plates 3799 Corning 
7. 24 well plates 3524 Corning 
8. BCA Protein Kit 23227 Thermo Scientific 
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9. Cell Scraper 3010 Corning 
 
Table 4.3: Instruments 
Sr.No. Instrument Manufacturer 
1. MTT Plate Reader Thermo Scientific 
2. Fluoroscent Plate Reader Thermo Scientific 
3. BCA Assay Plate Reader Thermo Scientific 
4. Western Blot Assembly Bio-Rad 
5. FACS Machine BD Biosciences 
6. FACS Software Cell Quest Pro 
7. HPLC System (Waters e2695) Waters Ltd. 
8. HPLC Software Empower3 
9. Microcentrifuge (Labofuge 
400R) 
Heraeus 
10. Heating Block Grant/Clifton 
11. Water bath Grant 
12. Lab Water Purifier Elga (Purelab Option) 
13. Homogeniser Scientific Laboratory Suppliers 
14. Vortex  (Vortex Genie 2) Scientific Industries 
15. Magnetic Stirrer Stuart Scientific 
16. Slide Drying Bench Raymond A Lamb 
17. Water Bath_Histology Raymond A Lamb 
18. Tissue Embedding Unit Raymond A Lamb 
19. Microtome Leica 
67 
 
20. Magnetic Stirrer (Permeability 
study) 
Amicon 
21. TEER Machine (Epithelial Volt-
ohmmeter) 
World Precision Instruments 
22. TEER Measuring Probe World Precision Instruments 
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4.2 Methods 
4.2.1 Cell Culture 
Cells were grown in T25/T75 flask containing corresponding Media for the 
particular cell line supplemented with 10% or 20% of Foetal Bovine Serum 
(FBS) as per requirement. The flasks inoculated with cells were maintained at 
controlled conditions in humidified incubator temperature maintained at 370C 
and supplemented with 5% CO2. The medium was replaced with fresh medium 
at an interval of every 3-4 days depending on cell growth rate as some cells 
grow faster or some have slow growth rate. At the time of medium change the 
old media was removed and discarded and cells were washed twice with 
Hank’s Balanced Salt Solution (HBSS) solution. Cells remain attached to the 
surface of the flask. Once cells were washed, HBSS solution was removed and 
fresh media was added to the flasks containing cells and returned back to the 
incubator. Cells were routinely passaged when they reached to approximately 
70 to 80% confluence. To passage cells, the old media from flasks were 
removed and cells are washed twice with HBSS. After washing, flasks were 
treated with the 0.25% trypsin/EDTA; 2ml/T25 or 3ml/T75 flask; for about 5-10 
mins to detach cells from the surface of flask. Flasks treated with trypsin were 
kept for incubation for about 5-10 min at 370C. After incubation detached cells 
were resuspended in the 10ml of fresh growth media. These cells were then 
centrifuged at 2000 rpm at room temperature. The supernatant (medium 
containing trypsin) was discarded and cell pellet was resuspended in 10ml of 
fresh growth media. Cell count was taken and 0.5 to 1ml of cell suspension 
were transferred to the new non vented flasks containing 10ml of fresh growth 
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medium. Flasks were placed in incubator and followed the same maintenance 
procedure (protocol followed from ICT lab manuals).  
Same procedure was applied to maintain all other cell lines mentioned in 
following Table 4.4. Only the medium was changed as per the requirement of 
particular cell line 
Table 4.4: Cell Lines and Media Used 
Sr. 
No. 
Cell Lines Media Used Source 
1. Caco-2 EMEM Media with 
20% FBS 
ICT,  University of Bradford, 
Bradford 
2. MDCK (NBL-2) EMEM Media with 
10% FBS 
ATCC (CCL-34) 
 
3. MDCKII DMEM Media with 
10% FBS 
Netherlands Cancer 
Institute, Amsterdam 
4. MDCKII-MDR1 DMEM Media with 
10% FBS 
Netherlands Cancer 
Institute, Amsterdam 
5. MDCKII-
BCRP1 
DMEM Media with 
10% FBS 
Netherlands Cancer 
Institute, Amsterdam 
6. MDCKII-MRP1 DMEM Media with 
10% FBS 
Netherlands Cancer 
Institute, Amsterdam 
7. PANC-1 DMEM Media with 
10% FBS + Glutamine 
ICT,  University of Bradford, 
Bradford 
8. SiHa EMEM Media with 
10% FBS 
ICT,  University of Bradford, 
Bradford 
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9. DLD-1 RPMI 1640 Media with 
10% FBS 
ICT,  University of Bradford, 
Bradford 
10. MCF-7 EMEM Media with 
10% FBS 
ICT,  University of Bradford, 
Bradford 
11. MCF-7/adr RPMI 1640 Media with 
10% FBS + 
Doxorubicin (8 µg/ml) 
ICT,  University of Bradford, 
Bradford 
12. U87MG RPMI 1640 Media with 
10% FBS 
ICT,  University of Bradford, 
Bradford 
13. LN229 DMEM Media with 
10% FBS + Glutamine 
ICT,  University of Bradford, 
Bradford 
14. H460 RPMI 1640 Media with 
10% FBS 
ICT,  University of Bradford, 
Bradford 
15. SH-SY5Y RPMI 1640 Media with 
10% FBS 
ICT,  University of Bradford, 
Bradford 
16. HCT 116 McCoy’s 5A Medium 
with 10% FBS 
ICT,  University of Bradford, 
Bradford 
17. HT 29 McCoy’s 5A Medium 
with 10% FBS 
ICT,  University of Bradford, 
Bradford 
 
4.2.2 Cell Count 
Once cells were detached from the flask after 0.25% trypsin/EDTA treatment, 
fresh media was added to flask and cells were collected in suspension. To get 
rid of trypsin from media, collected cell suspension were centrifuged at 2000 
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rpm at room temperature and supernatant was discarded gently without 
disturbing pellet. Pellet then resuspended in the fresh growth media. Approx. 
20µl of cell suspension was collected using micropipette and transferred it to 
the haemocytometer. 5 grids of the haemocytometer was used to count cells 
and finally mean of the 5 grids was taken to calculate the cell number per ml 
present in the collected suspension (protocol followed from ICT lab manuals). 
The final cell count expressed as: mean cell count × 104 cells/ml of medium. 
4.2.3 Galaxolide cytotoxicity (MTT Assay) 
MTT assay was performed to study toxicity of galaxolide on different cell lines 
(protocol followed from ICT lab manuals). To carry out this study concentration 
range of galaxolide with 500µM was used as a highest concentration and was 
diluted double fold to achieve serially lesser range of drug concentrations for 
the treatment on cells; it means next drug concentration is half the previous one 
and vice versa. Cells were treated and incubated with drug concentrations for 
72hrs.  
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Figure 4.1: Template of MTT plate_ Inoculation of cells 
 
On the Day-1 of assay, required cells were trypsinised, centrifuged and were 
resuspended in fresh media to get cell suspension. Cell count was done and 
cell suspension was prepared having approx. 1×104 cells per ml. 200µl cell 
suspension containing 2×103cells were inoculated per well in 96 well plate using 
multichannel pipette. Except the first row of well, cells were inoculated in all 
remaining rows (Figure 4.1), leaving first row as a blank control. Plates were 
placed for incubation at 370 C supplemented with 5% CO2 for 24 hrs.  
Once 24 hrs incubation done, plates were removed from the incubator and old 
media present in wells was removed with multichannel pipette. Empty well were 
then replaced with the freshly prepared drug concentrations. Row 1 and 2 
added with growth media without the drug while row 3 to 12 were replaced with 
lowest to highest galaxolide concentrations respectively obtained by the double 
fold serial dilution (Figure 4.2). Once drug solutions added to the respective 
wells, plates were returned to the incubator at 370 C supplemented with 5% 
CO2 for 72 hrs. 
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Figure 4.2: Galaxolide cytotoxicity_MTT assay 
 
After 72hr treatment, plates were taken out from the incubator and 20 µl MTT 
(Stock=5mg/ml; 100µg/well) dye was added to each well. Plated then followed 
by 4hr incubation. When incubation time over, plates were taken out and all 
media containing MTT was removed and replaced with 150 µl DMSO. Wells 
were mixed to dissolve the violet crystals formed. Plate count was taken at 
540nm using plate reader (Figure 4.3) and IC50 value was obtained from the 
graph plotted. The Figure 4.4 shows the flow chart for the protocol. 
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Figure 4.3: MTT Plate reader 
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Figure 4.4: MTT Assay_ Flow Chart 
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4.2.4 Effect of Galaxolide on drug toxicity 
Step 1: Seeding 
Cells were grown in a T75 cell culture flask until the cell density reaches 
approximately 80% of the flask surface area. Medium was discarded; cells were 
washed with Hank's balanced salt solution (HBSS) and then trypsinised in order 
to get freely floating cell suspension. Cells were counted and a suspension was 
prepared in complete tissue culture medium such that the cell density would be 
1×104 cells per ml. 200 µl of this suspension was seeded in each well except 
1st column of the 96 well plate leading to cell density of 2×103 cells per well. 
Cells were allowed to grow for 24 hours at 370 C supplemented with 5% CO2, 
so that they also stick to the bottom of the plate. 
Step 2: Drug exposure 
After 24 hours of growth, each well was emptied of the old medium and fed with 
200 µl of fresh medium containing serially increasing concentrations of drug. 
To explain with the help of following Figure 4.5, Column 1 was left empty; 
column 2 was fed with blank medium containing no drug. Column 3 to 12, were 
fed tissue culture medium containing concentrations of drugs (curcumin and 
temozolomide) ranging up to 500µM as a highest concentration, where each 
column in numeric order from 3 to 12 was exposed to twice the concentration 
of the drug than previous. Plates were further incubated for 24 hours. Similar 
procedure was repeated with drug concentrations supplemented with the 
known P-gp inhibitors verapamil (5µM) and cyclosporine-A (5 µM) along with 
galaxolide (1 µM). 
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Figure 4.5: MTT assay plate template_drug treatment 
 
Step 3: MTT assay 
Finally, 5 mg/ml solution of MTT was prepared in distilled water and 20 µl of it 
was added in each well. Plates were incubated for 4 hours and then medium 
was discarded. 150 µl of DMSO was added to each well and mixed to dissolve 
purple coloured crystals formed with MTT at the bottom of each well. The 
absorbance of each well was determined at 540 nm using plate reader. IC50 
value was obtained from the graphs plotted. 
4.2.5 Inoculation and Growth of cells on Transwells 
Collagen-coated transwells having pore size of 3.0µm was used throughout the 
studies. Various cells were grown on transwells with different cell number 
during inoculation as per the experimental requirement, but inoculation 
procedure is same for all. 
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Figure 4.6: Transwell 
 
Cells when reach approx.  80% or more confluence was used for experimental 
set up. Cells were washed and trypsinised as per above mentioned procedure 
and cell suspension was prepared after centrifugation using fresh media. Cells 
then counted using haemocytometer and cell suspension having cell density 1 
× 106 cells/ml was prepared. Each transwell inoculated with the 100µl cell 
suspension, it means 1 × 105 cells/transwell was seeded. Transwells were 
placed in well plates and moved to incubator for 2-4hrs incubation without 
addition of any media to the top or bottom chamber of transwells.  This step is 
done to allow cells to attach to the transwell membrane. After incubation plates 
were removed and 200µl media to top chamber and 1.5ml media to bottom 
chamber were added and plates were returned to the incubator set to the temp. 
370 C supplemented with 5% CO2. Medium was changed every three days of 
interval. The sequence of media removal and replacement is critical to success 
any assay that requires the cells to adhere to the membrane surface. When 
feeding the transwells it is important to maintain the net positive hydrostatic 
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pressure above the cells to prevent the cells from being pushed off the 
membrane. Therefore, the sequence of media removal and addition is always 
the same as: 
1. Remove media from the receiver or bottom chamber 
2. Remove media from the top/upper chamber 
3. Add media to the top/upper chamber 
4. Add media to receiver or bottom chamber. 
4.2.6 Inoculation and Growth of cells on Transwells with addition of 
Matrigel 
Cells were inoculated in presence of matrigel, to study its effect on cell growth 
and membrane forming ability of cell. Various cell lines were used as per 
requirement to carry this study. Cells when reached at approx. 80% confluence, 
flasks were removed from incubator and cells were washed and treated with 
trypsin. After trypsinisation cell suspension was prepared and cell count was 
taken. Cell suspension with 1 × 106 cells/ml cell density was prepared according 
to cell count. 1 ml of this cell suspension was taken and centrifuged. Pellet was 
collected and re-suspended in pre-cooled media containing ice cold matrigel 
(different concentrations as per requirement) in it. The suspension was mixed 
well and 100µl of it was inoculated per transwell. Transwells then incubated for 
4-6 hrs without adding media to the bottom chamber to allow cells to attach the 
membrane of transwells. After incubation 200µl media to top chamber and 
1.5ml media to bottom chamber was added and plated were placed in incubator 
at 370 C supplemented with 5% CO2. Medium change and other maintenance 
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procedure were followed as described above. The Figure 4.7 shows the brief 
procedure for inoculation of cells on transwells with and without matrigel. 
 
Figure 4.7: Flow chart of cell inoculation on transwell with and without 
matrigel 
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4.2.7 Transepithelial electrical resistance (TEER) measurement 
TEER is the resistance across the membrane or it measures the resistance to 
pass current across the cell monolayer. The TEER value was calculated by 
using following formula (Yu and Huang, 2011a): 
TEER (Ω.cm2) = [TEER(m) (Ω) – TEER(b) (Ω)]  × A (cm2) 
Where, 
          TEER     : Trans epithelial electrical resistance 
          TEER(m) : Resistance reading obtained for cell monolayer  
          TEER(b)  : Resistance reading obtained for the blank insert  
                   A   : Surface area of insert filter membrane  
To perform TEER measurement, plates previously inoculated with cells were 
taken out from the incubator at the certain time point as per requirement and 
transwell was transferred to new plate. Medium from upper and lower chamber 
was removed and replaced with fresh medium with 200µl at upper and 700µl in 
lower chamber. Along with this, one blank insert (transwell without cells) also 
prepared in same way containing 200µl media in upper and 700µl in bottom 
chamber. This blank was prepared to measure blank reading. The electrode 
(STX2 electrode) was kept in medium to equilibrate with media for about 10-15 
min prior to carry out readings. 
The electrode has two unequal arms with different lengths.  During the time of 
TEER measurement, the short probe was placed in upper chamber while long 
one was in basal chamber as shown in Figure 4.8 and the readings were 
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recorded for blank insert as well as for insert having cells by using EVOM2 
epithelial volt-ohmmeter Figure 4.9. 
 
Figure 4.8: Placement of electrode in transwell during TEER 
measurement 
 
 
Figure 4.9: EVOM2 Meter 
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4.3 Histology Study 
To study histology of cell membranes, various steps were followed from 
seeding of cells on transwell to prepare stained slides. All these steps are 
described in detail in following section. (Histology procedures were adapted 
from corning protocols for transwell and staining procedure followed from ICT 
lab manuals) 
4.3.1 Inoculation and growth of cells on transwells 
The cells were maintained in their respective medium with required 
supplements as per need at 370C with 5% CO2. To follow histology, cells when 
reached to approx. 80% confluence, were removed from incubator. Flasks were 
then washed with HBSS and trypsin was added to detach the cells from the 
surface. Cells with trypsin was incubated for 5-10 mins and then flasks were 
removed from incubator and a manual shake was given to flask to get the free 
floating cells. Once all cells were detached from the surface and free floating 
cells were observed, fresh media was added to flask and cell suspension was 
collected in tube and centrifuged to get trypsin free pellet. Pellet then 
resuspended in fresh growth media and cell count was taken using 
haemocytometer. Cell suspension was prepared as per the requirement. 
Transwells having 6.5mm diameter and 3.0µ pore size were placed on the wells 
of 24 well plate. Each transwell then inoculated with the 100µl of cell suspension 
(which may contains 1×105, 2×105 or 3×105 cells per transwells). Once cells 
were inoculated at required density, transwells were incubated for 2 hrs without 
addition of medium to lower compartment (basolateral or bottom well) to allow 
cells to attach the membrane. After 2 hrs well plates were removed from 
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incubator and 200 µl of growth medium to top well and 1.5 ml to the bottom well 
was added and plates were placed for incubation at 370C with 5% CO2. Medium 
was changed after every 3 days. Every time point plates were removed from 
incubator, one well was taken to new well plate and media was replaced with 
fresh media for the one well which have been removed. Top chamber replaced 
with 200 µl while bottom chamber was replaced with 700 µl media. TEER was 
measured and recorded for this well along with blank well which does not have 
cells grown on it.  
4.3.2 Fixation 
After TEER reading, media from well was removed and transwell having cells 
on it was transferred gently to the universal tube. Approx. 5 ml Bouin’s solution 
was added to universal tube ensuring transwell was completely covered under 
Bouin’s solution. Transwell was incubated for 1 hr with Bouin’s solution. After 
incubation Bouin’s solution was poured off and 70% ethanol was added to wash 
wells. Transwell was then washed gently with ethanol. This step was repeated 
until no more yellow colour of Bouin’s solution was removed. Once all yellow 
traces washed out, transwell was stored at room temperature in universal tube 
having 70% ethanol until all transwells got ready. 
4.3.3 Dehydration and cleaning 
Dehydration and cleaning was generally done by using automated tissue 
processor (Figure 4.11) for most of the tissues. Tissues were placed in the 
tissue processor cassettes (Figure 4.10) after fixation and then placed in the 
automated tissue processor and required programme was selected. Cassettes 
containing tissue was automatically passed through the different increasing 
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concentrations of ethanol to dehydrate tissue and then through histoclear or 
xylene solution to clean the tissue.  
 
 
Figure 4.10: Tissue processor cassette 
 
 
Figure 4.11: Automated Tissue processor 
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In case of this study, cells were grown on and fixed with the transwell 
membrane, and intact transwells with cells grown on it were directly used for 
further processing. Transwells were large in size to fit in the tissue processing 
cassettes. So to overcome this, above mentioned steps for dehydration and 
cleaning was done manually.  
Once all transwells were fixed, they were ready to go further for histology study. 
The next step was dehydration, which usually carried out by transferring 
transwells through solutions of increasing ethanol concentrations. After fixation, 
transwells were stored in 70% ethanol. The 70% ethanol then replaced with 
95% ethanol and incubated for 10 mins. Incubation then followed with removal 
of 95% ethanol and addition of 100% ethanol for 10 mins and this step with 
absolute ethanol was repeated twice. 
Once dehydration process was done, cell layer on transwells was needed to 
clean and this was done by addition was histoclear. Xylene was also used 
normally to clean the tissue, but here in this case with transwells, xylene reacted 
with polymer used to make transwells and dissolved the transwells in it. So in 
case of study with transwells, histoclear was used strictly. Incubation with 
histoclear was done for 10 mins. 
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4.3.4 Embedding 
Embedding was done on the tissue embedding station (Figure 4.12). Before 
starting dehydration process, tissue embedding station was switched on; this 
will melt the paraffin wax in the meantime. Oven was also set to 580C. 
 
Figure 4.12: Tissue embedding station 
 
Once incubation with histoclear was done, it was removed and transwells were 
moved to 24 well plates and liquid paraffin was added over it ensuring that 
transwells were completely embedded in paraffin wax. Plates were then 
transferred to the oven set at 580C. Transwells were incubated in liquid paraffin 
for 1hr. After 1 hr incubation plated were removed from the oven and replaced 
with fresh liquid paraffin and returned back to oven for another 1 hr. Plates were 
then removed from the oven, transwells were half emptied with paraffin, and 
moved to new 24 well plate and placed at room temperature for approx. 1 hr 
and then for 30 mins in the freeze. Plates then removed and membrane was 
gently cut off from each of the transwells with sharp blade. The harvested 
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membranes were then transferred to the plastic moulds (Figure 4.13). These 
moulds then used to prepare wax blocks by filling liquid paraffin to these 
moulds. The membranes were set at the bottom and each wax block was 
labelled with respective cells. Block then allowed cool and solidify for 1 hr on 
the cooling plate associated with the tissue embedding station. After 1 hr tissue 
embedding station was switched off and blocks were placed for overnight at 
room temperature. Next day, plastic moulds was removed and entire blocks 
were harvested (Figure 4.14) and stored in freezer until sections were taken. 
 
Figure 4.13: Plastic moulds 
 
Figure 4.14: Paraffin blocks with 
tissues 
 
4.3.5 Sectioning 
Before beginning to sections, water bath was switched on and was set to 500 
C.  Blocks formed earlier were placed in deep freezer for 30 mins. This may 
harden the blocks and would give clean and sharp sections as wax was better 
to cut when it was cooled. 
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Figure 4.15: Microtome 
 
Microtome was switched on keeping lock on ensuring that lever was not moving 
and blade was replaced with new sharp blade. Once all settings were done, 
blocks were removed one by one from the freezer and were fixed on the block 
holder on microtome (Figure 4.15). Lock was removed and lever was pulled 
outwards and moved in circular motion to take sections. Sections with 5µm 
thickness were obtained. The sections then moved to water bath (Figure 4.16) 
set to 500C for 1 min. Sections then transferred to the clean glass slide and 
slide was labelled with respective information. Slides then placed on slide 
drying hot plate (Figure 4.17) set at 500 C for 30 min to attach paraffin 
embedded sections firmly on glass slides. Once slides were dried and sections 
were attached firmly on the glass slides, slides were stored at room temperature 
until staining. 
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Figure 4.16: Water bath 
 
Figure 4.17: Slide drying hot plate 
 
4.3.6 H and E Staining 
Staining of sections can be done by using different stains. Here we used 
Hematoxylin-Eosin (H and E) staining method, which is most commonly used 
method. Hematoxylin is an active staining component which stains the nuclear 
component of cells a dark blue, while eosin stains the cytoplasmic organelles 
varying shades of pink, red or orange. The combination of hematoxylin and 
eosin provides a broad range of morphological information about the sections. 
4.3.6.1 De-waxing and rehydrating sections 
Slides prepared with sections were placed in a slide staining rack (Figure 4.18). 
The rack then was passed through the xylene and diluting ethanol solutions to 
de-waxing and rehydrating sections. Sections were first transferred to the pure 
xylene (Xylene-1) for 5 min, then transferred to another container containing 
pure xylene (Xylene-2) for 5 mins. After that sections were placed in container 
having 50% xylene/ethanol mixture for 5 mins and then moved to the Absolute 
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ethanol (Ethanol-1) for 5 min. Then again moved to Absolute ethanol (Ethanol-
2) followed with 90% ethanol and then finally in 70% ethanol for 2 min each. 
 
Figure 4.18: Slide staining rack 
 
4.3.6.2 Staining 
Once de-waxed and rehydrated, sections were stained in Hematoxylin for 10 
mins. After staining, sections were washed in slow running tap water and then 
placed in acid-alcohol (0.5% HCL in 70% Ethanol) solution for 5 sec to get rid 
of excess hematoxylin. Then washed briefly in tap water and moved to 
container having Scott’s tap water for 2 mins. Sections then counterstained in 
1% aqueous eosin for 1 min and finally washed under tap water. Sections then 
drained for 1 mins to run out excess water. 
4.3.6.3 Dehydrating, cleaning and Mounting 
When sections drained off excess water, they were dehydrated passing them 
through absolute ethanol-2 for 1 min, absolute ethanol-1 for 3 mins, 50% 
xylene/ethanol for 3 mins, xylene-2 for 3 mins and finally in clear xylene for 5 
mins. Clear xylene was used to clean the sections before mounting. Once every 
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step was done, sections were mounted in DPX medium. During mounting, 
coverslip was flooded with DPX medium and was placed gently over the slide 
containing sections. Any bubbles formed were removed using needle point and 
finally mounted slides were placed to dry at room temperature. Once dried, 
slides were observed under microscope and results were noted. The Figure 
4.19 shows the flow chart for H and E staining. 
 
Figure 4.19: Histology procedure flow chart 
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4.4 Western blotting 
Western blot analysis was done to study the expression of P-gp in cells 
(Procedure adapted from Dr. Simon Allison). Steps involved in western blot 
analysis are described as follow: 
4.4.1 Cell Harvesting and Lysis 
Cells were grown and harvested at the several time points to analyse the 
protein expression. At the time of cell harvesting, flasks were taken out from 
incubator and washed twice with the PBS. After wash cells were treated with 
trypsin and followed by addition of media to get cell suspension. To get rid of 
trypsin, cell suspension was centrifuged and pellet was collected. Pellet then 
washed twice with 5ml PBS to get rid of traces of media. After PBS wash, 200µl 
lysis buffer was added to the pellet and mixed by pipetting. Lysis buffer was 
prepared by mixture of RIPA lysis buffer, Protease inhibitor cocktail (PIC) and 
phosphatase inhibitor cocktail. 1ml of lysis buffer prepared with 965µl RIPA lysis 
buffer, 25µl Protease inhibitor cocktail and 10µl phosphatase inhibitor cocktail. 
Every time, lysis buffer was prepared fresh. Once pellet was mixed with lysis 
buffer, it was transferred to the chilled eppendorf tube and placed on wet ice for 
15 min. and then stored at -200C until all samples were ready. 
4.4.2 Sample preparation to load on gel 
Once all samples were harvested, cell lysates removed from the -20 freezer 
and placed on wet ice for 15 min to defrost it. Cell lysates were then followed 
to the homogenisation using homogenizer (Figure 4.20) to get uniform samples. 
During this step, homogenizer probe was positioned carefully at the middle of 
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the sample to avoid bubble formation (Figure 4.21). Each sample was sonicated 
thrice having 30 sec lag time between two sonication cycles. To avoid mixing 
of two samples during homogenisation, 2 eppendorf tubes containing distilled 
water was homogenised after and before each sample. After homogenisation 
all samples were places on wet ice and mixed with pipetting. 100µl of each 
homogenised sample was transferred to the new eppendorf tube and 50µl of 
Laemmli’s dye was added to each sample. Samples were stirred well and 
stored at -200C until they were loaded on the gel. The remaining lysate samples 
were used to carry BSA assay to quantify total protein concentration in the 
lysate. 
 
 
Figure 4.20: Homogenizer 
 
Figure 4.21: Position of probe 
during homogenisation 
 
4.4.3 BSA Assay 
BSA assay is done to determine the total protein concentration present in the 
cell lysates harvested for the western blot analysis. 
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BSA Assay was performed using 96 well plate. Different concentrations of BSA 
were used as standard with a range of 2.0mg/ml, 1.4mg/ml, 1.0mg/ml, 
0.8mg/ml, 0.4mg/ml, 0.2mg/ml and 0.0mg/ml. To perform assay, 10µl of 
standard sample was used for each well and for each samples four well were 
used. Same criteria were used for test samples; 4µl of test samples was added 
to each well and four wells were used for each sample. Once all standard and 
test samples were added to corresponding wells, addition of 200µl BSA reagent 
was done to each well. To add this reagent multichannel pipette was used to 
get uniform colour intensity. The BSA reagent is a mixture of Reagent A and 
Reagent B (Reagent A-25ml + Reagent B-0.5ml). Plate was incubated for 30 
min at room temperature and after incubation readings were taken using plate 
reader (Figure 4.23). Graph plotted using readings obtained and total protein 
concentration was calculated for each sample. Figure 4.22 shows the template 
of samples loaded on plate. 
 
Figure 4.22: BSA assay template 
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Figure 4.23: BSA assay plate reader 
 
4.4.4 Gel Preparation 
Two different gels with 7.5% and 15% concentrations were prepared. P-
glycoprotein molecule has larger molecular weight; 170KD, so it needs 7.5% 
gel to run while 15% gel prepared for the actin. These gels prepared using the 
gel making glass cassette (Figure 4.24). After preparation gels were allowed to 
solidify for 1 hr. 10% SDS solution was overlaid above the gel to avoid drying 
from the top edge. After 1hr, liquid SDS which was overlaid was drained off. 
Stacking gel with 4% concentration was prepared and overlaid it to previous gel 
and comb was inserted above it to form wells to load the samples. Stack gel 
allowed to solidify for 30 mins. When gel solidified, comb was removed gently 
and gel along with glass cassettes was ready to load the samples. Then gel 
was assembled in the electrophoresis assembly and flooded with the running 
buffer. The electrophoresis assembly then connected to the power unit. 
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Figure 4.24: Gel making glass cassette 
 
4.4.5 Loading and running samples on Gel 
The harvested samples after homogenisation and mixed with the Laemmli’s 
dye was removed from freezer. Samples and protein marker were defrosted in 
370C water bath. Using heating blocks (Figure 4.25), the samples were boiled 
at 1000C for 5 mins. After boiling samples were centrifuged to get down 
evaporated liquid and then vortexed.  
 
Figure 4.25: Heating block 
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Samples now ready to load on gel, was loaded considering equal amount of 
total protein (35µg) per well. First well was loaded with 8µg protein marker and 
last with 4µg protein marker to get an idea about direction of gel. In between 
two markers different test samples were loaded. Once all samples were loaded, 
lid was placed onto the chamber and power unit (Figure 4.26) was switched on 
to run at 70 volts for 1hr and after an hour power increased to 120 volts. The 
electrophoresis run until blue dye moved to the bottom of the gel and eventually 
gets out of the gel. In the meantime transfer buffer was prepared and 
nitrocellulose membrane was soaked into it. 
 
Figure 4.26: Gel running chamber and power unit 
 
4.4.6 Transferring the protein from the gel to the membrane 
When gel finished running, removed it from the electrophoresis assembly and 
then removed gently from the plastic tray using the green key. Well area was 
cut off with the spatula to make the gel smaller and gel was placed in the tray 
containing transfer buffer to avoid it from drying. Nitrocellulose membrane was 
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used to transfer proteins from gel was soaked already in transfer buffer. The 
transfer sandwich was prepared in a tray containing transfer buffer in a following 
order from white holder to black holder as sponge, 2 pieces of blotting paper, 
nitrocellulose membrane, gel, 2 pieces of blotting paper and  sponge as shown 
in the Figure 4.27. When applying the nitrocellulose membrane over the gel, 10 
ml stripette was rolled over it gently to ensure there was no any air bubbles 
between two layers. 
 
Figure 4.27: Transfer sandwich 
 
When transfer sandwich was prepared, it was transferred to the tank containing 
transfer buffer ensuring black side of cassette fits towards the black side of the 
tank (Figure 4.28). Tank then connected to the power unit and was run on 35 
mA for approx. 16 hrs. After run membrane with transferred proteins was 
removed and dried for about 1hr and then stored at -200C in sealed polythene 
bag until ready for next work. 
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Figure 4.28: Transfer cassette and tank with power supply 
 
4.4.7 Antibody staining 
Membranes were removed from storage and allowed to thaw at room 
temperature for 15 min. After thawing membranes were transferred to the 
container containing PBS with 0.1% Tween 20 (PBST) and incubated for 15 
min at room temperature with shaking on orbital shaker (Figure 4.29). PBST 
then poured off and replaced with the blocking solutions (5% Milk Powder-
Marvel) and incubated at room temperature for 1 hr. In mean time primary 
antibody solution was prepared in blocking solution as per the data sheet. 1 hr 
incubation then followed with removal of blocking solution and then addition of 
primary antibody. Membranes treated with primary antibody incubated 
overnight on shaking condition at 40C. 
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Figure 4.29: Orbital shaker 
 
Once incubation done, primary antibody solution was removed from container 
and blots were replaced with PBST and incubated at room temperature for 5 
mins with shaking. The process was repeated thrice to remove unbound 
primary antibody traces. When washing done blots were incubated with 
secondary antibody prepared in blocking solution. Blots then incubated for 1 hr 
on shaking at room temperature. After incubation with secondary antibody, 
blots were washed thrice with PBST for 5 mins each time at room temperature 
with shaking condition. After washing, blots were drained on tissue paper and 
fixed on the developing box. Blots then flooded with the ECL solution for 1 min 
and then covered with the photocopy paper and then moved to dark room to 
develop the films.   
4.4.8 Developing Films 
Film developing was completely done in the dark room. Blots were immediately 
proceed for photo film development once treated with the ECL reagent. In dark 
room three separate trays containing developer solution, distilled water and 
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fixer solution respectively was arranged as shown in the Figure 4.30. Films 
were exposed to the blots fixed in developing box with various exposure times. 
After exposure films were transferred to the tray-1 containing developer solution 
for 2 mins, then moved to the tray-2 for 1 min containing distilled water to get 
rid of developer solution from the film. Finally films were transferred to the tray-
3 containing fixer solution for at least of 2 mins and then at the end films were 
moved back to the tray-2 having distilled water. All developed films then 
removed from the distilled water and air dried and then marked according to the 
protein marker and labelled.  
Developer and fixer solution was prepared in dark room. Developer solution 
was prepared with 50 ml developer diluted to 500 ml using distilled water while 
same volume of fixer solution was prepared with 75 ml fixer diluted to 500 ml 
using distilled water.  
 
Figure 4.30: Film developing set-up 
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4.5 Fluorescence activated cell sorting (FACS) 
Fluorescence activated cell sorting (FACS) is a technique which can be used 
to study protein expression (Procedure adapted from Dr. Simon Allison). P-gp 
expression was analysed by this method as well. Following are the steps 
involved in FACS analysis. 
4.5.1 Cell Treatment 
Cells were seeded in T75 flasks (2 flasks per cell line) and grown to confluence. 
Medium changed every three days. When appropriate confluence was 
acquired, cells were trypsinised and collected in suspension and centrifuged at 
1000 rcf for 5 minutes. Supernatant was discarded and pellet was collected. 
4.5.2 Fixation 
Before fixation, collected pellet was washed twice with PBS. During washing 
pellet was transferred to the 15ml Falcon tube. After PBS wash pellet was 
resuspended in 1ml ice-cold (-20) methanol in PBS (90:10).  
To avoid clumps of cells during resuspension; pellet was initially resuspended 
in 100μl PBS and then 900l of ice-cold methanol was added drop wise with 
continuous vortex. This suspension then incubated on ice for 30 min and then 
transferred to -200 C until required for analysis. 
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Figure 4.31: FACS machine (BD Biosciences) 
 
4.5.3 Staining with Antibody 
4.5.3.1 Staining with specific primary and secondary antibody 
Fixed samples removed from -200 C storage, and centrifuged to get sell pellet. 
Obtained cell pellet was washed twice with incubation buffer (PBS containing 
0.5% BSA). This washing step was done to get rid of methanol. After washing 
and centrifugation, pellet was obtained, which was resuspended in 200l 
incubation buffer. 
Suspended pellet incubated for 10min at room temperature and 4l of primary 
antibody (final concentration 1:50) per vial containing 200l of cell suspension 
in incubation buffer was added. The suspension then kept for incubation at 
room temperature for about 1hr. 
1hr incubation followed by centrifugation to collect cell pellet. Pellet was washed 
twice with incubation buffer and finally resuspended in 200l incubation buffer 
containing secondary antibody having final concentration 1:1000 (1l antiboby 
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diluted to 1000l incubation buffer). Cells with secondary antibody were 
incubated for 30min in dark condition at room temperature. Once incubation 
done, volume of samples was matched to 1ml by addition of 800l of incubation 
buffer (200l initial volume) and samples were analysed by FACS (Figure 4.31). 
Each cell line having two vials as one treated with primary and secondary 
antibody and other one treated with secondary antibody alone. Each sample 
analysed three times 
4.5.3.2 Staining with positive and negative control antibodies 
Same like above, in second set of study each cell sample were equally divided 
in two vials to get equal protein concentration. Antibody staining protocol was 
used same as above. Cells were treated with Positive and negative control 
primary antibodies and incubated for 1hr at room temperature. Once incubation 
with primary antibodies done, then cells were centrifuged and pellet was 
washed twice with incubation buffer and followed by the corresponding 
secondary antibody treatment as mentioned in above protocol. Once all 
treatments and incubations with both primary and secondary antibodies were 
done, volume of sample matched to 1ml by adding required amount of 
incubation buffer, and finally samples were analysed with FACS taking three 
reads per sample. 
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4.6 Rhodamine efflux Assay 
Rhodamine efflux assay protocol was adapted from previously developed 
method. Procedure to study rhodamine efflux assay was used with several 
modifications in it to achieve better results. Black bottom 96 well plates were 
used to carry this assay. 
1. Protocol-1: 
Day-1 
 
Figure 4.32: Rh123 assay_ cells inoculation 
 
Cells were grown to approx. 80% confluence, and then used to carry out study. 
Flask with grown cells was removed from incubator and cells were washed 
twice with PBS and then trypsinised. After addition of trypsin cells were 
incubated for about 5 mins and then media was added once cells were 
detached from the surface of the flask. Trypsinised cells were then centrifuged 
to get rid of media containing trypsin and pellet was collected which then 
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resuspended in the fresh growth medium, Cell count was taken and cell 
suspension with 1×105 cells/ml was prepared. With multichannel pipette, 200µl 
cell suspension to each well was inoculated except 1st row (Figure 4.32); which 
means 2×104 cells/well was inoculated. Plated then placed for the incubation at 
370 C with 5% CO2 and incubated for 24 hrs. 
Day-2 
 
Figure 4.33: Rh123 assay_Rhodamine 123 treatment 
 
Next day when 24 hrs incubation done, plates were removed from incubator 
and placed in laminar. Old media from each well was removed and replaced 
with fresh media containing 8µM rhodamine-123 in it. Rhodamine containing 
media was replaced in all wells except 1st and 2nd row as shown in the Figure 
4.33 Cells then placed back for 1 hr incubation with rhodamine-123.  
108 
 
After 1hr incubation, rhodamine containing media was removed from all the 
wells and each well was replaced with the fresh media or corresponding 
inhibitor solutions as shown in the Figure 4.34 below. Once all wells were 
replaced with their corresponding solutions; plates then moved to plate reader 
which was set to continuous reading mode with 370C incubation temperature to 
incubate plates throughout readings. Readings were taken started from zero 
time reading and followed with every hr reading up to 24 hrs. After 24 hrs, 
viability of cells was tested using tryphan blue cell count method to ensure the 
cell viability after 24 hrs reading. 
 
Figure 4.34: Rh123 assay_Pgp inhibitor treatment 
 
2. Protocol-2: 
This protocol is slight modification of above protocol-1.All changes were done 
on Day-2 procedure; while Day-1 procedure is unchanged throughout. Day-1 
procedure was same; while there was one step added in Day-2 procedure. After 
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incubation with rh123 for 1hr, instead of replacing fresh media or corresponding 
inhibitor solutions directly, cells were washed thrice with fresh media after 
Rh123 incubation was removed, and then replaced with media solutions 
containing respective inhibitors with different concentrations. This step is done 
to get rid of excess rh123, which is not penetrated in cells. Finally well plates 
were moved to the plate reader to measure readings as mentioned above in 
Protocol-1. 
3. Protocol-3 
Like protocol-2, this protocol is modification as well derived from protocol-1. 
On Day-2, Cells were incubated with Rhodamine-123 solution for 1hr. Unlike 
of protocol-1 and 2; Rhodamine-123 solution was prepared in respective 
inhibitor solution, and rhodamine-123 was treated in presence of P-gp 
inhibitors. After 1hr incubation, rhodamine-123 solution was removed and cells 
were washed thrice with fresh media as done in protocol-1. After washing wells 
were replaced with corresponding inhibitor solutions. Plates then taken to the 
plate reader and readings were taken as mentioned above. 
4. Protocol-4 
In this protocol, on Day-2 wells were removed from incubator and old media 
was taken out. Before Rhodamine-123 treatment, cells were pre-incubated for 
1 hr with respective inhibitor solutions. After 1 hr incubation, inhibitor solutions 
were replaced with the rhodamine-123 solution prepared again in inhibitor 
solutions and plates were placed back for incubation for 1hr. After 1hr 
incubation plates were removed from incubator and rhodamine-123 solution 
was taken out and plates were washed thrice with the fresh media and replaced 
with corresponding inhibitor solutions prepared in growth media. Plates then 
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moved to plate reader (Figure 4.35) and readings were recorded as per 
previously mentioned. 
 
Figure 4.35: Fluorescence plate reader 
 
4.7 HPLC Method development for Curcumin Quantification 
To study curcumin permeability, it is necessary to develop analytical method to 
quantify the amount of curcumin permeated through the cell monolayers. HPLC 
method is developed for curcumin analysis from previously reported method (Li 
et al., 2009). 
4.7.1 Method development without use of internal standard 
Two different HPLC methods were developed with and without use of internal 
standard. To develop these methods, the solvent preparation and HPLC 
conditions are explained below. 
4.7.1.1 Preparation of curcumin solutions 
Curcumin solutions were prepared in growth media to analyse with the HPLC. 
Curcumin is water insoluble so DMSO is used to dissolve it for the preparation 
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of desired concentrations. Initially solution with 10mM was prepared in 1ml of 
DMSO which was considered as a stock solution, and then it is diluted to 100 
µM in the growth medium which is considered as a working 
solution/concentration. To prepare the working concentration with 100µM, 10 
µl of stock solution was taken and diluted it to the 10ml with the growth medium. 
This curcumin solution was further diluted with growth media to achieve desired 
concentrations. 
Once desired concentrations was prepared in the media, the prepared samples 
then followed with the extraction method. During extraction, equal volume of 
acetonitrile was added to the samples prepared. Mixed well and incubated for 
10-15 mins at room temperature to precipitate proteins present in the media. 
After incubation samples were centrifuged at 13000 rcf for 15 mins at 40C. 
Supernatant was collected gently and transferred to the HPLC vial and then 
analysed with the HPLC. 
4.7.1.2 Preparation of mobile phase-0.1% trifluoroacetic acid:Acetonitrile 
(40:60) 
Isocratic mobile phase was used for the analysis of curcumin. At first 0.1% 
trifluoroacetic acid was prepared at a volume of 1L. 1L of distilled water was 
taken and 1ml of distilled water replaced with trifluoroacetic acid, which gives 
0.1% triflouroacetic acid. 400ml of trifluoroacetic acid was taken and 600 ml of 
acetonitrile was added to it to make total volume 1L, which gives mobile phase 
having both solvents; 0.1% triflouroacetic acid and acetonitrile in a ratio of 
40:60. 
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4.7.1.3 HPLC System 
Quantification of curcumin was done by using Waters e2695 HPLC system with 
Waters 2998 Photodiode Array Detector. The peaks were analysed by using 
Empower software.  Column used was Waters Symmetry C18 5µ and 
4.6×250mm. Isocratic mobile phase was used.   Mobile phase solvents were 
0.1% trifluoroacetic acid and Acetonitrile mixed in ratio of 40:60. All the solvents 
used were HPLC grade. All samples were analysed using flow rate 1ml/min 
with an injection volume 20µl. During analysis the samples were stored at 100C 
while column was stored at 250C. The run time for per sample was 15 min and 
the detection of analytes was made at the wavelength of 420nm. The following 
Table 4.5 describes the HPLC system and conditions. 
Table 4.5: HPLC method for curcumin without internal standard 
 
Run Time: 15min 
Mobile Phase: 0.1% Trifluoroacetic acid: Acetonitrile (ACN) [40:60] - 
Isocratic 
Column: Waters Symmetry C18; 5µ; 4.6 X 250mm 
Wavelength: 420nm 
Flow Rate: 1ml/min 
Column Temp.: 250C 
Sample Temp.:100C 
Detector: Waters 2998 Photodiode Array Detector 
Software: Empower 3 
HPLC System: Waters e2695 
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4.7.2 Method development with internal standard 
In this method emodin is used as an internal standard for the curcumin. Internal 
standard can be useful to minimize the error occurred by injection volumes.  
4.7.2.1 Preparation of curcumin and Emodin (Internal Standard) solutions 
Curcumin solutions were prepared similarly as described in above procedure 
(4.7.1.1). Emodin was used as internal standard for curcumin. As emodin is 
water insoluble, it was dissolved in DMSO and stock solution of 0.5mM was 
prepared in DMSO. 20µM emodin was used throughout the studies, so to get 
this working concentration, stock solution was diluted accordingly in 
acetonitrile. During extraction step this emodin containing acetonitrile was 
mixed to curcumin samples instead of plain acetonitrile. Samples then mixed 
well and incubated for 10-15 mins at room temperature and then centrifuged at 
13000 rcf for 15 mins at 40 C. Supernatant then collected gently and transferred 
to the HPLC vials. Pellet was discarded. Supernatant was analysed then with 
HPLC. 
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Table 4.6: HPLC method for curcumin with internal standard 
 
Run Time: 15min 
Mobile Phase: 0.1% Trifluoroacetic acid: Acetonitrile (ACN) [40:60] - 
Isocratic 
Column: Waters Symmetry C18; 5µ; 4.6 X 250mm 
Wavelength: 420nm 
Flow Rate: 1.5ml/min 
Column Temp.: 250C 
Sample Temp.:100C 
Detector: Waters 2998 
                 Photodiode Array Detector 
Software: Empower 3 
HPLC System: Warers e2695 
 
Similar HPLC system was used as above with only change in flow rate. Flow 
rate was changed to 1.5ml/min; while all other conditions were kept unchanged. 
The Table 4.6 will describes the HPLC system and conditions used. 
4.7.3 Curcumin analysis in Serum containing and Serum free media with 
1:1 and 1:2 extraction methods: 
This study was carried out to understand amount of curcumin yield in different 
media using different extraction methods. The experiment was set in two 
different groups; of which one having curcumin solutions prepared in serum 
containing media that means regular growth media while other group had 
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curcumin solutions prepared in serum free media.  Each of the group was 
followed with the two different extraction methods of which one contain 
extraction with equal amount of acetonitrile that means acetonitrile was added 
to sample during extraction was having equal amount as that of sample so 
called as 1:1 extraction method. The other extraction method was having one 
part of sample volume and two parts of the acetonitrile during extraction which 
is named as 1:2 extraction method. These extraction methods were applied to 
both the above groups. Once respective volume of acetonitrile was added, 
samples were incubated for 10-15 mins at room temperature and after 
incubation centrifuged at 13000 rcf for 15 mi at 40 C. Supernatant was collected 
gently and transferred to the HPLC vials and analysis were done. Peak areas 
were recorded and graphs were plotted accordingly. 
4.7.4 Extraction Efficiency in Serum Media 
From the results obtained in previous study, serum media with 1:1 extraction 
method was selected for the further studies. The extraction efficiency of 
curcumin in selected serum media was studied. To study extraction efficiency, 
two sets of curcumin samples were prepared separately, one in serum media 
and other in pure acetonitrile. 1:1 Extraction method was applied that is equal 
volume of acetonitrile was added to the samples prepared in serum media and 
acetonitrile. Then incubated for 10-15 min and followed with centrifugation at 
13000 rcf for 15 mins at 40 C. Only samples prepared in serum media gave 
supernatant and pellet, so supernatant from media samples were collected 
gently and transferred to the HPLC vials. Samples prepared in acetonitrile did 
not yield two fractions like supernatant and pellet so they were transferred to 
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HPLC vials straight away. All the samples then analysed by the HPLC and peak 
areas were recorded. Obtained peak areas of both the samples were used to 
compare them together and calculate extraction efficiency. Extraction efficiency 
was calculated by using following formula. 
 
 
Where, 
PA_EXT= Peak Area after Extraction 
PA_Not EXT= Peak Area without extraction (sample in pure solvent) 
4.7.5 Curcumin Analysis in 4% BSA Media 
4% BSA media was used for the later permeation studies. The BSA media was 
prepared with addition of 4% BSA in Hank’s Balanced Salt Solution (HBSS) 
with PH 7.0. The media was used as receiver media in permeation study, so it 
needs to study curcumin yield in above mentioned media. So curcumin samples 
were prepared using 4% BSA media and analysed with HPLC. To study the 
difference in yield, the curcumin samples were prepared in three different 
solvents as curcumin in pure acetonitrile, curcumin in HBSS without BSA and 
curcumin in 4% BSA, internal standard was directly added to these samples 
during curcumin formulation. Of these three samples, pure acetonitrile and 
HBSS without BSA prepared samples were directly analysed with HPLC. While 
samples prepared in 4% BSA media were extracted with two different extraction 
methods as 1:1 and 1:2. After extraction these two samples were analysed by 
HPLC. Peak areas were recorded for all samples and yield of curcumin in form 
𝑬𝒙𝒕𝒓𝒂𝒄𝒕𝒊𝒐𝒏 𝑬𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚(%) =
𝑷𝑨𝑬𝑿𝑻
𝑷𝑨𝑵𝒐𝒕𝑬𝑿𝑻
× 𝟏𝟎𝟎 
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of extraction efficiency was calculated with comparing peak areas of acetonitrile 
with rest of the samples.  
4.7.6 Curcumin Extraction Efficiency in 4% BSA Media 
Further to previous study, extraction efficiency of curcumin was studied in 4% 
BSA media with 1:1 extraction method. As these mentioned conditions gave 
high curcumin yield in previous study, the media was used for the permeation 
study. To calculate extraction efficiency, two sets of curcumin concentrations 
were prepared. One set was prepared in acetonitrile with curcumin 
concentrations 6.25µM, 12.5µM, 25µM and 50µM and another set was 
prepared in 4% BSA media with same curcumin concentrations. Once all 
samples were prepared, acetonitrile with 20µM emodin was prepared. This 
acetonitrile with emodin was used for the extraction and added to all the 
prepared sampled in equal volume of samples. All samples were then 
incubated at room temperature for 10-15 mins and then centrifuged at 13000 
rcf for 15 mins at 40 C. Samples then removed after centrifugation and 
supernatant was collected gently and transferred to the HPLC vials. All samples 
were then analysed with HPLC and peak areas for all samples were recorded 
and compared to calculate the extraction efficiency. Same formula as above 
was used to calculate the extraction efficiency. 
4.8 Permeability Study 
To study permeability study, it is necessary to form the uniform and intact cell 
membrane on the transwell. Once membrane is formed drug samples were 
applied to the apical side of membrane and permeation was monitored. 
Processes involved in this study are described as follow. 
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4.8.1 Generation of Cell membrane on transwells 
Cells when reached to approx.  80% or more confluence was used for 
experimental set up. Flasks were taken out from incubator, cells were washed 
and trypsinised as per above mentioned procedure and cell suspension was 
prepared. Cell count was taken using haemocytometer and cell suspension 
having cell density 1 × 106 cells/ml was prepared. Each transwell inoculated 
with the 100µl cell suspension, it means 1 × 105 cells/transwell was seeded. 
Transwells were placed in well plates and moved to incubator for 2 hrs 
incubation without addition of any media to the bottom chamber of transwells.  
This step is done to allow cells to attach to the transwell membrane. After 
incubation plates were removed and 200µl media to top chamber and 1.5ml 
media to bottom chamber were added and plates were returned for the 
incubation at 370 C supplemented with 5% CO2. Medium was changed every 
three days of interval until cell membranes were ready for permeability study. 
TEER value was measured before and after the permeation to assess the 
confluence of cell monolayer. 
4.8.2 Preparation of donor and receiver media 
Curcumin is used as a drug sample while galaxolide as a permeation enhancer 
in this study. 
To carry out permeability study through the cell membranes grown on 
transwells, donor and receiver media were needed. Donor media was prepared 
with drug concentrations while receiver media was the media without any drug 
concentration. Several donor and receiver media was prepared to carry out 
permeability study. Curcumin was the drug used to carry out permeability along 
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with the addition of galaxolide which was supposed to be the permeability 
enhancer. According to the need of experiment various donor and receiver 
media was prepared. 
In initial studies, donor media was prepared in the growth medium. 50µM and 
100µM curcumin solution was prepared in growth media. Curcumin is water 
insoluble compound, so it was initially dissolved in the DMSO solution and then 
further diluted with the assay media to get required working concentration 
making sure that DMSO concentration in donor media was not more than 1%. 
To study effect of galaxolide on permeability of curcumin, donor media was 
supplemented with 1µM or 5µM galaxolide in addition with above mentioned 
curcumin solutions. Galaxolide as well insoluble in water, so same as like 
curcumin, it was initially dissolved in DMSO and then further diluted with assay 
media to get working concentrations. The pH of this donor media was 7.4 
throughout the studies. This donor media was supported with the receiver 
media which is nothing but regular growth media having pH 7.4. These donor 
and receiver media was used to study permeability of curcumin through several 
cell lines. 
The other donor and receiver mediums were prepared in the HBSS solutions. 
To prepare donor media HBSS was supplemented with 20mM HEPES buffer 
having pH 6.5. The drug solutions were prepared in this donor media and drug 
solutions are curcumin, curcumin + galaxolide and curcumin + verapamil. 
Curcumin was used at concentration of 50µM while concentrations of 
galaxolide and verapamil were used 5µM each. All drug solutions were 
prepared as mentioned above. Unlike curcumin and galaxolide, verapamil is 
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water soluble, so it was directly dissolved in distilled water to get stock solution 
and further diluted with assay media in order to get working solution. The 
receiver media contain 4% BSA prepared in HBSS with addition of 20mM 
HEPES buffer. The pH of receiver media was set to the 7.0.  
The donor media was applied to the upper compartment while receiver media 
was added in the lower compartment to study the permeability of curcumin 
through cell membrane. 
Following figures; Figure 4.36, Figure 4.37 and Figure 4.38 describes the 
different experimental set ups with different donor and receiver media. 
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Figure 4.36: Permeability study_100µM curcumin in media 
 
 
Figure 4.37: Permeability study_50µM curcumin in media 
 
 
Figure 4.38: Permeability study_50µM curcumin in HBSS 
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4.8.3 Permeability Study 
 
Figure 4.39: Magnetic stirrer 
 
Cells were grown on the transwells until get intact cell membrane. The growth 
time on transwells was different for different cell lines, so cells were grown as 
per their individual requirements. Once cell membrane was intact and ready to 
carry out permeation study, transwells were removed from the incubator. Old 
media was removed from transwells using micropipette and replaced with the 
fresh media. Medium change order was same as described earlier. In the 
meantime, TEER measurement assembly was made ready, and TEER 
measuring probe was placed for calibration in media. Once media was changed 
for each transwell, TEER value was measured for each transwell along with the 
one blank transwell. TEER values were recorded. Transwells which were 
planned to treat with curcumin+galaxolide drug combination were pre-treated 
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with respective galaxolide concentration. Plates were placed in incubator for 
1hr. After 1hr pre-treatment of galaxolide, plates were removed from incubator; 
transwells were allocated as per need. 200µl donor media with drug solutions 
was added to each transwell and transwells were placed in receiver 
compartment containing 1.2ml receiver media in it and a piece of stirrer wire. 
The permeation assembly was immedietly moved to the magnetic stirrer (Figure 
4.39) fitted in the incubator. The permeation study was carried out at 370C 
supplemented with 5% CO2. Sample was collected at each time point. 
During sample collection, 600µl solution from receiver media was collected and 
replaced with same amount of fresh receiver media. The solution from upper 
compartment (donor media) was remained unchanged till end of the study.  In 
earlier studies, during sample collection, solutions from both the compartments 
were replaced every time. The samples were collected on various time points 
and finally analysed by HPLC. Once all samples were collected and study was 
done, TEER was measured once again and histology study of cell membranes 
was carried to check integrity of cell membranes. 
4.8.4 HPLC Analysis 
 Samples collected were then analysed with HPLC method to detect amount of 
curcumin permeated at different time points. 600µl sample was collected at 
each time point. These samples were then extracted with HPLC grade 
acetonitrile. For extraction of samples, same amount of acetonitrile was added 
to the samples and samples were mixed well with vortex and incubated for 
15min at room temperature. Once precipitate was appeared, samples were 
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centrifuged at 13000rcf, for 15 mins at 40C. Supernatant was collected in and 
analysed with HPLC method described as above.  
Quantification of curcumin was done by HPLC, using Waters e2695 HPLC 
system with Waters 2998 Photodiode Array Detector. The peaks were analysed 
by using Empower software.  Column used as Waters Symmetry C18 5µ and 
4.6×250mm.  Mobile phase solvents were 0.1% trifluoro-acetic acid and 
Acetonitrile mixed in ratio of 40:60. Isocratic mobile phase was used. All the 
solvents used were HPLC grade. All samples were analysed using flow rate 
1ml/min with an injection volume 20µl. Samples which were prepared with 
internal standard, were analysed using flow rate 1.5ml/min. During analysis the 
samples were stored at 100C while column was stored at 250C. The run time 
for per sample was 15 min and the detection of analytes was made at the 
wavelength of 420nm. 
The samples analysed using internal standard, were extracted using 
acetonitrile containing 20µM emodin in it. Other procedures were followed as 
same. HPLC data was recorded and analysed. The apparent permeation rate 
was calculated using formula (Yu and Huang, 2011a): 
𝑷𝒂𝒑𝒑 = (
𝒅𝑸
𝒅𝒕
) (
𝟏
𝑨𝑪𝟎
) 
Where, 
dQ/dt = rate of curcumin permeation 
A = surface area of the transwell insert 
C0= initial concentration of curcumin 
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4.8.5 Histology study of cell membranes after permeability 
Transwell membranes after permeability study were removed from magnetic 
stirrer and placed in well plates. Drug solutions were removed and transwells 
were washed twice with fresh media and finally 200µl in top chamber and 700µl 
in bottom chamber was flooded with fresh media. TEER readings were taken 
as mentioned earlier along with blank transwell. Transwells then fixed in Bouin’s 
solution for 1 hr and then washed and stored in 70% ethanol. Histology study 
was carried when all transwells were ready. 
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5 : P-glycoprotein expression and 
inhibition 
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5.1 Introduction 
The main objective in this chapter is to determine the safe concentration of 
galaxolide to use in cell based assays. Another objective is to study the P-gp 
expression in various cell lines, and later use these P-gp expressing cells to 
study P-gp inhibition assay and to determine the ability of galaxolide to inhibit 
P-gp. 
5.2 Galaxolide Cytotoxicity 
This research is focused to explore the P-gp inhibitory activity of galaxolide, 
and to use this characteristic of galaxolide for the improvement of drug 
permeation through the biological membranes. Galaxolide is key compound in 
experiment and used as novel efflux inhibitor molecule in this research and that 
is why it was necessary to study its toxicity on cell lines. So to determine safe 
concentration of galaxolide, toxicity study was done on various cell lines using 
MTT assay. 
The general purpose of the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5diphenyl 
tetrazolium bromide) assay is to measure viable cells in relatively high 
throughput 96-well plates, without the need of cell counting. The assay is based 
on the conversion of MTT into formazan crystals by living cells, which 
determines mitochondrial activity. For most cells, the total mitochondrial activity 
is related to the number of viable cells. The MTT assay is mainly used to 
measure the in vitro cytotoxic effects of drugs on cell lines. 
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Figure 5.1: Conversion of the tetrazolium salt MTT into formazan 
crystals 
 (Mosmann, 1983) 
 
 
 
Figure 5.2: MTT well plates A) before B) after addition of MTT dye 
The colour formation is proportional to the number of living cells. Figure (B) 
shows the colour intensity goes on reducing on higher drug concentration 
side (right hand side). This is because of the more cell death at high drug 
concentration.  
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The principle of the MTT assay is based on the mitochondrial activity of viable 
cells and for most of the cells it is constant; so any increase or decrease in the 
number of viable cells is directly proportional to change in mitochondrial activity. 
As mentioned earlier the mitochondrial activity is reflected by the formation of 
formazan crystals, which can be solubilised using DMSO for homogenous 
measurement. The optical density (OD) of formazan can be detected at 540nm. 
So any increase or decrease in viable cell number can be detected by 
measuring formazan concentration reflected in optical density. 
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Figure 5.3: MTT Assay_ Dose response curves for various cell lines  
(A) Caco-2, (B) SH-SY5Y, (C)LN-229, (D) U87MG, (E) MDCKII, (F) MDCKII-MDR1, 
(G) MDCKII-BCRP, (H) MDCKII-MRP1 and (I) MDCK 
 
The Figure 5.3 shows the dose responsive curve for the various cell lines which 
contains values plotted on X and Y-axis as concentration (µM) vs cell survival 
(%) respectively. The dose response curves are steady at the initial stage which 
means more number of cell survival is there at lower drug concentration range 
and as concentration is increasing, the survival rate dropped exponentially and 
after that once again graph shows steady phase, and which has very few or no 
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cell survival at these stage, and this is because of the very high concentration 
of the drug exposure to the cells. Different cell lines were treated with galaxolide 
concentrations prepared with two fold dilution along with blank wells and 
untreated cells as a control of an experiment. When plates were measured with 
plate reader, the readings are used to plot dose responsive curves. To achieve 
these dose responsive curves, untreated cells are set as 100% survival and 
various concentrations of galaxolide were used against these untreated cells to 
calculate the percent survival of cells at given concentration of the galaxolide. 
By using these dose responsive curves IC50 value (The value of IC50 for a drug, 
is the dose required to inhibit half the population of a tested cells in vitro after a 
specified test duration) of galaxolide for each given cell line is calculated (Table 
5.1).  
Table 5.1: Various cell lines with corresponding IC50 values of Galaxolide 
Cell line Galaxolide_IC50 (μM) ± SD (n=3) 
Caco2 109.27 ± 2.99 
SH-SY5Y 96.82 ± 7.19 
LN229 66.92 ± 6.41 
U87MG 41.08 ± 7.32 
MDCK 51.98 ± 2.32 
MDCKII 50.51 ± 7.62 
MDCKII-MDR1 51.51 ± 6.98 
MDCKII-BCRP 50.77 ± 9.30 
MDCKII-MRP1 64.19± 0.61 
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Figure 5.4: Various cell lines with corresponding IC50 values of 
Galaxolide 
 
Total nine different cell lines were used to study galaxolide toxicity. Some cells 
were cancer cell lines (LN229 and U87MG) while some were normal cells 
(Caco-2, SH-SY5Y, MDCK, MDCKII, MDCKII-MDR1, MDCKII-BCRP and 
MDCKII-MRP1. Amongst the tested cells against galaxolide, Caco-2 cell line 
shows highest IC50 value which is about 98.87 µM while U87MG cell line shows 
lowest IC50 value; 40.45µM. All other tested cells; SH-SY5Y (95.03µM), LN229 
(66.90µM), MDCK (52.29µM) have shown different IC50 values when tested for 
galaxolide toxicity. The derivatives of MDCK cell lines such as MDCKII cell line, 
MDCKII-MDR1 (MDR1/P-gp overexpressing cell lines), MDCKII-BCRP (BCRP 
overexpressing cell line) and MDCKII-MRP1 (MRP1 overexpressing cell line) 
have IC50 values 55.02µM, 51.76µM, 49.56µM, and 64.19µM respectively. Data 
observed in above experiments shows that, Caco-2 cells are more resistive 
against galaxolide compared to all other cell lines. Also no cell line amongst the 
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tested cells have IC50 value below 40µM, that means it is safer to use galaxolide 
below this concentration to carry out further experiments to evaluate galaxolide. 
5.3 Effect of Galaxolide on drug toxicity 
Use of galaxolide in this research was to evaluate it as an efflux protein inhibitor 
molecule such as P-glycoprotein inhibitor and to suppress the multidrug 
resistance conferred by the target cell, and as a result of which the drug 
molecule treated in combination with galaxolide should show higher activity 
against the targeted cells. This could be achieved by the suppression of the 
multi drug resistance with galaxolide in cells and allow accumulation of the drug 
inside the targeted cell. The drug toxicity assay/MTT assay was carried to study 
this hypothesis. Curcumin and Temozolomide were used as the drug 
candidates and was administered to the cells with and without the galaxolide. 
Drug candidates were applied in combination with known P-glycoprotein 
inhibitors such as Cyclosporine A and Verapamil as a positive control to track 
down the galaxolide activity. Dose response curves were obtained from the 
measurements observed (Figure 5.5, Figure 5.6 and Figure 5.7) and IC50 values 
were obtained and compared to study the effect of galaxolide. U87MG and 
LN229 cell lines were used for this study. Both these cells are derived from the 
glioblastoma cells, and one of research objective was to improve drug delivery 
to brain cancer, so these cell models were used to study effect of galaxolide on 
drugs toxicity with respect to glioblastoma cells. 
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Figure 5.5: Dose Responsive Curve of U87MG cells  
with curcumin and Curcumin+ P-gp inhibitors (galaxolide, verapamil and 
cyclosporine A) 
 
 
Figure 5.6: Dose Responsive Curve of LN229 cells  
with curcumin and Curcumin+ P-gp inhibitors (galaxolide, verapamil and 
cyclosporine A) 
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Figure 5.7: Dose Responsive Curve of LN229 cells  
with Temozolomide and Temozolomide+ P-gp inhibitors (galaxolide, verapamil 
and cyclosporine A) 
 
Curcumin and Temozolomide were treated with and without galaxolide and 
known P-gp inhibitor compounds. The dose responsive curves were obtained 
for each of the drug combinations as observed in the Figure 5.5, Figure 5.6 and 
Figure 5.7. For each curve, the graph line started with steady line at the lower 
concentration range (approx. 0.97 µM to 15 µM) and it felt down as 
concentration goes on increasing (approx. from 15 µM to 125 µM) and again it 
was appeared to be steady at the higher concentrations (125 µM to 500 µM). 
There was some rise in graph line which have been observed at the end of the 
curve line (near 250 µM concentration), and it was not the reading measured 
because of the mitochondrial activity of living cells and these might be the false 
positive results. These rise were possibly because of the readings observed 
due to pellets formed by the drugs at higher concentrations. Both drug 
molecules were water insoluble, or having very less water solubility and 
0
20
40
60
80
100
120
0.1 1 10 100 1000
C
el
l S
er
vi
va
l (
%
)
Concentration (µM)
LN229
Temo
Temo+Gal (1µM)
Temo+Ver (5µM)
Temo+CsA (5µM)
137 
 
because of that, drugs were prepared in the DMSO solutions and then final 
concentrations were prepared in the growth media. As media have water as a 
base components, drugs with higher concentration during preparation of 
dilutions formed precipitate and did not shown clear solution. So there was 
possibility that these precipitates formed might have been interfered with the 
optical density during the reading measurement, and as a result of which false 
positive results observed here. These curve lines and readings were used to 
calculate corresponding IC50 value for each of the drug combinations. 
Table 5.2: IC50 values of Curcumin and Curumin+inhibitors on U87MG 
cells 
Drugs IC50 (μM) ± SD (n=3) 
Cur 25.78 ± 1.96 
Cur+Gal 37.77 ± 4.32 
Cur+Ver 21.72 ± 2.79 
Cur+CsA 23.92 ± 2.41 
  
 
Figure 5.8: IC50 values of Curcumin and Curumin+inhibitors on U87MG 
cells 
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Cell line U87MG treated with curcumin with and without co-administration of 
galaxolide and P-gp inhibitor molecules. Table 5.2 and Figure 5.8 shows the 
results obtained after the assay. Co-administration of curcumin and galaxolide 
shows the highest IC50 value than other drug combinations. Actually we 
expected lowest IC50with curcumin+galaxolide combination than curcumin only, 
because if galaxolide has P-gp inhibition avtivity, then it could stop efflux of 
drugs from the cells and eventually accumulation of drug would kill more cells 
at lower concentration. Positive controls, curcumin+ verapamil and 
curcumin+CsA shows lower IC50 than curcumin.  
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Table 5.3: IC50 values of Curcumin and Curumin+inhibitors on LN229 cells 
Drugs IC50 (μM) ± SD (n=3) 
Cur 22.29 ± 1.02 
Cur+Gal 29.40 ± 1.08 
Cur+Ver 26.08 ± 0.69 
Cur+CsA 23.30 ± 2.26 
  
 
Figure 5.9: IC50 values of Curcumin and Curumin+inhibitors on LN229 
cells 
 
As like with U87Mg cell lines, LN229 cells shown higher IC50 for the 
curcumin+galaxolide dose (29.27 µM) than the curcumin only (22.25 µM) and 
other drug combinations. Here in LN229 cell lines, unlike U87MG, even 
curcumin+verapamil and curcumin+CsA doses shown higher IC50 as well, than 
curcumin dose which were 26.22µM and 23.12µM respectively (Table 5.3 and 
Figure 5.9). From the results obtained with both of the cell lines, it seems that 
curcumin is possibly the poor substrate of the P-gp, and because of that even 
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in presence of the inhibitor molecules it did not shown any major difference in 
the IC50 values and also shown the lower IC50 than the curcumin+inhibitor 
doses. 
Table 5.4: IC50 values of Temozolomide and Temozolomide+inhibitors on 
LN229 cells 
Drug IC50 (µM) ± SD (n=3) 
Temo 85.05 ± 8.26 
Temo+Gal 92.14 ± 5.19 
Temo+Ver 97.77 ± 1.80  
Temo+CsA 75.17 ± 5.43 
  
 
Figure 5.10: IC50 values of Temozolomide and Temozolomide+inhibitors 
on LN229 cells 
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Studies with curcumin does not gave any clear idea about the effect of inhibitor 
molecules on toxicity of drug when administered in combination, so the 
curcumin was replaced with other drug; temozolomide. Study done with LN229 
cell line which is derived from glioblastoma and temozolomide is a known drug 
used against glioblastoma. Temozolomide also shown similar results to 
curcumin, as there were no differences in IC50 values. Temozolomide with and 
without galaxolide had almost same IC50 values, 89.75 µM and 91.42µM 
respectively. Temozolomide+verapamil (99.55µM) dose shown highest while 
temozolomide+CsA (73.65µM) shown lowest IC50 amongst these doses. 
5.4 P-glycoprotein expression study 
These experiments were performed to study characteristics of galaxolide to 
inhibit P-glycoprotein activity, and eventually to develop galaxolide as an in vitro 
P-glycoprotein inhibitor. To carry out the study, it was first necessary to confirm 
the expression of P-glycoprotein in cell lines which we were using in 
experiments. Caco-2 and MDCK cell lines were used to study P-glycoprotein 
expression as these cell lines later used to carry out permeability studies. 
Protein expression was analysed using two techniques; Western blotting and 
flow cytometry (FACS). 
5.4.1 P-glycoprotein expression by western blot 
Western blot (WB) also called immunoblot is an analytical method to detect 
protein, which is widely used to detect specific proteins in a given sample of 
tissue homogenate or extract. Identification of protein of interest is based on 
two distinguishing properties; a) molecular weight and b) antibody binding 
specificity. Western blot is highly sensitive technique. 
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Antibodies bind to specific sequences of amino acids, known as the epitope. 
Because amino acid sequences are different from protein to protein, antibodies 
can recognize specific proteins among a group of many. Therefore, a single 
protein can be identified in a cell lysate that contains thousands of different 
proteins and its abundance quantified through western blot analysis. First, 
proteins are separated from each other based on their size. Second, antibodies 
are used to detect the protein of interest. Finally, a substrate that reacts with an 
enzyme is used to view the antibody/protein complex. 
 
Figure 5.11: Chemiluminescence detection 
 
Most proteins do not absorb visible wavelengths of light, and hence will not be 
visible during the course of electrophoresis. To ensure that the proteins are not 
eluted from the gel into the lower buffer reservoir, a small molecular weight, 
anionic dye, bromophenol blue is added to the protein before it is placed on the 
gel. The electrophoresis is halted when the dye reaches near the end of the 
running gel. The gel assembly is removed from the electrophoresis chamber, 
the glass plates separated, and the gel washed into buffer (transfer buffer). 
After a standard SDS-slab electrophoresis experiment is run, the gel is overlaid 
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with a piece of nitrocellulose filter paper. The sandwich of gel and filter paper is 
placed back into an electrophoresis chamber, such that the proteins migrate 
from the gel into the nitrocellulose, where they irreversibly bind. The filter paper 
can be removed and soaked in a solution containing a specific antibody to a 
protein of interest on the nitrocellulose. Enzyme linked secondary antibody is 
then added to this protein- antibody complex. The detection method used is 
dependent upon the enzyme to which the secondary antibody is conjugated. 
The most common enzyme used in Western Blotting is horseradish peroxidase 
(HRP), and the substrate used for detection is known as chemiluminescent 
substrate. The secondary antibody, which binds the antibody specific for the 
protein of interest, is conjugated to an enzyme; when it acts on the substrate, 
light is emitted (Figure 5.11).The produced light then gathered on X-ray film and 
used to develop the films. Films then analysed for the bands appeared on it. 
5.4.1.1 Quantification of total protein from cell lysates 
BSA protein assay was done to study the total protein concentration present in 
the cell lysates harvested for the WB analysis. To carry out successful WB, it 
was necessary to load equal amount of protein on gel for every sample, so BSA 
protein assay helped to calculate total protein present in cell lysates. 
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Figure 5.12: BSA Protein Assay linearity curve 
 
BSA assay was done with known BSA concentration to get linear calibration 
curve (Figure 5.12). Cell samples were analysed along with standards. The 
colorimetric reading was plotted against the calibration curve to evaluate total 
protein concentrations present in the lysate. From obtained data, equal amount 
of proteins were loaded on the gel and other processes as mentioned above in 
methods were done to get final blots (Figure 5.13 and Figure 5.14). 
                               A                                                          B 
 
Figure 5.13: Western blot analysis of P-glycoprotein  
A) Caco-2 and B) MDCK 
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P-glycoprotein is a large protein molecule with the molecular weight 170kD. 
Several bands were appeared in above blots. Figure 5.13 shows the blots A 
and B which were analysed for the P-glycoprotein expression in Caco-2 and 
MDCK cell lines respectively. Both blots shown similar expression bands. First 
column of both blots shows the bands for positive control for the P-glycoprotein 
and MCF-7/adr cell line was used as positive control as this cell line 
overexpress the P-glycoprotein. In blot A, column 2 to column 8 are the various 
Caco-2 samples harvested at different time points, such as every 5 days from 
day 5 to day 30, and this was done to check the differences in expression level 
of P-glycoprotein on different incubation time point. Similar samples were 
harvested for MDCK cell lines, and they were located in column 2 to column 7, 
while column 8 again contains positive control. 
As mentioned above, P-glycoprotein is a 170kD protein molecule. Figure 5.13 
showing blots A and B, where very light bands were appeared around 170kD 
region. Blot for Caco-2 shown dark bands around 130kD and 95kD; while blot 
for MDCK shown darks band around 130kD, which was similar like Caco-2 and 
other appeared near 72kD. The bands appeared in Caco-2 near 95kD and in 
MDCK near 72kd did not show its presence in a column where the positive 
control was present. This means these were not the bands for P-glycoproteins 
and were non-specific and unknown proteins. The bands near 170kD; though 
they were very light in appearance; shown the presence of P-glycoprotein 
expression in both the cell lines. In Caco-2 this band with 170kD located slightly 
above the band of 130kD. This band clearly shows expression of P-glycoprotein 
in abundance in positive control as compared to the different Caco-2 test 
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samples. Also it shown very low expression in samples which was harvested at 
day-5 and expression seems increasing with the increase in sample harvesting 
time.  The band which appeared near 130kD, was probably for the sister P-
glycoprotein (spgp); which is generally 140kD-150kD protein molecule. The 
spgp have high similarities in sequence with the P-glycoprotein; but this spgp 
is not a member of multigene family of P-glycoprotein (Childs et al., 1995; 
Gerloff et al., 1998). 
The lower bands around 95kD in Caco-2 and near 72kD in MDCK were 
probably the bands of mini-Pgp protein molecules. These mini-Pgp are having 
molecular weights between 65kD to 96kD and have studied in some aquatic 
animals as well as it found to be expressed in natural killer cells instead of 
expression of regular 170kD P-glycoprotein (Kawai et al., 1994; Trambas et al., 
2001; Valton et al., 2015). So there is possibility that these bands in above blots 
were possibly the mini-Pgp and they shown expression in Caco-2 and MDCK 
cells but not in positive control cells MCF-7/adr. The study performed without 
negative control and more ever the primary antibody used in this study, did not 
have any published review till now, so these results couldn’t be robust. So 
repeated the western blot study with new antibody C219 (Anti P-glycoprotein 
Mouse Antibody - Merck-517310) and previous antibody (Anti-ABCB1/MDR1 
Antibody-LS-C178472) as well. This new antibody have publication support as 
it was used in number of studies. In this study positive and negative controls 
were used along with the cell samples to support the results obtained. 
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Both blots in above Figure 5.14 were prepared to study P-glycoprotein 
expression with two different antibodies as mentioned above. Blot A treated 
with Anti ABCB1 antibody; which did not have any publication support while blot 
B is treated with C219 antibody; which was used in several published work. In 
both blots, first column is for positive control sample and MDCKII-MDR1 cell 
lines which overexpress P-glycoprotein was used as positive control, row 
second contains negative control; K562 cell line was used as negative control 
which did not express or shows very little expression of P-glycoprotein. Column 
3 and 4 was loaded with Caco-2 samples (harvested on day 10 and 15 
respectively) while column 5 and 6 contains MDCK cell samples (harvested on 
day 10 and 15 respectively).  
                   A                                                            B 
 
Figure 5.14: Western blot for analysis of P-glycoprotein A) Anti ABCB1 
antibody B) C219 Antibody  
[Lane-1: Positive control. Lane-2: Negative control, Lane 3 and 4- Caco-2 
samples (Day-10 and 15 respectively) and Lane 5 and 6- MDCK samples 
(Day 10 and 15 respectively)] 
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Blot A treated with anti ABCB1 antibody; same antibody used in previous study. 
Purpose to do this repeated study was to analyse expression with both positive 
and negative controls. Bands in this blot appeared was to be non-specific and 
unknown. Bands near 250 kD were present in both positive and negative 
control, while they were completely absent in Caco-2 and MDCK cell samples. 
These bands should not be P-glycoprotein as it shows much higher molecular 
weight around 250 kD and were present in negative control as well. Next bands 
appeared around 150kD and 130kD, and these were present in all samples 
including positive and negative control as well, so this indicateed that these 
bands were also not P-glycoprotein. As mentioned above, these bands could 
be spgp according to molecular weight, but this possibility also raises questions, 
because it shown presence in negative control as well. But if the case is like, 
negative control cells; K562 have expression of spgp and not regular P-gp then 
these bands should be of spgp, but we didn’t have any supporting data to 
confirm these assumptions for expression of spgp in these cell lines. Next 
bands seems near 85 kD approximately. This bands were present in positive 
control cells, absent in negative control cells, again present in both Caco-2 test 
samples and absent in MDCK test samples. The band in positive control was 
slightly lighter than bands present in Caco-2 samples. These bands probably 
the mini-Pgp, because mini-Pgp have molecular weight between 65kD to 96kD 
as explained above, and this mini-Pgp should have expressed in Caco-2 cells 
only and in lower quantity in positive control cells MDCKII-MDR1 while MDCK 
cells and negative control cells; K562 did not show expression of this mini-Pgp 
and because of that there were no appearance of bands on the blots developed. 
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Blot B have prepared with same samples as the previous one (blot A) and was 
treated with primary antibody C219.This film shows clear bands at the various 
molecular weight region. Bands appeared near 250kD and 95kD region were 
completely non-specific and unknown bands as they appeared in all samples 
including controls as well. Bands around 150kD and 130kD were present in all 
test samples and positive control and were absent in negative control. This 
indicates these were the bands of P-glycoprotein and spgp as this antibody was 
able to detect both these proteins from the samples. This study had confirmed 
that the cell lines Caco-2 and MDCK were able to express P-glycoprotein, and 
were able to play a good in vitro cell model to carry out further studies related 
to P-glycoprotein inhibition. 
5.4.2 P-glycoprotein analysis by fluorescence activated cell sorting 
(FACS) method  
Fluorescence-activated cell sorting (FACS) is a specialized type of flow 
cytometry. It provides a method for sorting a heterogeneous mixture of 
biological cells, one cell at a time, based upon the specific light 
scattering and fluorescent characteristics of each cell. It is a useful scientific 
instrument, as it provides fast, objective and quantitative recording of 
fluorescent signals from individual cells as well as physical separation of cells 
of particular interest. 
The process begins by placing the cells into a flask and forcing the cells to enter 
a small nozzle one at a time (Figure 5.15). The cells travel down the nozzle 
which is vibrated at an optimal frequency to produce drops at fixed distance 
from the nozzle. As the cells flow down the stream of liquid, they are scanned 
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by a laser. Some of the laser light is scattered by the cells and this is used to 
count the cells. This scattered light can also be used to measure the size of the 
cells. 
If we wanted to study the detection of specific protein, we could do so by tagging 
those proteins of interest with an antibody linked to a fluorescent dye. The laser 
light excites the dye which emits a colour of light that is detected by the 
photomultiplier tube, or light detector. By collecting the information from the light 
(scatter and fluorescence) a computer can determine the expression levels of 
the desired proteins. 
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Figure 5.15: FACS- how it works 
 
 
Figure 5.16: FACS detection mechanism 
 
The Figure 5.16 shows the primary systems of the flow cytometry 
schematically. These are diplomatic systems which presents samples to the 
interrogation point and takes away the waist. The lasers, which are the light 
source for the scatter and fluorescence, the optics (dichroic) which gathers and 
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direct the light, the detectors which receive the lights and the electronics and 
peripheral computer system which converts the signals from detectors into 
digital data and perform the necessary analysis. The interrogation point is the 
heart of the system. This is where the laser and the sample intersects, and the 
optics collects the resulting scatter in fluorescence.  
One of the most common ways to study cellular characteristics using flow 
cytometry involves the use of fluorescent molecule such as labelled antibodies. 
When laser light of the right wavelength strikes to these molecules, a 
fluorescent signal emitted and detected by the flow cytometer. How is this 
fluorescence information collected? The fluorescence light coming from 
labelled cells as they pass through the laser travels along the same path as the 
side scatter signal. As the light travels along this path, it is directed to the series 
of filters and mirrors, so that particular wavelength ranges are delivered to the 
appropriate detectors. Fluorescent data is generally collected in a way as 
forward and side scatter data. In a population of labelled cells some will be 
brighter than others. As each cell crosses the path of the laser a fluorescence 
signal is generated. The fluorescent light is then directed to the appropriate 
detector where it is translated into a voltage pulse proportional to the amount 
of fluorescence emitted. All of the voltage pulses are recorded and can be 
represented graphically.     
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Figure 5.17: Cytometric events displays the P-glycoprotein expression 
peaks for P-glycoprotein expression (green Peaks) (Purple peaks denotes 
negative control) 
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FACS analysis was done for various cell lines (Figure 5.17) to study P-
glycoprotein expression. In above mentioned analysis Anti-ABCB1 antibody 
was used as primary antibody to detect P-glycoprotein. Each samples were 
analysed in two sets as one set treated with primary and secondary antibody to 
detect P-gp specifically while set two was treated with secondary antibody 
which act as negative control in this study. Green coloured histogram in above 
figure determines the signal for P-glycoprotein while violet coloured histogram 
determines the signal for control. The graph displays a relative fluorescence or 
light scatter intensity on X-axis against number of events (cell count) on Y-axis. 
Histograms were achieved for cell lines mentioned above. In every graph, 
histograms for P-gp were more positively differentiated from the negative 
control histograms. These positive histograms clearly shown the expression of 
P-glycoprotein in analysed cell lines. The cell line U87MG shown comparatively 
less expression of P-glycoprotein as graph obtained for this cell line seems with 
lesser differentiation in P-gp positive histogram and negative control histogram. 
Both histograms seems to slightly overlapping at the base region. The cell line 
LN229 shown two histograms completely departed from each other, and P-gp 
positive histogram seemed to appear on more positive side. This could clearly 
show higher expression of P-glycoprotein in LN229 as compared to other cell 
lines analysed along with. The remaining cell lines such as Caco-2, MDCK. 
MDCKII, MDCKII-MDR1, DLD-1 and SH-SY5Y shown the cells treated with 
positive antibody have histogram at the more positive region than the negative 
control histogram. Both histograms were well separated without any overlaps, 
and confirms that these cell lines as well shown the P-glycoprotein expression. 
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To get more accurate data with this study, same experiment was repeated with 
two different antibodies for P-glycoprotein (C219 and Anti-ABCB1) and for 
negative control, isotype antibodies of these positive antibodies were used. The 
repeated study carried with Caco-2cell line and MDCKII-MDR1 cell line which 
is P-glycoprotein overexpressing cell line. The isotype antibodies (negative 
control antibody) was used to minimize the false result and to interpret data 
more specifically. The results observed in this study were mentioned below 
(Figure 5.18) 
                           A                                                     B 
 
 
                           C                                                     D 
 
Figure 5.18: Flow cytometry analysis of P-glycoprotein 
with different antibodies; C219 (A,C) and Anti-ABCB1 (B,D) 
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The graph above shows the histograms obtained with two different antibodies 
for P-glycoprotein and their isotype antibodies. The histograms obtained with 
positive antibody were plotted with green line while histograms with negative 
control isotype antibody were plotted with violet coloured solid plot. The Figure 
5.18(A and C) shows the histograms with the C219 antibody for both cell lines 
MDCKII-MDR1 and Caco-2. The histograms with the P-gp positive antibody 
shown very low fluorescence intensity than the negative control histogram. 
These histograms shown dominance of negative control peaks over the positive 
peaks. So according to observations with C219 antibody, the above mentioned 
cell lines did not show presence of P-glycoprotein. But on the other hand similar 
samples were analysed with another antibody; Anti-ABCB1; and surprisingly 
results seemed completely reverse (Figure 5.18; B and D). The positive 
antibody samples shown histograms with higher fluorescence intensity. Though 
both the positive peak and negative control peaks were overlapping, positive 
peaks were clearly seems with higher fluorescence than negative control.  
The C219 antibody in above experiment shown the negative results for the P-
glycoprotein, while other antibody; Anti-ABCB-1; shown positive results in both 
the instances with or without isotype antibody. According to results obtained in 
above studies, it seems that C219 antibody was not suitable for the FACS 
studies. Because this antibody shows the negative results even in the MDCKII-
MDR1 cell lines, and this cell line is known to overexpress P-glycoprotein. 
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5.5 P-glycoprotein inhibition study 
Rh123 assay was used to study the P-glycoprotein inhibition with galaxolide as 
a novel P-gp inhibitor molecule and with known P-gp inhibitor compounds; 
verapamil and cyclosporine A. 
The phenomenon of resistance of tumours to chemically unrelated anticancer 
drugs, termed multidrug resistance, represents a major challenge to the field of 
oncology. Multidrug resistance can be present at the time of diagnosis, or can 
be acquired after initial treatment of a cancer. Although multiple mechanisms 
mediate multidrug resistance, the first mediator of multidrug resistance to be 
characterized at the molecular level was MDR1 (Multi-drug resistance gene), 
also known as P-glycoprotein (P-gp) and ABCB1. MDR1 mediates resistance 
to various classes of chemotherapeutic agents by actively pumping the drugs 
from the cytosol and plasma membrane into the extracellular space. At least 
nine proteins related to MDR1 have been characterized to date and shown to 
mediate efflux of small molecules from cells. Two of these MDR1 relatives, 
multidrug-resistance-associated protein 1 (MRP1, or ABCC1) and breast 
cancer resistance protein (BCRP, or ABCG2), have also been demonstrated to 
mediate multidrug resistance in tumour cells. These proteins belong to a larger 
family of ABC proteins that function as transporters of ions, nutrients, and 
peptides. Multiple efforts have been made to standardize methods for MDR1 
detection using flow cytometry, immunohistochemistry and immunoblotting. It 
has been estimated that at least 50% of human cancers express the MDR1 
phenotype.MDR1 activity is also observed in various cell types in normal 
tissues. Brain microvascular endothelial cells express MDR1, which contributes 
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to the blood-brain barrier. It was proposed that expression of MDR1 in 
hematopoietic stem cells, intestine, and reproductive tissues (testicular 
endothelium and placental syncytiotrophoblast) protects these cells from the 
fatal effects of xenobiotics (Beck et al., 1996; Gottesman et al., 2002). 
Assessment of activity of MDR1, MRP1 and BCRP in cultured cells has been 
facilitated by the observation that several fluorescent small molecules, such as 
DiOC2(3), rhodamine 123, and calcein AM, which serve as substrates for 
MDR1 and its relatives.  When these dyes added to the cells, it penetrates and 
emits fluorescence. As these dyes are the substrates of efflux proteins, they 
are pumped out from the cells interior to extracellular space. The efflux can be 
reversed by addition of efflux inhibitor molecules. This phenomenon is used to 
carry the Rh123 efflux assay in this study. Rh123 readily pass through cell 
membranes via both active and passive transport mechanisms and accumulate 
in mitochondria. Fluorescence is produced by accumulation of dye in the 
mitochondria (Altenberg et al., 1994; Forster et al., 2012). 
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5.5.1 Rhodamine 123 Assay 
 
Figure 5.19: Basic principle of Rh123 assay 
In drug sensitive cells, non-fluorescent rh123 (orange diamonds) rapidly 
penetrates and accumulates in mitochondria and converts in fluorescent 
rh123 (red stars), and this accumulated rh123 emits high fluorescence. In 
multi-drug resistant cells, efflux proteins are present and they exclude rh123 
(both fluorescent and non-fluorescent rh123) rapidly from the cells, and thus 
rh123 does not accumulates in the cells and eventually emits less 
fluorescence [adapted from: (Altenberg et al., 1994; Forster et al., 2012)]. 
 
Rhodamine 123 dye is a substrate for the ABC transporter proteins. When cells 
are incubated with Rh123, the dye penetrates into the cells and produce 
fluorescence due to mitochondrial activity. But on the other hand the cells with 
efflux proteins can efflux the dye outside the cells and reduce the fluorescence. 
So if these efflux proteins were blocked with inhibitor molecules, the dye will 
retain inside the cell and will emit fluorescence. The fluorescence is then 
measured and percentage is calculated against the fluorescence obtained with 
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blank wells. So this principle is used in this assay to evaluate the characteristic 
of galaxolide to inhibit the P-gp and other efflux proteins (BCRP/MRP1). 
Verapamil and Cyclosporine-A are known P-gp inhibitors and used as positive 
controls in this study. As mentioned in methods section, assay was carried with 
different modifications in procedures to study the effect of inhibitors with 
different exposure times. Following are the results obtained for the assay. 
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Figure 5.20: % Fluorescence in Rh123 assay with different inhibitors 
A) Caco-2, B) MDCK and C) MDCKII cells (4.6, 1) 
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Figure 5.21: % Fluorescence in Rh123 assay with different inhibitors 
D) MDCKII-MDR1, E) MDCKII-BCRP and F) MDCKII-MRP1 cells (4.6, 1) 
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The fluorescent dye rh123 was used as an indicator of efflux transport activity 
and fluorescence obtained from it used as a measure of inhibition by each 
compound at the specified concentration. Assay was carried using various cell 
lines like Caco-2 and MDCK in which expression of P-glycoprotein was studied. 
Other cells used were MDCKII cells which is derivative of MDCK cell line and 
efflux protein overexpressing MDCKII cells; MDCKII-MDR1 (Overexpressing P-
gp protein). MDCKII-BCRP (over expressing BCRP protein) and MDCKII-
MRP1 (overexpressing MRP1 protein). The results obtained in above Figure 
5.20(A, B and C) and Figure 5.21 (D, E and F) shown the fluorescence pattern 
of rhodamine 123 in presence and absence of various inhibitor molecules. 
These results were obtained with protocol (4.6, 1) described earlier in methods 
section. Inhibitors were used in various range of concentrations to see the effect 
of concentration on the efflux pattern of Rh123. Galaxolide was used in range 
like 0.5µM, 1µM, 2µM, 5µM and 10µM; Verapamil and CsA, both are known P-
gp inhibitors and used with two concentrations (5µM and 10µM). Results shown 
here describes only selected concentration at which activity observed higher 
and this was done for the ease of understanding graph.  
Fluorescence obtained with blank samples; cells without treatment of Rh123 
were set to the 100% and fluorescence for cells treated with Rh123 were 
calculated against blank samples and fluorescence pattern is observed as a 
function of time for the differences in various samples. Caco-2 and MDCK 
(Figure 5.20, A and B) cells shown similar fluorescence pattern, in which blank 
sample shown straight line at the bottom around 100% fluorescence. Positive 
control sample; cells treated with rh123 and not applied any inhibitor molecule 
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shown incline in first 2hr and from next reading taken at 4hr shown a slight 
decline and the decline is till the last reading taken at the 16hr time. In Caco-2 
this decline was not so sudden but in MDCK cells after 12 hrs fluorescence 
shown the sudden decline. This fluorescence pattern of rh123 without any 
inhibitor shown the efflux of rh123 from the cells. On the other hand, samples 
treated with rh123 and various inhibitor molecules (Gal 1µM and 5µM; Ver 5µM, 
CsA 5µM) shown the same fluorescence pattern like the control sample. There 
was no any remarkable difference in fluorescent patterns observed with and 
without application of inhibitor molecules to the rh123 treated cell samples. As 
mentioned above, this experiment carried with procedure (4.6, 1) in which cells 
were not washed after incubation with rh123. So it is possibility that, we did not 
see any different in rh123 decay patterns in control sample and samples with 
inhibitors as well. It might be possible that the rh123 is wiped out from the cells 
in control set, but because of cells were not washed after incubation, they 
shown fluorescence with that excess rh123 even after they were excluded from 
the cells, and because of that there was no any differences in fluorescence 
obtained by control samples and samples treated with inhibitor molecules. 
Same method was applied to the MDCKII cells and its derivatives, MDCKII-
MDR1, MDCKII-BCRP and MDCKII-MRP1. These cells were modified to 
express specific efflux proteins, and so used to perform this assay and it was 
useful for comparative assessment of the ability of galaxolide to inhibit these 
specific efflux proteins. As shown in figures above (Figure 5.20, C and Figure 
5.21, D, E, F), MDCKII cell line and its derivatives did not show clear results for 
the inhibition activity of galaxolide, as there was mixed population of graphs 
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were obtained for the fluorescent activity. Galaxolide at 5µM concentration 
shown highest activity against all three efflux proteins, while galaxolide at 1µM 
and other known inhibitors, Ver and CsA did not show any inhibitory activity. 
They shown fluorescence even less than the control cells where we did not 
applied inhibitors. This data did not interpret anything as it gives mixed results, 
and as mentioned above, this might be due to the excess rh123 remained. To 
overcome this issue the protocol was modified, in which cells were washed after 
rh123 incubation step. And results for that experiment Are plotted below. 
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Figure 5.22: % Fluorescence in Rh123 assay with different inhibitors 
A)MDCKII,  B) MDCKII-MDR1, C) MDCKII-BCRP and D) MDCKII-MRP1 cells 
(4.6, 2) 
 
Figure 5.22 (A, B, C, D) shows the results for rh123 assay performed with 
method (4.6, 2) in which slight modifications were done than previous method. 
Cells were washed after rh123 incubation before addition of corresponding 
inhibitor solutions to the respective wells. The step was done to get rid of excess 
rh123 present in the sample wells and to avoid the false results obtained in 
previous experiment. 
In this repeated experiment promising results were obtained which can define 
the inhibitory activity of galaxolide along with known inhibitors; verapamil and 
cyclosporine A; against all three efflux proteins. The graphs (Figure 5.22) 
shown the increased fluorescence in all samples which had inhibitor solutions 
in it, while control sample which was treated with only rh123 show the decay of 
fluorescence as a function of time. The graph with rh123 decay shown the 
similar path in all four cell lines. The fluorescence with rh123 observed higher 
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in initial 2 hrs and after that the fluorescence declined gradually over the time. 
This data shown that efflux proteins were active and were responsible for the 
efflux of rh123 from the cells. On the other hand fluorescence intensity for 
samples treated with galaxolide and known inhibitor molecules seemed 
increasing gradually as the time increases. This kind of results were expected 
only when efflux proteins were inhibited or other strong substrate was added to 
the assay. The addition of strong substrate or inhibitor molecules could engage 
or block the efflux proteins like P-gp and other ABC protein family members. 
Such blocked or inhibited efflux proteins are not able to efflux rh123 from the 
cells and as a result of which rh123 accumulates in the cells and in presence 
of mitochondria it gives fluorescence. This fluorescence lasts without decay 
until and unless inhibitor molecules are removed, and that is why there was no 
any decline in the fluorescence with inhibitor molecules and galaxolide. 
In case of MDCKII-MDR1 cell line which overexpresses MDR1 protein i.e. P-
glycoprotein, Verapamil shown highest inhibitory activity against P-gp as 
compared to galaxolide and cyclosporine A. Galaxolide at 1µM concentration 
shown better inhibitory activity against P-gp as compared to galaxolide at 5µM 
and cyclosporine A. Cyclosporine A shows least P-gp inhibition activity and was 
approximately similar with galaxolide at 5µM. Even cyclosporine A shown least 
inhibitory activity, it did not shown any decay in the fluorescence as like the 
control. These results suggest that galaxolide has an ability to inhibit P-
glycoprotein and it seems better P-gp inhibitor than the known inhibitor 
cyclosporine A.   
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Observations with MDCKII-BCRP shown similar decline with rh123 
fluorescence as like MDCKII and MDCKII-MDR1. Galaxolide at both 
concentrations (1µM and 5µM) shown higher fluorescence which means 
highest inhibitory activity against BCRP as compared to other inhibitors, like 
verapamil and cyclosporine A. Cyclosporine A again shown least activity 
against BCRP as well. Galaxolide shows strong activity against BCRP as it 
shown higher fluorescence intensity immediately after 2 hrs and fluorescent 
intensity keeps increasing as per time. But in verapamil and cyclosporine A, the 
fluorescent intensity is very low till 6 hrs and which was near to blank readings 
and after that fluorescence intensity goes on increasing and with verapamil it 
reached to the maximum level even higher than the galaxolide. The data 
suggests that the verapamil and cyclosporine A had a poor inhibitory activity 
against the BCRP in initial time of assay but, as a function of time the activity 
increases. So it seems these two inhibitors need more time to react with BCRP 
and once reacted they show their inhibitory effect on BCRP for longer time. So 
at the end it could be stated that galaxolide have an inhibitory activity against 
BCRP as well along with the MDR1/P-gp protein. 
MDCKII-MRP1 data shown fluorescence pattern similar to BCRP cells. Here 
also galaxolide showing highest inhibitory activity against MRP1 proteins as it 
shows higher fluorescence intensity since beginning of the assay. Verapamil 
and cyclosporine A shown least fluorescence in the beginning and then 
fluorescence keeps increasing as time increases. As per data obtained it seems 
that like BCRP, verapamil and cyclosporine A were also poor substrates of 
MRP1. Galaxolide seemed to be a better inhibitor of MRP1 as well than 
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verapamil and cyclosporine A. So now it was clear that galaxolide had an 
activity against all three efflux proteins, and it seemed to be a broad range efflux 
protein inhibitor. It shown advantage over known inhibitors verapamil and 
cyclosporine A, as these two inhibitors had good activity only against MDR1 
while they show poor activity against BCRP and MRP1 unlike the galaxolide. 
As seen in BCRP and MRP1 overexpressing cells, verapamil and cyclosporine 
A inhibition activity is less than the galaxolide and as a result of which these 
inhibitors shown very low fluorescence intensity in the beginning of assay which 
then gradually increased approximately after 4-6 hrs. To reduce this lag, 
protocol was modified. Cells were incubated with rh123 which was prepared in 
solutions with corresponding inhibitor concentrations (refer 4.6, 3). The idea 
behind this was just to reduce the lag phase acquired by verapamil and 
cyclosporine A while inhibition of BCRP and MRP1. 
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Figure 5.23:  % Fluorescence in Rh123 assay with different inhibitors 
A)MDCKII,  B) MDCKII-MDR1, C) MDCKII-BCRP and D) MDCKII-MRP1 cells 
(4.6,3) 
 
As mentioned above, this assay was modified with procedure (4.6, 3) described 
above, to reduce the lag phase acquired by verapamil and cyclosporine A to 
inhibit the BCRP and MRP1. To achieve this goal to reduce lag phase, cells 
were incubated in rh123 prepared in corresponding inhibitor concentrations. 
Here in Figure 5.23 it is seen that the modification in protocol was successful in 
some extent to reduce the lag phase of verapamil and cyclosporine A to inhibit 
BCRP and MRP1 proteins. In previous experiment it was seen that verapamil 
shown highest activity against MDR1 while cyclosporine A shown least activity 
as compared to galaxolide. Here, with this modified procedure huge difference 
in activities of verapamil and cyclosporine A against MDR1 was observed. 
Cyclosporine A unlike previous activity shown the highest fluorescence 
intensity than both verapamil and the galaxolide. Galaxolide did not show any 
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difference in activity as a result of over pre-incubation. Inhibition activity of 
verapamil and cyclosporine A against BCRP have seen improved than previous 
results but there was some lag observed. It indicates that verapamil and 
cyclosporine A needs more exposure time to inhibit BCRP protein. While 
galaxolide gave high fluorescence at both the concentrations (1µM and 5µM). 
Galaxolide at 1µM concentration given better inhibition activity than 5µM 
concentration, though the difference was not too high. An improved activity of 
verapamil and cyclosporine A against MRP1 protein was observed, however 
these inhibitors still needs time to show their activity against MRP1. This could 
be stated by observing the slight lag of lower fluorescence intensity with these 
inhibitors. In reverse of these inhibitors, galaxolide shown better inhibition 
activity against all these efflux proteins, even with modified protocol. It did not 
show any big difference in fluorescence even after over incubation as it already 
shown higher fluorescence intensity from the beginning of assay. It means 
galaxolide has ability to inhibit these efflux proteins as immediately as its 
exposure to these efflux proteins.  
This assay was further modified to observe further improvement in inhibition 
activity of verapamil and cyclosporine A against BCRP and MRP1 proteins. 
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Figure 5.24:  % Fluorescence in Rh123 assay with different inhibitors 
A)MDCKII,  B) MDCKII-MDR1, C) MDCKII-BCRP and D) MDCKII-MRP1 cells 
(4.6,4) 
 
Results for assay was observed in Figure 5.24 (A, B, C and D) and these were 
achieved with further modification of assay procedure explained in methods 
section (4.6, 4). The fluorescence pattern for verapamil and cyclosporine A 
seemed similar like last experiment and there was no any promising change 
observed even after further pre-incubation of cells in presence of respective 
inhibitors. As like earlier results, these two known inhibitors shown strong 
inhibition activity only against MDR1 proteins, while it shown comparatively 
poor activity against BCRP and MRP1 proteins. In BCRP overexpressing cells, 
the activity after 12 hrs seemed to increasing rapidly. This sudden incline 
observed even in control samples where we did not applied any inhibitor which 
could stop the decay of fluorescence and show high intensity. This was 
unacceptable observation as compared to other graphs and mechanism of 
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assay. So it seems that it might be false reading observed by the plate reading 
as a result of some unknown factors.  
From all results observed above, rh123 assay gives clear picture on the 
inhibition of efflux proteins. As seen in all our different procedures, Galaxolide 
gives better inhibition activity than other known inhibitors. Galaxolide shown 
better activity at 1µM concentration than 5µM and unlike verapamil and 
cyclosporine A it had strong inhibition activity against all three efflux proteins; 
MDR1, BCRP and MRP1. In reverse of this Verapamil and cyclosporine A had 
strong inhibition action only against MDR1 while these two compounds shown 
poor activity against BCRP and MRP1. So here from obtained results it could 
be clear that, galaxolide could be a novel efflux transport inhibitor molecule 
which has broad range of activity against all three major efflux proteins. 
5.6 Summary 
The objective of this study was to evaluate galaxolide as a novel efflux transport 
inhibitor and use this characteristics for the improvement of drug therapies 
against diseases in which cell confers MDR and does not respond to 
chemotherapy. This characteristic of galaxolide could also be used to pass the 
drug molecules through biological membranes which expresses efflux proteins 
and creates a major hurdle for the drug penetration and eventually affects drug 
treatment.  
Before going further it was necessary to study the toxicity of galaxolide on 
various cell lines, so cell toxicity assays like MTT assay was performed. The 
assay provides us information that galaxolide was not toxic to normal cells as it 
shows much higher IC50 values than the concentrations actually used for our 
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studies. Various cell lines were used for this study including some cancer cells 
as well. Galaxolide shows less toxicity for all those cells and in fact very minute 
toxicity at the concentrations was used to perform other experiments. Once safe 
concentration of galaxolide was determined, it was necessary to study the P-
gp expression in cells which were planned to use in experiments. So P-gp 
expression was studied using two well-known methods like western blot and 
flow cytometry. Both studies were carried using two different antibodies used 
for P-gp detection. But as we seen antibody C219 gives positive results in 
western blot as we clearly see the bands, while other antibody anti-ABCB1 
gives good results with flow cytometry. Expression of P-gp was observed in two 
cell lines Caco-2 and MDCK. Other technique, immunohistochemistry was also 
used to study P-gp expression, but due to some technical reasons and time 
limitations further optimization of the method was not done and no any results 
were mentioned. In later section of this chapter P-gp inhibition study was 
performed, in which rh123 efflux assay was used to study P-gp inhibition or 
efflux transporter inhibition. Several protocols were used with slight differences 
to carry this study. And finally it was found that galaxolide unlike other known 
inhibitors; verapamil and cyclosporine A; had better activity against all three 
major efflux proteins; MDR1, BCRP and MRP1. So it proves that the galaxolide 
is better efflux transporter inhibitor than verapamil and cyclosporine A, as it has 
immediate inhibitory action against these proteins. 
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6 : Permeability Study 
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6.1 Introduction 
In this chapter permeability of curcumin through various cell membranes was 
explored as well as the development of HPLC methods for the quantification of 
curcumin is also studied.  
6.2 Cell based Permeability study 
Cell based permeation studies involve a transwell cell culture setup, in which 
the cells were grown on a permeable filter membrane inserts. Dense cell layers 
polarize on this filter layer to apical and basolateral sides (basolateral side 
facing to the solid filter growth support). The test compounds can be applied on 
either side of the cell layer (to the cell insert or the culture plate medium), which 
allows study of the permeation / transport form apical to basolateral (AB) and 
basolateral to apical (BA) directions. Here in this study permeation was 
performed only in one direction; apical to basolateral (AB) direction as per the 
requirement of our studies.  
 Typically the study involves sampling of the test compounds on both sides at 
given time points, followed by analysis of the test item concentration by HPLC 
method. Based on the measured concentrations, apparent permeation 
coefficient is calculated (Papp). We also check the cell layer was intact in each 
well by a TEER (trans-epithelial electrical resistance) measurement before the 
experiment. 
The cell based permeation models have some active drug transporter systems, 
including P-glycoprotein efflux transporter (P-gp, also known as multidrug 
resistance protein 1, MDR1, a member of the ABC transporters). The 
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involvement of the transporters can be estimated both in the apical-to-
basolateral vs basolateral-to-apical permeability’s. As seen in earlier studies, 
galaxolide have P-gp inhibition activity, so it was used with curcumin in 
permeability study to observe effect of galaxolide on the permeation of 
curcumin. In addition, known P-gp inhibitor was used with curcumin during 
permeation to assess the activity of galaxolide. 
To complete successful permeation study, it was necessary to have good 
analytical method so that the permeation of drug accurately could be 
determined. Curcumin was used as a drug molecule, so it was necessary to 
developed HPLC analysis method for it. Several HPLC methods were 
developed for the curcumin detection, out which one was developed without 
use of internal standard while other method was developed using internal 
standard. Internal standard was used to minimize the error in quantification. 
The most common reason to use internal standard is to eliminate variations 
with the injection volume. Because an internal standard method uses the ratio 
of responses for standard and analyte, quantitation does not depend on the 
amount of material injected. Further modifications in HPLC method for curcumin 
quantification are done according to the receiver media used in the permeation 
study. Several different extraction methods and solvents are used and finally 
extraction efficiency is determined in each method and according to that data 
and final HPLC method was chosen for the curcumin quantification. All method 
details and sample preparations are explained in methods section above (4.7). 
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6.3 HPLC analysis of curcumin 
HPLC methods were developed with different receiver media. Also the method 
developed in presence and absence of internal standards. All the results for 
these developed HPLC methods were described briefly here. 
6.3.1 HPLC analysis without internal standard 
The details of this method development were described in section 4.7.1. To 
obtain linearity curve, acetonitrile was used as solvent for curcumin. To identify 
peak for curcumin, blank acetonitrile was injected and analysed with HPLC, 
while to differentiate curcumin peak from media peak, extracted media also 
injected individually without curcumin in it. And later these solvents were used 
to prepare samples of curcumin. Following are the different samples showing 
peaks for the curcumin as well as blanks solvents. 
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Figure 6.1: HPLC chromatogram for curcumin (RT=6.1±0.1) 
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Figure 6.2: HPLC calibration curve for curcumin 
 
Figure 6.1 shows the peak for curcumin and blank solvents. To identify peak 
for curcumin, blank samples for acetonitrile and media were injected and HPLC 
analysis was performed. This blank samples help to differentiate the peaks 
particularly observed in receiver media. From above data obtained, it clearly 
seems that, retention time (RT) for curcumin is 6.1±0.1 and is far away from the 
peak of blank media which observed around RT 3.1±0.1.The method gives fine 
peak for the curcumin without interference of any other peak in both solvent 
systems; media and acetonitrile; so this method was used to obtain calibration 
curve. Linearity was done using different concentrations of curcumin prepared 
in acetonitrile. Area obtained for different curcumin concentration was plotted 
against the concentration and linear calibration curve was obtained with R2 
value which is 0.9945 (Figure 6.2).This method of curcumin quantification was 
used for the analysis for initial permeation studies. Before developing further 
methods, studies performed to determine effect of media component and 
extraction method on the yield quantification of the curcumin. So serum media 
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and serum free media were used to examine curcumin detection in both the 
media.  
6.3.2 Curcumin analysis in serum media and serum free media 
During permeability study, receiver media needs to be preparing to collect the 
sample permeated. Receiver media plays an important role in permeation 
study. So it was necessary to analyse the drug of interest in possible receiver 
mediums. Growth media was used as receiver media and to choose effective 
receiver media, analysis of curcumin was done in both serum media and serum 
free media. So samples were prepared in these two mediums and extracted 
with acetonitrile by 1:1 and 1:2 extraction methods (4.7.3).  
 
Figure 6.3: HPLC calibration curve for Curcumin with different solvents 
and extraction method 
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As mentioned above two different solvents were used; serum media and serum 
free media; and both sample sets were extracted with two different methods. 
Figure 6.3 gives the calibration curves for respective samples. Samples 
prepared in serum media gave higher yield after extraction as compared to the 
samples prepared in serum free media. There was no any major difference of 
extraction methods on the yield of curcumin. Both extraction methods (1:1 and 
1:2) gave approx. similar yield in their respective samples. Extraction method 
did not have high impact on curcumin yield from the receiver media, but serum 
played important role in yield. So in all permeability studies 1:1 extraction 
method, and serum containing growth medium was used. To get more accurate 
results, new method was developed using internal standard. The internal 
standard used to minimize errors. 
6.3.3 HPLC method with internal standard 
The method development part was described in section 4.7.2. Emodin was 
used as an internal standard for curcumin. Ratio of curcumin to internal 
standard (IS) was used to quantify curcumin concentration in the sample. Since 
emodin was used as internal, standard, few changes were done in the HPLC 
system and are described earlier section 4.7.2. Same like previous, various 
individual samples were injected to perform HPLC, to differentiate peaks of 
blank, curcumin and internal standard. 
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Figure 6.4: HPLC chromatogram for curcumin (RT=5.1±0.1) with emodin 
(RT=9.2±0.1) as internal standard  
 
 
Figure 6.5: HPLC calibration curve for Curcumin with emodin as IS 
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Method for curcumin analysis was developed using internal standard. Both 
curcumin and IS gives sharp peaks which were completely distinct from one 
another. In Figure 6.4, first picture shown the peak for blank media. Only media 
was injected and performed HPLC, so this peak was observed and which was 
considered as blank peak. In next sample, addition of IS was done to the media 
and this mixture gives peak which was described in second picture of the same 
figure. The peak around RT 3 was blank peak as described in the first sample, 
and the other peak was observed near RT 9.2±0.1 and this peak was for internal 
standard. Next sample injected, had mixture of curcumin and IS in media. The 
third picture in above figure gave three different peaks. Out of which, peak near 
RT 3 and peak at RT 9.2±0.1 were the peaks for the blank and IS respectively, 
and third peak which is at RT 5.1±0.1 was definitely for the curcumin. So in this 
way HPLC method was developed for curcumin with IS. Calibration curve for 
curcumin with this method was determined. Graph was plotted with peak area 
ratio vs concentration. Linear calibration curve with R2 value 0.996 is obtained 
(Figure 6.5).  
6.3.4 Extraction efficiency of curcumin in serum media 
All the above studies were performed to develop efficient HPLC method for 
curcumin analysis. Serum media was selected as a receiver media to carry out 
permeability study with curcumin. It is also necessary to determine exactly what 
percentage of curcumin is present in the extracts of the media. To study 
extraction efficiency, two sets of curcumin concentrations were analysed, one 
set is prepared in pure acetonitrile and other set is prepared in serum media. 
Any amount detected in acetonitrile, is considered as 100% recovery. Curcumin 
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recovered in serum media is calculated against curcumin recovered in 
acetonitrile, and percentage of recovery is determined. This percentage is then 
considered as extraction efficiency.  
 
Figure 6.6: Extraction efficiency (%) of curcumin in different media 
 
Table 6.1: Extraction efficiency (%) of curcumin in different medium 
Media Extraction efficiency (%) ± SD (n=2) 
Acetonitrile 100 ± 0 
EMEM 69.10 ± 15.47 
DMEM 62.82 ± 9.06 
RPMI 1640 55.51 ± 20.13 
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EMEM, DMEM and RPMI 1640; to study extraction. EMEM media shown higher 
extraction as compare to other two media, though the difference was not too 
high. EMEM shows 69.09 ± 15.47 % of recovery of curcumin while DMEM and 
RPMI 1640 shows 62.82 ± 9.06 % and 55.50 ± 20.12 % of recovery as 
compared to the pure acetonitrile recovery. Though these media shows 
relatively poor extraction efficiency for curcumin recovery, these media were 
used further to carry permeability studies. Table 6.1 describes values of 
extraction efficiency for different media. 
Several trials such as use of serum and serum free media or change in 
acetonitrile percentage during extraction were done to increase extraction 
efficiency using these media, but none of them were successful. So decided to 
use one more receiver media, which was used by some researchers to study 
permeation. This receiver media was HBSS with 4% BSA having pH 7.4 (Yu 
and Huang, 2011a). The media preparation is described in section 4.7.5.  
6.3.5 Curcumin analysis in 4% BSA media 
This media was prepared with addition of 4% BSA in HBSS at pH was 
maintained at 7.4. 20mM HEPES buffer was added to media to maintain 
desired pH. This media was used to develop HPLC method with 1:1 extraction 
process. Similar to earlier process developed with IS, samples were prepared 
and analysed using HPLC. 
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Figure 6.7: HPLC calibration curve for curcumin in 4% BSA media 
 
Calibration curve was obtained with this method (Figure 6.7) with R2 value 
0.9998.  This calibration curve was further used to quantify amount of curcumin 
present in unknown samples obtained after permeability study. Extraction 
efficiency for this media was studied to assess the curcumin recovery from the 
samples collected in 4% BSA receiver media. 
6.3.6 Curcumin extraction in 4% BSA receiver media 
To study extraction efficiency 4% BSA media, curcumin solutions were 
prepared three different solvents such as pure acetonitrile, HBSS without BSA 
and HBSS with 4% BSA. All these samples contains same concentration of 
curcumin. Samples were extracted with 1:1 extraction process, while samples 
prepared in 4% BSA media was extracted with both 1:1 and 1:2 extraction 
process. Recovery in acetonitrile considered as 100% extraction and other 
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solvents were compared against acetonitrile recovery to determine % extraction 
with respective media. 
 
Figure 6.8: Effect of BSA and solvent amount on extraction efficiency of 
curcumin from HBSS media.  
 
As seen in Figure 6.8, curcumin samples prepared in HBSS gave very poor 
yield of curcumin while samples prepared in 4% BSA media gave almost 100% 
recovery of curcumin. Both extraction processes 1:1 and 1:2 gave 100% 
recovery in 4% BSA media. So data suggested that, the 4% BSA media gave 
best receiver media amongst all above receiver media as it shown highest 
recovery of curcumin after extraction process. The values for extraction 
percentage for specific media are described in Table 6.2.  
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Table 6.2: % extraction of curcumin in different HBSS media 
Sample Extraction Efficiency (%) ± SD (n=3) 
Curcumin in acetonitrile 100.00 ± 0.0 
Curcumin in HBSS 31.58 ± 0.01 
1:1 Extraction 109.76 ± 0.40 
1:2 Extraction 108.62 ± 0.58 
 
A HPLC method for curcumin analysis using different mediums as a solvent 
was developed. It was observed that, curcumin recovery was higher in serum 
containing media than the serum free media. And was even higher 4% BSA 
media. From series of experiments it was found that, any media containing 
protein molecules shown the higher recovery of curcumin compared to media 
lacking additional protein molecules. This might be due to curcumin degradation 
in alkaline condition in the media, while, in protein containing media, curcumin 
could bind proteins or BSA strongly and could reduce the chances of 
degradation. The binding is stronger at alkaline pH than acidic, and receiver 
media used in this study was alkaline (pH 7.4) (Mitra, 2015; Wahlang et al., 
2011). So it is possible that the proteins or BSA present in the receiver media, 
protects curcumin from the degradation and eventually gives higher recovery. 
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6.4 Permeability Study 
Several permeability experiments performed for curcumin with and without co-
administration of galaxolide. All permeation studies were carried on day-12 from 
the date of plating of cells on transwell because of the trans epithelial electric 
resistance (TEER) value, which was higher on this day. The TEER value was 
measured to evaluate the confluence and integrity of cell membrane. For every 
permeability experiment, TEER was measured before and after permeation. 
Only those transwells with TEER above 300 Ω.cm2 were used for permeation 
studies (Wahlang et al., 2011; Yu and Huang, 2011a). 
6.4.1 Permeation study with growth media as donor and receiver media 
As mentioned above, various different protocols were followed to study 
curcumin permeability through Caco-2. There were some minor changes in 
each protocols and are described here with each results. 
Permeation study-1 
In this study (Figure 6.9, Figure 6.10), growth media was used as a base for 
both donor and receiver media. The donor media prepared with 100 µM 
curcumin to carry permeation and 20µM galaxolide was used, to study its effect 
on permeation of curcumin and receiver media was fresh growth medium. Top 
chamber provided with 100 µL of donor media and bottom chamber with 600 
µL receiver media. Two donor media; one had curcumin only and other had 
curcumin+galaxolide; were incubated separately on corresponding cell 
membranes and permeation was performed. Samples were collected at every 
5 mins for 1hr and then continued to collect at every hour up to 6 hrs. At every 
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sample collection time point, both the mediums (donor and receiver media) 
were replaced with respective fresh media to maintain constant diffusion 
gradient. Each drug sample studied for permeation was done in triplets. 
 
Figure 6.9: Effect of galaxolide on permeation of curcumin through caco-
2 monolayer 
 
 
Figure 6.10: Comparison of permeation rate of curcumin with and without 
galaxolide  (P > 0.05) 
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As shown in Figure 6.9, the permeation was approx. 15% after 1 hr of 
permeability study, and at the end of study after 6 hrs the permeation was about 
70%. The high percentage of permeation was only because, replacement of 
donor media every time during the sample collection with fresh donor media. 
That means every time there was new set of fresh curcumin concentration, 
which in turn gave approximately same permeation amount of curcumin every 
time. These permeated values then put together by taking their cumulative 
value and plotted on graph. And as a result of cumulative data higher 
permeation was observed. Same results were obtained in both the drug 
samples; cur and cur+gal. No promising difference in permeation percentage 
of curcumin was observed through Caco-2 with and without galaxolide in this 
study. Permeation rate (Papp) was also determined with these two drug samples 
through Caco-2 (Figure 6.10). The Papp for cur and cur+gal was (7.15 ± 0.9) × 
10-4 and (6.75 ± 1.2) × 10-4 respectively. This rate was considered as higher 
permeation rate (Yu and Huang, 2011a) and as seen earlier this might be 
because of the permeation procedure  followed as described above. Addition 
of galaxolide to donor media shown slightly low permeation rate and this data 
did not seem to be statistically significant (P> 0.05) using paired t-test. 
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Permeation study-2 
This study was repeated with similar donor and receiver media. This time unlike 
previous experiment, samples were collected at every 5 min up to 1hr only. 
 
 
Figure 6.11: Effect of galaxolide on permeation of curcumin through caco-
2 monolayer 
 
 
Figure 6.12: Comparison of permeation rate of curcumin with and without 
galaxolide    (P > 0.05) 
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Figure 6.11 showing approx. 5% permeation with curcumin and 5.5% 
permeation when galaxolide was added with curcumin and this permeation 
percentage investigated after 1 hr. Here also donor and receiver media were 
replaced with fresh mediums at the time of every sample collection point. The 
Papp for the curcumin and cur+gal through Caco-2 was (3.22 ± 0.2) × 10-4 and 
(3.32 ± 0.2) × 10-4 respectively (Figure 6.12). The permeation rate seemed to 
be similar with no any major difference. We did not see any major effect of 
galaxolide on the permeation of curcumin through Caco-2. Though the 
permeation rate after galaxolide addition observed slightly higher than that of 
one without galaxolide addition, this difference was statistically insignificant (P 
> 0.05). The permeation rate was determined in this study and as mentioned 
above it’s considered very high permeation rate, and like previous study it was 
possibly because of the procedure followed. Because the curcumin 
concentration was maintained at constant in donor media throughout study and 
did not allowed it to go down. So this abundance quantity of curcumin might 
have given higher permeation rate. 
Permeation study-3 
The permeation protocol was then further modified with no change in 
experimental condition. Just one thing changed that the sample collection time. 
Earlier samples were collected at every 5 mins and this might did not allowed 
enough time to permeate curcumin through the Caco-2 monolayer and because 
of that there might be unwanted results. So in this experiment samples were 
collected at every 15 mins and study was performed up to 90 mins. 
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Figure 6.13: Effect of galaxolide on permeation of curcumin through caco-
2 monolayer 
 
 
Figure 6.14: Comparison of permeation rate of curcumin with and without 
galaxolide    (P < 0.05) 
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In this study slightly different results were observed than previous experiment. 
As seen in Figure 6.13 less than 2% permeation of curcumin through Caco-2 
monolayers was observed; while the permeation of curcumin shown more than 
2% when galaxolide was added to donor media through. Papp was also 
determined with both the drug samples; with and without addition of galaxolide 
(Figure 6.14). The permeation rate observed for curcumin was (7.00 ± 0.1) × 
10-5 and the permeation rate for cur+gal was (7.56 ± 0.04) × 10-4. The 
permeation rate with cur+gal was significantly higher than the permeation rate 
with cur only (P < 0.05). Some enhancement was observed in curcumin 
permeation through the Caco-2 monolayer when galaxolide was added with 
curcumin in donor media (Figure 6.13). So its possibility that galaxolide could 
enhance the curcumin permeability. Though the permeation enhancement was 
observed in curcumin with galaxolide, there was no big difference in between 
both drug solutions permeation rate.  
Permeation study-4 
Galaxolide did not show robust effect with permeation enhancement. 
Galaxolide with 20 µM concentration was used, and this concentration was 
selected randomly. So few more concentrations of galaxolide were used except 
currently used 20µM and repeated permeation experiment with galaxolide 
concentrations such as 40µM, 60µM, 80µM and 100µM to study its effect on 
permeation of curcumin. 
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Figure 6.15: Effect of different galaxolide concentrations on permeation 
of curcumin through caco-2 monolayer 
 
 
Figure 6.16: Comparison of permeation rate of curcumin with different 
galaxolide concentration 
(cur+gal 40: P < 0.05; cur+gal 60: P > 0.05; cur+gal 80: P < 0.05; cur+gal 100: 
P < 0.05; ) 
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Figure 6.15 showing the results for the permeation study with different 
galaxolide concentrations with curcumin as mentioned above. In this 
experiment as like earlier experiment, samples were collected at every 15 mins 
for up to 90 mins and analysed for the permeation amount. As seen in Figure 
6.15, donor media with curcumin only (dark blue line) shown 6.42% permeation 
of curcumin after 90 mins through Caco-2 monolayer and which was better 
permeation percentage than other drug samples prepared with galaxolide (40 
µM, 60µM and 80µM) and applied to permeate. The donor media prepared with 
40µM galaxolide (red line) gave 5.25 % permeation, donor media prepared with 
60µM galaxolide (green line) shown 5.91 % and donor media prepared with 
80µM (purple line) galaxolide shown 5.96 % permeation of curcumin through 
Caco-2 monolayers. While donor media prepared with 100µM galaxolide (bright 
blue line) shown highest permeation percentage and which was almost 7.02 
and was even higher than previously mentioned permeation study done with 
curcumin only samples. Papp for each of these drug samples was calculated 
(Figure 6.16).Permeation rate for donor media having curcumin only (without 
galaxolide) was (2.72 ± 0.002) × 10-4 and this rate was considered as much 
higher rate of permeation. Like this other curcumin combinations with various 
galaxolide concentration show similar values for permeation rate. Permeation 
rate with 40µM galaxolide was (2.23 ± 0.0) × 10-4, with 60µM galaxolide was 
(2.40 ± 0.002) × 10-4, with 80µM galaxolide was (2.55 ± 0.01) × 10-4 and 100µM 
galaxolide was (2.91 ± 0.009) × 10-4. Permeation rate was higher with 100µM 
galaxolide than other galaxolide concentrations. Minute differences were 
observed in permeation of curcumin with and without presence of galaxolide. 
202 
 
These differences in all galaxolide concentration were statistically significant as 
all have P < 0.05 except 60µM galaxolide which have P > 0.05 (0.36). 
With all these permeation experiments, one common thing was seen that in all 
permeation procedures top chamber was supplied with fresh donor media every 
time samples were collected. This action have given higher permeation 
percentage and higher permeation rate in all experiments. Even galaxolide 
concentrations was changed and even sample collection time points were 
changed, or even there was change in duration of permeation study, same kind 
of results were observed. There was no any major effect of galaxolide on 
permeation of curcumin through the Caco-2 monolayer. In some instances data 
observed, where it seems some enhancement in permeation with galaxolide, 
while in some instances there was decrease in permeation rate with galaxolide. 
Though these differences was there, these enhancement and reduction in 
permeation did not have promising differences with their counter drug solutions 
studied with. So it’s hard to say here that galaxolide have role in enhancement 
of permeation of curcumin through Caco-2. One more thing that any known 
control was not used along with galaxolide to study the actual effect of 
galaxolide on permeation of curcumin. Study performed to apply P-gp inhibitory 
characteristics of galaxolide to enhance permeation of curcumin by preventing 
efflux of curcumin. No any robust data was observed which can show 
enhancement of permeation of curcumin, and there was no any known P-gp 
inhibitors for a control was used. So it was hard to predict here anything about 
galaxolide effect on permeation of curcumin in all studies above. 
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Permeation study-5 
To overcome these shortfalls of above experiments, permeation experiments 
were repeated with newly modified procedures and also with positive controls; 
known P-gp inhibitors verapamil and galaxolide; and negative control in which 
permeability was performed through blank transwells on which cells were not 
grown. Also different cell lines were used to study permeability of curcumin 
through various cells forming multi-cell layers as well. Like earlier permeation 
studies, growth medium was used to prepare donor and receiver media. 
Changes were done in curcumin concentration that, donor media was prepared 
with 50µM and 100µM curcumin instead of only 100µM curcumin. Lower 
concentration of curcumin was used to eradicate the possibility of cell to 
saturate with high curcumin concentration and which might eventually affect 
permeation. One more major change was done in galaxolide concentration. 
1µM galaxolide was used to study its effect on permeation. This concentration 
of galaxolide was chosen from the data obtained in rh123 assay in earlier 
chapter (5.5.1). As per results obtained in rh123 assay, it was seen that 
galaxolide had highest P-gp activity at 1µM concentration and this was the 
reason that this concentration was selected to use with permeation study. 
Some modifications in protocol was done. 100µL donor media in top chamber 
and 1.2 ml (1200µL) in bottom chamber was added. Donor media was not 
changed throughout study. It was added only once at the beginning of study 
and never changed until experiment finishes. While receiver media was 
collected every time point, and only half the receiver media was taken out and 
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replaced with fresh media. Samples were collected at every 15 mins up to 90 
mins. 
To carry this permeability study, different cell lines were used like Caco-2, 
MDCKII-MDR1, MDCKII-BCRP and DLD-1. DLD-1 cell line produce multi-cell 
layer and that iss why this cell line was used to study effect of galaxolide on 
curcumin permeation through multi-cell layers (DLD-1 multi cell layers are 
shown in histology chapter 7). Other cell lines Caco-2 and MDCKII (and 
derivatives of MDCKII) are the cells which are widely used cell models for the 
permeability studies. 
These cell lines were grown in different growth media to carry out regular cell 
maintenance processes. So in this study these respective media were used to 
prepare donor and receiver media while studying permeability using these cell 
lines. HPLC was also performed to study calibration curve of curcumin with 
each media (Figure 6.17, Figure 6.18 Figure 6.19) and for every media the 
recovery (% extraction) of curcumin was determined after extraction process. 
These results for these extraction studies are explained in Figure 6.6. 
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Figure 6.17: HPLC calibration curve for curcumin in DMEM Medium 
 
Figure 6.18: HPLC calibration curve for curcumin in EMEM Medium 
 
Figure 6.19: HPLC calibration curve for curcumin in RPMI 1640 medium 
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Unfortunately, with this modified method expected results were not observed. 
All samples for all cell lines did not shown a single peak for curcumin after 
permeation. Similar extraction methods were followed, and similar analysis 
method were used. All conditions were similar, but still failed to get permeation 
results. If it could say that curcumin was unable to permeate through cell 
membranes, it did not seen logical, because even through blank transwells 
permeation was not observed. This means there was something which could 
avoid curcumin from detection. As per new protocol followed, donor media was 
not replaced till the end of study, it means there was limited amount of curcumin 
in donor media, and as time passes the concentration of curcumin would go 
decreasing as permeation occurs. And whatever curcumin would permeate, 
could be in very little quantity. So obviously there could be very low permeation 
percentage as compare to the earlier studies performed. But there was no any 
evidence for permeation. So characteristic of curcumin was investigated to 
check its stability. And it was found that, curcumin readily goes under 
degradation and rate of degradation is higher at alkaline pH i.e. above7.0; while 
it has low degradation rate acidic pH i.e below 7.0. pH 7.4 shows the highest 
degradation of curcumin, and this pH was commonly used to transport studies 
(Wahlang et al., 2011). Here growth medium was used to prepare donor and 
receiver media. The growth medium generally has pH 7.4. As seen earlier, 
curcumin had highest degradation rate at this pH, so there was possibility that 
the curcumin used to study permeation had degraded and as a result of that its 
presence was not observer in samples collected during permeation study. 
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In earlier studies similar donor and receiver media was used, and despite of 
that permeation of curcumin was measured. But that time fresh donor media 
was used every time, and due to fresh donor media the curcumin was 
permeated before it gone under degradation. Here in this modified procedure, 
fresh donor media was not used after every sample collection time. So 
curcumin present in donor media have been possibly degraded during the 
process, or there is possibility that it had been permeated and then degraded 
there in receiver media before going to the analysis. Already it was possibly 
permeated in very low concentration, and above that it had degraded, and that 
is why it was possibility that, due to degradation there was no any results for 
this permeation study carried with various cells. Curcumin degradation could 
be confirmed by analysing its degradation products in receiver and donor 
media, but this study was not focused in that direction, so did not proceeded for 
this analysis. 
6.4.2 Permeability study using 4% BSA in HBSS media 
Because of unnecessary permeability values observed, donor media and 
receiver media were changed. New media were used; HBSS supplemented 
with 20mM HEPES having pH 6.5 to prepare donor media; while to achieve 
receiver media 4% BSA was added to HBSS supplemented with 20mM HEPES 
and pH is set to the 7.0. These different pH for both donor and receiver media 
and addition of 4% BSA to receiver media could mimic the in vivo condition as 
explained by Huang el.al.(Yu and Huang, 2011a). 
The permeability study with this donor and receiver media was done with two 
cell lines, Caco-2 and MDCKII-MDR1. Caco-2 cell line was used as intestinal 
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cell model while MDCKII-MDR1 was used as an in vitro blood-brain barrier 
model. Three different donor media were prepared, one having 50 µM 
curcumin, second with 50µM curcumin supplemented with 1µM galaxolide and 
third with 50µM curcumin supplemented with 5µM verapamil. Verapamil 
supplemented donor media was used as a positive control of the permeability 
study. 600µL donor media applied in top chamber and did not replaced at the 
time of sample collection; while 1.2 ml receiver media added to the bottom 
chamber and 600µL receiver media was removed during sample collection and 
replaced with the same volume of fresh donor media. Sample collected at every 
15 mins and permeability study carried up to 90 mins. As mentioned earlier, cell 
membranes conferring TEER above 300 Ω.cm2 were used only to study 
permeability. 
 
Figure 6.20: Curcumin permeation across MDCKII-MDR1 
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Figure 6.21: Comparison of permeation rate of curcumin and curcumin 
with galaxolide and verapamil through MDCKII-MDR1 
Permeation of curcumin with newly developed donor and receiver media was 
observed. Donor media having curcumin (blue line in graph) shown 4.78% of 
curcumin permeation through the MDCKII-MDR1 cells and was the highest 
permeation as compare to the other two drug samples. Donor media having 
cur+ver (purple line in graph) shown 4.24 % permeation while donor media 
prepared with cur+gal (green line in graph) shown 2.94 % of curcumin 
permeation through the MDCKII-MDR1 cells. Cur+gal shown least permeation 
of curcumin as compared to other drug samples (Figure 6.20). The permeation 
rate for curcumin through MDCKII-MDR1 without addition of any P-gp inhibitor 
was (3.17 ± 0.4) × 10-4 while permeation rate for cur+gal was (2.04 ± 0.5) × 10-
4 and for cur+ver the permeation rate was (2.94 ± 0.3) × 10-4. The permeation 
rate for curcumin was significantly higher than the permeation rate for cur+gal 
(P < 0.05) and cur+ver (P < 0.05). No any enhancement was observed in 
permeation of curcumin with the addition of galaxolide and verapamil. Similar 
study was carried with Caco-2 cells. 
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Figure 6.22: Curcumin permeation across Caco-2 
 
 
Figure 6.23: Comparison of permeation rate of curcumin and curcumin 
with galaxolide and verapamil through Caco-2 
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Figure 6.22 describes the permeation of curcumin through Caco-2 cell 
membrane. 2.51 % of curcumin permeation was observed, when donor media 
applied with only curcumin (blue line in graph), while cur+gal (green line in 
graph) shown 1.51 % curcumin permeation and cur+ver (purple line in graph) 
shown 1.93 % curcumin permeation across the caco-2 cells. The percentage 
of curcumin permeation was comparatively less through Caco-2 than MDCKII-
MDR1 cells. As like results obtained with MDCKII-MDR1 cells, observation with 
Caco-2 permeation shown that the curcumin without addition of inhibitor 
molecules shown the higher permeation rate, while inhibitor addition did not 
show any enhancement in curcumin permeability across the cell membranes. 
The permeation rate through Caco-2 was determined (Figure 6.23). For donor 
media with curcumin only, the permeation rate was (2.20 ± 0.4) × 10-4 while the 
permeation rate for cur+gal was (1.24 ± 0.2) × 10-4 and for cur+ver the 
permeation rate was (1.56 ± 0.1) × 10-4. The permeation rate was higher in 
curcumin only sample than inhibitor supplemented samples though this data 
was not statistically significant (P > 0.05). 
It was observed in these studies that, permeation with addition of galaxolide 
and known inhibitor was less than the permeation with curcumin only. This 
result suggested that there was possibility that curcumin did not effluxes by the 
P-gp transporter or it could be the poor substrate for the P-gp. Studies also 
suggested that P-gp efflux did not play any role in the permeation of curcumin 
(Wahlang et al., 2011). And this might be the reason that there was no any 
enhancement of curcumin permeation with addition of galaxolide and 
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verapamil. The overall permeation rate of curcumin was very low, and so it 
could be clear that curcumin had poor permeability across the membranes. 
6.5 Histological analysis during permeation studies. 
Histology was done after the permeation study, to observe the integrity of cell 
monolayer during permeability study. Cell monolayers immediately after 
permeation were fixed and followed with histological processes. 
A)                                                        B) 
  
C)                                                        D) 
  
Figure 6.24: Histology of Caco-2 cell membrane 
before (A) and after (B,C and D) permeation study 
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Figure 6.24 showing the microscopic pictures of the cell membranes before (A) 
permeation and after (B, C and D) permeation study. As seen in pictures, there 
was no any breach in the membrane after 90 mins of permeation study. All 
membranes were as intact even after permeation experiment as they were 
before the permeation experiment. So it was confirmed that, the permeation 
observed in our studies was not because of the breaches in the membrane.  
6.6 Summary 
This chapter was focused on the development of HPLC method for the analysis 
of curcumin and the permeability of curcumin through the cell membranes and 
effect of galaxolide on the permeation of curcumin.  
In this chapter, HPLC methods for the curcumin was developed. Various 
methods were developed such as, initially method developed without use of 
internal standard. The method gave clear sharp and isolated peaks. This 
method was used to analyse the permeated curcumin in initial studies. Later 
new HPLC method was developed for curcumin analysis with internal standard 
application. Previous method was modified to get this new method, and internal 
standard was used to reduce volume dependant errors. For analysis of 
curcumin, curcumin was prepared in different mediums and some of which 
contains serum and some did not. Extraction efficiency was determined in these 
media and finally, found that, curcumin recovery was better in the serum 
containing media. Also studied the effect of different extraction methods on the 
recovery of curcumin and found that extraction methods (1:1 and 1:2) did not 
had major impact on curcumin recovery, but presence of serum had role in 
recovery. So serum media was selected for sample preparations and to study 
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curcumin calibration. Further to this, for different cell lines, curcumin calibration 
was performed in different serum media. Later 4% BSA media was used for the 
sample preparation and determined calibration and extraction efficiency in this 
media. The 4% BSA media gave highest extraction efficiency and which was 
almost 100%. All those media had protein present in it gave high recovery after 
extraction process. Further curcumin have high binding affinity with BSA and 
this binding could protect curcumin from the degradation and that’s why there 
was high recovery in BSA containing media. 
After successful development of HPLC method for analysis of curcumin, 
permeability of curcumin was performed. For curcumin permeability various 
protocols were used. In first part the protocol used, in which donor and receiver 
media was replaced at every time point, and as a result of which high 
permeation percentage and higher Papp was observed. Both donor and receiver 
media were prepared in regular growth media. Further modified protocol, in 
which donor media was not changed every time. Just receiver media have been 
replaced with certain amount of volume at every sample collection point. No 
any results were observed in this study. Positive and negative control were also 
used in this study to monitor the permeation, there was no evidence of 
permeation in controls as well. Reason for this might be the degradation of 
curcumin, as curcumin has high degradation rate at alkaline pH. And the donor 
and receiver media had pH 7.4. So media was changed in later experiment, 
and this time used very controlled media. Both the donor and receiver media 
were set at the particular pH with the addition of HEPES buffer. The HEPES 
buffer helps to maintain the pH set at certain value. With these modified donor 
215 
 
and receiver media, the permeation of curcumin was observed through the cell 
membranes. But it was observed that permeation and permeation rate was 
higher with curcumin only samples than the samples supplemented with 
galaxolide as a P-gp inhibitor and verapamil. These results could say that the 
P-gp efflux transporter did not play any role in the curcumin permeation, and so 
there was no enhancement of permeation of curcumin with galaxolide. Finally 
histology of cell membranes were performed before and after permeations, to 
determine the integrity of membranes. It was observed that the cell membranes 
were remained intact and without any breaches within even after permeation 
experiment. So it could be clear that there was no any false penetration of 
curcumin in whatever data produced. 
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7 : Histology study 
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7.1 Introduction 
Histology is the scientific study of the fine detail of biological cells and tissues 
using microscopes to look at specimens of tissues that have been carefully 
prepared using special processes called "histological techniques" or it is also 
defined as the study of microscopic anatomy of cells and tissues. It is 
commonly performed by examining cells and tissues under a light 
microscope or electron microscope, which have been sectioned, stained and 
mounted on a microscope slide. The ability to visualize or differentially identify 
microscopic structures is frequently enhanced through the use of histological 
stains.  
In this study, histology tool was used to study the membrane forming ability of 
different cell lines. Different cell lines were used to carry permeation 
experiment, but before moving for permeation, it was necessary to study the 
integrity of cell membranes. TEER values was used to assess integrity of cell 
membranes, and then studied the histology of cell membranes with respect to 
TEER values. TEER is nothing but the electrical resistance across the cell layer. 
Relationship between TEER and histology was studied to see the effect of 
growing cells on the TEER value. TEER values should be increased as cells 
grows and get confluent. The TEER was used to assure the integrity of the cell 
layers (Yu and Huang, 2011b). 
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7.2 Histology of DLD-1 cell 
The cell line shown the rapid growth in flasks and transwells. Cell were grown 
on transwells for 6 days. TEER was measured every day after TEER 
measurement wells were fixed and followed with histology. 
 
Figure 7.1: Graphical presentation of TEER values for DLD-1 against days 
of incubation 
 
As seen in Figure 7.1, the DLD-1 cells shown gradual increase in TEER values 
from 14.63Ω.cm2 to the 126.06 Ω.cm2, as cells grows and forms membrane on 
the transwells. The increase in TEER values shown that, the DLD-1 forms more 
confluent cell membrane on Day-6 as compare to day-1. TEER was lower on 
day-1 possibly because the cells were not attached to each other so tightly, and 
as a result of which applied current passed through the gaps present in between 
cells and displayed low TEER readings; in reverse of this, as incubation time 
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goes increasing, cells started to form firm attachment, which did not allowed 
applied current to pass easily and confers high resistance, and that is why the 
TEER was higher as incubation time increases. This is the possible reason, for 
observed higher TEER on day-6. To assess the confluence of the cell layers, 
the transwells were fixed and followed for histology study. The Histological 
sections gave the clear idea about the confluence of cell layers. 
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  Day-1                                                            Day-2 
  
   Day-3                                                           Day-4 
  
   Day-5                                                             Day-6 
  
Figure 7.2: Histology images of DLD-1 membranes formed on different 
days 
 
 
Figure 7.2 showing histology images of DLD-1 cell membranes on different 
days. As seen in images, on day-1, the section shows very thin cell layer, which 
was the reason for the low TEER value; while as incubation period increased 
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up to Day-6 the thickness of cell layers goes on increasing and as a result of 
which TEER goes higher. Besides the thin cell layer, there were some 
intercellular spaces, which might also the reason for the lowered TEER, and 
these intracellular spaces could be seen in images from day-1 to day-3. From 
day-4, these intracellular spaces reduced and seen comparatively intact cell 
membranes on day-4 to day-6. So from these pictures it was clear that, though 
cells are forming complete cell membranes, but there were some gaps present 
in cells, which might be responsible for the low TEER. These gaps can produce 
the leaky membranes, and as those spaces were filled by cellular components 
during the period of time, membrane becomes more confluent. And this 
confluence and integrity was assessed with the help of TEER. Histology 
pictures also clarify that, DLD-1 cells were forming multi-cell layer membranes, 
and multi-cell layers were increasing with the incubation time. 
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7.3 Histology of PANC-1 cells 
PANC-1 cells were also grown on transwells and TEER was measured for 6 
days. PANC-1 cells shown the slow growth as compare to the DLD-1, and also 
shown the least elevation in the TEER values at the end of Day-6. 
 
Figure 7.3: Graphical presentation of TEER values for PANC-1 against 
days of incubation 
 
The TEER was increased from 7.04Ω.cm2to 10.23Ω.cm2 after 6 days incubation 
(Figure 7.3). PANC-1 did not show significant elevation in TEER, even after 
increasing incubation. Cells were seems to grow on the transwells, but were 
unable to give higher TEER values. There was very little increase in TEER, 
from the day-1 to day-2. These cell membranes were followed to study histology 
and the reason for this low TEER was assessed by histology sections. 
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Day-1                                                               Day-2 
  
Day-3                                                               Day-4 
  
Day-5                                                               Day-6 
  
Figure 7.4: Histology images of membranes formed by PANC-1 cells 
 
Figure 7.4 shows that the PANC-1 was grown in multilayer, but the layers 
formed by this cell line were not in uniform membrane structure. The cells seem 
to be loosely attached to each other, forming intracellular spaces. Also these 
image shown that the cells were growing in clumps and there were gaps 
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between two clumps. And all these intercellular spaces and the gaps between 
cell clumps were responsible for the low TEER values in PANC-1 even after 
cells were grown in enough number. The cell lines was unable to grow in 
uniform layers, and have ability to form clumps. This clumps forming ability of 
PANC-1 allowed to form very leaky membrane and this was the reason there 
was very low TEER through the PANC-1. 
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7.4 Histology of SiHa cells 
As like DLD-1 and PANC-1; SiHa cells were cultured on transwells and allowed 
them to grow to form membranes. Cells were grown for 6 days and TEER was 
measured every day. Same wells after TEER measurement were fixed and 
used for histology study. 
 
Figure 7.5: Graphical presentation of TEER values for SiHa against days 
of incubation 
SiHa cells also shown the low TEER values, with little elevation from 3.30Ω.cm2 
to the 6.82 Ω.cm2 on day-6 (Figure 7.5). The SiHa cells have shown faster 
growth than PANC-1 but were unable to give higher TEER values. To find the 
reason behind low TEER, histological study was performed for these cell 
membranes. 
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Day-1                                                                 Day-2 
  
Day-3                                                                 Day-4 
  
Day-5                                                                 Day-6 
  
Figure 7.6: Histology images of membranes formed by SiHa cells 
 
The histology images of SiHa (Figure 7.6) shows the multi-cell layer growth. On 
Day-1 there was monolayer of cells with spaces between the cells. The multi-
cell layer starts to form from the Day-2, and the cells were grown in dome 
shaped structure. The images shown the breaches between the cells, which 
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might provide the space to pass current through it, which results in the low 
TEER values. The low TEER value indicates the loose intercellular 
associations, which might highly favours passive paracellular diffusion (Wang 
et al., 2005b).        
Histological study was performed for these three cell lines, to study their 
membrane forming ability, so these cells could be used to perform permeation 
and to study drug permeability through multi-cell layers. But, only DLD-1 cell 
shown the formation of confluent cell membranes. 
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7.5 Histology of Caco-2 cell lines 
Caco-2 cells were grown on transwells and media was changed on every three 
days and the TEER was measured on every three days till the 21 days. 
 
Figure 7.7: Graphical presentation of TEER values for Caco-2 against 
days of incubation 
 
Figure 7.7 showing the TEER values obtained for the Caco-2 cells on different 
days. The TEER was increasing with incubation time and the highest TEER 
value was observed on the day-12 and which was almost 915.31 Ω.cm2. After 
the day-12 the TEER started decreasing and on day-21 it dropped to the 58.96 
Ω.cm2 which was a lowest TEER observed.  To study reason behind this rise 
and fall of TEER, the histology study was performed for these cell membranes. 
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Day-3                                                                Day-6 
  
Day-9                                                                Day-12 
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Figure 7.8: Histology of membranes formed by Caco-2 cells 
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Figure 7.8  showing the pictures for the membranes formed by the Caco-2 cell 
lines. The Caco-2 cells form monolayer and the single cells were aligned to 
form cell membrane. On day-12 where the highest TEER was observed, the 
cell membrane was healthier than the cell membranes observed on other days 
and was also confluent without any intracellular spaces. After day-12, the cell 
membrane observed to be shrunken and unhealthy, which might be then did 
not able to maintain its integrity and as a result of which, drop in TEER after 
day-12 was observed. This might be happen, because there was limited supply 
of nutrients in the transwells and this supply was not enough to feed all cells. 
And due to insufficient supply of nutrients, cells started dying and the 
membrane lose its integrity. And this was the possible reason that there was 
the decline in TEER after highest TEER on day-12. 
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7.6 Histology of MDCKII Cells 
MDCKII cells were cultured on the transwells and every 3 days media was 
changed to maintain cells in healthy condition. TEER was measured on every 
5 days, from day-1 to day-20. 
 
Figure 7.9: Graphical presentation of TEER values for MDCKII cells 
against days of incubation 
As seen in Figure 7.9, TEER was very low at day-1 and was only 1.54 Ω.cm2. 
From Day-5 the TEER was increased at high level and it was observed 
29.81Ω.cm2 while on day-10, 15 and 20 the TEER values were 24.75Ω.cm2, 
24.64Ω.cm2 and 20.9Ω.cm2 respectively. The TEER observed consistence 
between day 10 and day 15 and on day 20 it shown some decline. These 
transwells were fixed on above mentioned time points and performed histology 
study. 
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Day-1                                                                  Day-5 
  
Day-10                                                                Day-15 
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Figure 7.10: Histology of membranes formed by MDCKII cells 
 
Figure 7.10 shows histology images of membranes formed by MDCKII cells 
with respect to different incubation time period. On day-1 very few cells on 
transwell membranes was observed. Cells did not observed grown completely 
and it was because, cells did not get enough time to grow since inoculation on 
transwells. But on the other hand, images for transwells incubated for day-5 to 
day-20 shown complete membrane of MDCKII cells over the transwells. The 
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MDCKII cell lines formed monolayer, and as seen in picture intact monolayer 
was observed except on day-1. And this was the reason very low TEER was 
recorded on day-1 while on others days comparatively higher TEER values 
were observed. 
7.7 Histology of MDCKII-MDR1 cells 
MDCKII-MDR1 cell line was a derivative of MDCKII cell line having ability to 
over express P-gp/MDR-1 proteins. Same like MDCKII, MDR1 cells were 
maintained in similar experimental conditions and performed TEER 
measurement. 
 
Figure 7.11: Graphical presentation of TEER values for MDCKII-MDR1 
against days of incubation 
 
TEER was very low on day-1 while from day 5 to day 20 the TEER was 
increased comparatively at high level. On day 14 the highest TEER value was 
observed and was about 45.65Ω.cm2 and as mentioned earlier it was very high 
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as compared to the day 1 TEER which was just 2.42Ω.cm2. Except day 1, TEER 
value for all other days observed higher with some differences as seen in Figure 
7.11.  
Day-1                                                                       Day-5 
  
Day-10                                                                     Day-15 
  
Day-20 
 
Figure 7.12: Histology of membranes formed by MDCKII-MDR1 cells 
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The Figure 7.12 shows the histology images for membraned formed by 
MDCKII-MDR1 cells. As seen in day 1 image, that cells were not firmly attached 
to the transwell membranes. Cells observed distinct and separated from one 
another, having huge spaces between them. Also there were very few number 
of cells, and this was because inappropriate incubation time. And this was the 
reason that low TEER was observed on day 1. Except day 1, all other images 
on different day’s shown uniform monolayer formed on the transwell 
membranes, and due to this intact membrane, higher TEER compared to the 
day 1 was observed. Also there was low TEER on day 10 as compared to the 
day 5 even after long incubation time. As seen in picture on day 10, that the 
membrane shrunken and unhealthy unlike other membranes. This might be the 
reason behind decreased TEER on day 10. On day 15 highest TEER was 
observed and as seen in histology images, the membrane formed on day 15 
observed more intact than other. Cells appeared healthier, and because of that 
cells might have formed the strong binding between them. And as a result of 
which high TEER was observed. 
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7.8 Histology of MDCKII-BCRP cells 
MDCKII-BCRP was also derivative of MDCKII cell line which overexpresses 
BCRP proteins. Like MDR1, similar experimental conditions for this cell line to 
grow and form cell membranes were used. 
 
Figure 7.13: Graphical presentation of TEER values for MDCKII-BCRP 
against days of incubation 
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Figure 7.14: Histology of membranes formed by MDCKII-BCRP cells 
 
The BCRP cell line as well shows very low TEER at day-1 and from day 5 to 
day 20 higher TEER was observed. On day 10 highest TEER was observed 
which was almost 61.71 Ω.cm2 and very high as compare to the TEER 
observed on day 1 and which was just 0.99Ω.cm2 (Figure 7.13).  
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Histology study explored the membranes formed by the MDCKII-BCRP cells 
(Figure 7.14).Images explored the reason behind low TEER on day 1 and high 
TEER on other days except day 1. Image for day 1 membrane shown the 
membrane which was not completely formed and have gaps between cells. 
Also the image explores the insufficient number if cells present on the transwell 
membrane to form the intact membrane. The less number of cells were 
because of the short incubation time. Other images than day1 images shown 
completely formed membrane of MDCKII-BCRP cells. And the membrane was 
intact and this intact structure was responsible for the high TEER which was 
not seen in day 1 image.  
7.9 Histology of MDCKII-MRP1 cells 
MDCKII-MRP1 was also a derivative of MDCKII cell line which over expresses 
MRP1 protein. As like other derivatives, MRP1 cell line was also maintained 
using similar experimental conditions. 
 
Figure 7.15: Graphical presentation of TEER values for MDCKII-MRP1 
against days of incubation 
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Figure 7.16: Histology of membranes formed by MDCKII-MRP1 cells 
 
The MRP1 also delivered the similar set of results as the lower TEER on day 1 
was observed and the TEER seems to be increased from day 5 to day 20 
(Figure 7.15). The highest TEER for MRP1 was observed at day 20 and was 
about 46.86 Ω.cm2. Other TEER values on day 5 to day 15 were nearly similar 
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to each other and did not show big differences between them. The TEER seems 
to be gradually increasing till day 20. 
Histological study for these transwells was done to observe the membranes 
formed by these cells (Figure 7.16). The images obtained after histology, shown 
the leaky membranes on day 1 and from day 5 the membrane seems intact and 
uniform. As mentioned earlier, the leaky membrane on day 1 was responsible 
for the low TEER value.  
As seen above that, different cell lines were forming membranes on the 
transwell inserts. TEER was determined for every cell lines to assess the 
integrity of membranes formed by these cell lines. DLD-1 PANC-1 and SiHa 
cell lines had an ability to form multi-cell layers. Though these cells form multi-
cell layer membranes on transwells, only DLD-1 was able to form intact and 
uniform cell membranes. Other cell lines PANC-1 and SiHa were not able to 
form intact membranes. Instead these cell lines forming clumps of growth on 
the transwell membranes. These structures of these cell membranes were not 
able to confer uniform and intact cell layer. These cells form membranes having 
breaches and intracellular spaces in between them. And these breaches were 
responsible for the low TEER values. The low TEER directly informs us about 
the breaches present in cell membranes. This was the reason that TEER was 
used to check the integrity of cell membranes. Histology for Caco-2 cells, 
MDCKII cells and derivatives of MDCKII cells was also studied. All these cells 
including Caco-2 and MDCKII with its all derivatives formed the monolayers on 
transwells. These monolayers were giving intact cell membranes, and these 
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membranes could be seen in images above with different TEER values with 
different incubation time. 
A PANC-1 and SiHa cell did not able to form intact cell membranes. There was 
breaches in membranes formed by these cells. To overcome this issue with 
membrane forming ability of these cell lines, matrigel was applied to the cell 
suspension during inoculation. These cells then used to perform the histology 
to study effect of matrigel on membrane forming ability of cells.  
7.10 Effect of matrigel on TEER and histology 
Matrigel matrix is a reconstituted basement membrane preparation that was 
extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumour 
rich in extracellular matrix proteins. This material contains approximately 
60%laminin, 30% collagen IV, and 8%  entactin. Entactin is a bridging molecule 
that interacts with laminin and collagen IV, and contributes to the structural 
organization of these extracellular matrix molecules. Matrigel matrix also 
contains heparin sulfate proteoglycan (perlecan), TGF-β, epidermal growth 
factor, insulin-like growth factor, fibroblast growth factor, tissue plasminogen 
activator, and other growth factors which occur naturally in the EHS tumour. 
Matrigel have activity to enhance the tumour growth and is also supports an 
optimal growth of cell cultures (Bao et al., 1994; Fridman et al., 1991; Hughes 
et al., 2010; Kleinman and Martin, 2005). This growth promoting characteristics 
of matrigel was used to enhance the membranes forming ability of cells. 
Different concentrations of matrigel were used to study its effect on growth of 
membranes. 
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7.10.1 Application of 50% (500µl/ml) matrigel 
In this experiment, 50% of matrigel was applied to the media. Cell suspension 
with desired cell number was prepared and centrifuges to get pellet. And this 
pellet was then dissolved to the media which contained 50% matrigel. All 
matrigel concentrations were prepared with similar dilutions. The cells with and 
without matrigel were cultured on transwells and incubated for 6 days. TEER 
was measured on day 1 and day 6 only and the same transwells after TEER 
measurements were used to study histology. 
 
Figure 7.17: Application of 50 % matrigel to HT29 cells 
 
 
Figure 7.18:  Application of 50 % matrigel to HCT 116 cells 
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Graphs in above figures shows the different between TEER values with and 
without application of matrigel. The HT29 cells (Figure 7.17) shown no 
difference in TEER values with and without application of matrigel on day-1 and 
day-6 as well. TEER values observed nearly similar in both the cases. The cell 
membrane without matrigel shown TEER increase from 3.23 Ω.cm2 to 
6.20Ω.cm2, while cell membrane with addition of 50% matrigel shown TEER 
values 2.79Ω.cm2 and 6.75Ω.cm2 on days 1 and 6 respectively. If both the 
TEER values were compared with respect to matrigel addition, there was no 
any enhancement in TEER with HT29 cells.  Application of 50% matrigel to HCT 
116 cells (Figure 7.18) shown big differences in TEER values between two 
samples on day 6, while on day 1, there was nearly similar TEER which was 
very low; 0.99Ω.cm2 and 0.84Ω.cm2 for cell without addition of matrigel and with 
matrigel respectively. On day 6 we observed TEER value (10.56Ω.cm2) without 
addition of matrigel higher than TEER value (7.11Ω.cm2) with matrigel. 
Histology for both the cell lines mentioned above was performed. 
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Without Matrigel (M-) 
Day-1                                                                    Day-6 
  
With Matrigel (M+) 
Day-1                                                                    Day-6 
  
Figure 7.19: Effect of 50 % matrigel on membrane forming ability of 
HT29 cells 
 
Histology study provided the images for the cell membranes treated with 50% 
matrigel.  Figure 7.19 shows the membranes formed by HT 29 cells and also 
observed that the HT29 cells were growing in multi-layers. In image, without 
addition of matrigel HT29 cell on day 6 forms good multilayer, but the multi-
layer membrane did not formed in continuous manner. The membrane looks to 
be grown in patches. Other image with addition of 50% matrigel shown the 
presence of matrigel around the cells and cells looks like to be trapped within 
the matrigel. It observed that, matrigel did not allowed cells to grow freely. There 
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was clear difference between cell densities present in membranes with and 
without matrigel application. 
Without Matrigel (M-) 
Day-1                                                                    Day-6 
  
With Matrigel (M+) 
Day-1                                                                    Day-6 
  
Figure 7.20: Effect of 50 % matrigel on membrane forming ability of HCT 
116 cells 
 
Figure 7.20 shows the membranes formed by the HCT 116, and same like 
HT29, the membranes formed by cells where matrigel was added, shows less 
cell density, while cells without matrigel shown better growth. HCT 116 without 
matrigel shown multi-cell layer membrane formed. The membrane had 
intracellular spaces and loses cell-cell attachments. This might be the reason 
that high TEER was not observed. With matrigel TEER was lower on day 6, 
and it was possibly because the low cell density present in membrane. Both the 
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cell lines with application of matrigel shown less growth of cells. Though there 
was membrane formed, but this was just matrigel overlaid not the cells. So this 
higher concentration of matrigel did not allowed cell growth.  
As seen earlier, high concentration of matrigel was suppressing cell growth, so 
these experiments were repeated with lower matrigel concentrations.  
7.10.2 Application of 2.5% (25µl/ml) matrigel 
In previous experiment, it was seen that 50 % matrigel have restricted cell 
growth at some extent and that is why intact cell membranes were unable to 
grow. So lower concentrations of matrigel was used to support growth of cells 
and to form uniform membranes. And 2.5 % matrigel was used this time and 
added to cell suspension at the time of culturing cells on transwells. 
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(D)  
 
(E) 
 
Figure 7.21: Application of 2.5% matrigel cells  
A) SiHa, B) MCF-7, C) HCT 116, D) H460 and E) HT29 
 
Various cell lines were used such as SiHa, MCF-7, HCT 116. H470 and HT29 
cells. TEER for all cell lines were determined on day 1 and day 6. Cells were 
cultured on transwells with and without matrigel. Figure 7.21 shown the graphs 
obtained for TEER values for different cell lines in presence of matrigel and 
without matrigel. 
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A SiHa cell line did not show major difference in TEER values between both the 
cell samples. TEER was nearly equal through SiHa cell membranes even after 
application of 2.5% matrigel to the cells. For SiHa cells without application of 
matrigel TEER across membrane was 2.20 Ω.cm2 on day 1 and 9.79Ω.cm2 on 
day 6. While with application of matrigel TEER across SiHa membrane was 
2.53Ω.cm2 on day 1 and on day 6 TEER was 9.68Ω.cm2. MCF-7 was next cell 
line used to study membrane forming ability with matrigel. The MCF-7 was a 
slow growing cell line, so it shown very low TEER on day 1 with both cell 
samples. Without matrigel addition TEER was 1.43 Ω.cm2 while with matrigel 
TEER value across MCF-7 cell membrane was 1.54 Ω.cm2 on day 1. Both 
TEER values were nearly similar. On day 6 slight higher TEER across MCF-7 
cells grown with matrigel than those grown without matrigel was observed. But 
TEER with MCF-7 membranes was too low even on day 6. And this low TEER 
might be possibly because, MCF-7 is slowly growing cell line and because of 
that it did not have formed membrane on transwells and as a result of which 
higher TEER was not observed across MCF-7 cell membrane. HCT 116 cells 
shown comparatively high TEER across its membrane formed by cells grown 
in presence of matrigel. TEER across HCT 116 grown with matrigel was 
4.18Ω.cm2 on day 1 and 24.31Ω.cm2 on day 6. These TEER values were higher 
than TEER obtained by cells without matrigel application. Here with HCT 116 
the difference in TEER values was observed and TEER seems to be increased 
with addition of matrigel. Similar study performed with H460 cells and like 
HCT116, TEER values observed higher across the cell membrane grown in 
presence of matrigel. TEER across matrigel applied cell membrane was 
9.46Ω.cm2 on day 1 and 14.52Ω.cm2 on day 6, while TEER across cell 
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membrane grown in absence of matrigel was 6.05Ω.cm2 on day 1 and 
10.89Ω.cm2 on day 6. Next cell line used was HT29. The cell line shows 
increased TEER across cell membranes in presence of matrigel as compared 
to the cell membranes grown without matrigel. TEER across matrigel applied 
cell membrane was 2.09Ω.cm2 and 10.12Ω.cm2 on days 1 and 6 respectively. 
While TEER across cell membranes grown in absence of matrigel was 
0.99Ω.cm2 and 4.51Ω.cm2 on days 1 and 6 respectively. 
Here in this study, with application of 2.5 % (25µl/ml) matrigel, cell growth 
seems to be enhanced and it could be stated from the increasing TEER across 
the matrigel applied cell membranes. To support this statement, these 
membranes further used to perform histology study, which would give robust 
idea about the membrane structures.  
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Without Matrigel (M-) 
Day-1                                                                    Day-6 
  
With Matrigel (M+) 
Day-1                                                                    Day-6 
  
Figure 7.22: Effect of 2.5 % matrigel on membrane forming ability of 
SiHa cells 
 
Without Matrigel (M-) 
Day-1                                                                    Day-6 
  
With Matrigel (M+) 
Day-1                                                                    Day-6 
  
Figure 7.23: Effect of 2.5 % matrigel on membrane forming ability of 
MCF-7 cells 
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Without Matrigel (M-) 
Day-1                                                                    Day-6 
  
With Matrigel (M+) 
Day-1                                                                    Day-6 
  
Figure 7.24: Effect of 2.5 % matrigel on membrane forming ability of 
HCT116 cells 
 
Without Matrigel (M-) 
Day-1                                                                    Day-6 
  
With Matrigel (M+) 
Day-1                                                                    Day-6 
  
Figure 7.25: Effect of 2.5 % matrigel on membrane forming ability of 
H460 cells 
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Without Matrigel (M-) 
Day-1                                                                    Day-6 
  
 
With Matrigel (M+) 
Day-1                                                                    Day-6 
  
 
Figure 7.26: Effect of 2.5 % matrigel on membrane forming ability of 
HT29 cells 
 
Figure 7.22, Figure 7.23, Figure 7.24, Figure 7.25 and Figure 7.26 shows 
histology images for cell lines forming membranes on transwells with and 
without application of matrigel. As seen here, the SiHa cells did not show major 
difference in TEER values on day 1 and 6. On day 1 images of SiHa cell grown 
in presence of matrigel shown higher density of cells present on transwells. 
Though the cell number was high, they have not formed intact membrane on 
day 1. Cells did not seems to be attached to each other and this might be the 
reason that there was no difference in TEER values on day 1. On day 6 cell 
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membrane grown without matrigel seems very week and with low cell density, 
while cells grown in presence of matrigel shows nice growth forming membrane 
with high cell density. Also the cells were grown in multi-layers. So it was 
confirmed that matrigel supports the growth of cells and that is why more cells 
observed in membrane. But even though the membrane was thick and multi-
layered, the images shown inter cellular spaces and cells with lose attachments 
within the membrane. So these cells provide leaky membrane and this was the 
possible reason that there was no increased TEER with matrigel addition 
despite observing thick membrane. Very low TEER with MCF-7 cells was 
observed and it was stated that the low TEER might be because of the slow 
growth of cells. Histology images explored the exact reason for low TEER. 
There were very few cells were present on transwell and this was most possibly 
because slower growth of cells. But the high cell density was observed on day 
6 in presence of matrigel as compare to the cells grown without matrigel. 
Though this enhanced cell number was not to form membrane, but still there 
was enhanced growth in presence of matrigel. 
Images of HCT 116 cells shown formation of nice intact membrane on day 6. 
On day 1 both cell samples; with and without matrigel; shown uniform alignment 
of cells on membrane and on day 6 these cells have delivered an intact cell 
membranes developed in multi-cell layers. Both cell samples grown in presence 
of matrigel and without matrigel gave a uniform cell membrane. But cell 
membrane grown without matrigel shown cells with lose binding with each 
other. There was also intra cellular spaces in this membrane. Such breaches in 
membrane could form leaky membrane and this was the reason low TEER was 
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observed across this membrane grown without matrigel. On the other hand cell 
membrane formed by cells treated with matrigel formed a membrane which 
observed more intact. Still there were few intercellular spaces but these were 
less in number as compare to the membrane grown without matrigel. Cells in 
this membrane observed to be attaches firmly with one another and these tight 
attachments were responsible for the high TEER values observed. Similar kind 
of results were observed with the H460 cells. Growth of cells seems to be 
enhanced by the presence of matrigel in culture and which was resulted in the 
generation of uniform cell membrane. HT29 cells, in absence of matrigel shows 
growth in the form of cell clumps on the transwell membrane. While cells grown 
in presence of matrigel did not show clumps of cells, instead observed that the 
cells grown uniformly over the transwell forming multi-cell layer membrane 
which was more intact. In all above one thing was seen in common that 
application of matrigel was responsible to boost the growth of cells. Also 
matrigel helped cells to distribute uniformly over the transwells and because of 
uniform distribution the cells grown without clumps. Matrigel provided a strong 
basement membrane for the cells to attach and to grow. 
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7.11 Summary 
TEER measurement and histology study for various cell lines was performed. 
The study was performed to assess the membrane forming ability of cells as 
well as to study the integrity of cell membranes.  
In first section of this chapter the histology of various cell lines were studied 
including DLD-1, PANC-1, SiHa, Caco-2, MDCKII and its derivatives. It was 
observed that DLD-1, PANC-1 and Siha were forming multi-cell layers. Despite 
of multilayers, only DLD-1 gave uniform and intact membrane while other two 
cell lines were grown in patches on the transwells. These cells forms the cell 
clumps and so shown the breaches in membrane and were not delivering ideal 
cell membrane. There was also the lower TEER with PANC-1 and SiHa while 
DLD-1 cells gave higher TEER values and TEER kept increasing over the 
incubation time. The Caco-2, MDCKII and its derivatives were forming 
monolayer on the transwells. These cells gave higher TEER around the days 
12-15 and so these cells were used to perform permeability study on those 
days. These cells form ideal cell membranes to perform drug permeability 
studies. 
As seen that PANC-1 and SiHa were not growing in uniform membrane, and so 
matrigel was used in culture to promote the membrane forming ability of such 
cells. Initially higher concentration of matrigel was used in culture and which 
was almost 50 % of the total cell suspension. This high concentration resulted 
in the suppression of cellular growth. The matrigel turns in to solid gel above 
40C and this higher concentration at incubation temperature might have formed 
the thick gel in transwells. So this gel formation have been not allowed the cells 
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to grow freely as this matrigel had trapped the cells inside it. Eventually there 
was no membranes observed with application of such higher concentration of 
matrigel. Same experiment was repeated with lower concentration of matrigel 
(2.5 %). This concentration of matrigel supported the cell growth and enhanced 
the membrane forming abilities of cells. But still there was no big differences in 
TEER across these membranes. Even though some cells did not shown the 
formation of intact membranes, but still enhanced growth with matrigel was 
observed. To achieve more intact membranes with higher TEER across them, 
cells need to grow for longer duration. The higher incubation time might give 
good cell membranes with higher TEER. 
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8.1 Conclusion 
This study was performed to develop novel efflux inhibitor molecule and to 
evaluate it for improvement in drug delivery. So to achieve this goal several 
experiments were designed, and from the research done here following 
conclusions can be drawn: 
 The novel compound galaxolide have been tested for its toxicity against 
the various cell lines. From the data observed through these experiments 
it was confirmed that galaxolide is non-toxic for the cells. It does not have 
any harmful effects on both normal cells as well as cancer cells. So 
galaxolide can be used with other drugs without interfering the toxicity of 
co-drug. The experiment determining effect of galaxolide on the toxicity 
of other drugs was also performed. Study was unable to find any 
enhancement in toxicity of drug with addition of galaxolide. Actually the 
drug used is curcumin, and as it is seen that curcumin is not active 
substrate for efflux proteins and that is why galaxolide addition to this 
formulation does not show enhanced toxic activity against cells. 
P-gp expression and inhibition studies were also performed. To study P-
gp expression two techniques were used; western blot and FACS. These 
studies were determined the expression of P-glycoprotein in Caco-2 and 
MDCK cell lines with both the methods. The P-gp inhibition studied with 
Rh123 assay and it is observed that galaxolide have P-gp inhibition 
activity. Even galaxolide shows inhibition activity against other efflux 
proteins like BCRP and MRP1. So it is clear that galaxolide is a potent 
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efflux protein inhibitor molecule and is more effective than verapamil and 
cyclosporine A.  
 To study effect of galaxolide on drug permeability, first of all HPLC 
method with various receiver media was developed. Study determined 
that, receiver media having protein molecules present in it, gives the 
higher recovery of curcumin after extraction as compared to the receiver 
media without protein molecules. Reason for this was explained in 
results section. Also the pH is very critical factor for the curcumin 
recovery as curcumin has higher degradation at alkaline pH than acidic 
pH. So the preparation of donor and receiver media were done 
accordingly in later parts of experiments. Permeation study with 
curcumin done with various donor and receiver media and observed 
different results depending on the permeation duration and content of 
receiver media. But there was no any enhancement in permeation of 
curcumin with addition of galaxolide in any of these experiments. And as 
explained earlier, this is because curcumin is not active P-gp substrate. 
But still galaxolide can be useful to enhance the treatment of drugs which 
are active P-gp substrates. 
 The histology studies are performed to assess the membrane forming 
abilities of various cell lines, so that they are useful to carry permeation 
study. It is observed that Caco-2, and MDCKII along with its derivatives, 
form nice monolayers on transwells. These membranes show higher 
TEER across them and are developed to be ideal cell membranes for 
permeability study. DLD-1 as well forms multi-cell layer membrane, 
which intact and gives high TEER values across it. So DLD-1 cells can 
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be used to study permeability of drugs across multi-cell layers. Other 
cells which did not form uniform membranes, so the matrigel was applied 
to those cells. And it is observed that the matrigel enhances the cell 
growth and also helps cells to form uniform membranes. Though there 
was no any results showing higher TEER with matrigel, but if cells were 
incubated for longer duration, definitely there would be generation of 
good membranes with matrigel. So matrigel could be the efficient tool to 
form cell membranes. 
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8.2 Future Work 
The current findings in this research can highlight the following aspects for 
future studies:  
 Effect of galaxolide on drug toxicity of P-gp active drugs 
 Use of P-gp active substrates to study the effect of galaxolide on 
permeation enhancement. 
 Permeation study through the multi-cell layer membranes 
 Immunohistochemistry study of cell membranes to study expression of 
P-gp in membranes 
 Use of dyes such as calcein AM and DiOC2(3) along with rh123 to study 
the efflux protein inhibition assays to study inhibition action of galaxolide. 
Also the use of FACS for analysis of data instead of plate reader only. 
 Use of Matrigel to develop more efficient cell membranes conferring high 
TEER across them. 
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